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SUMMARY
In this thesis, two novel enzyme immunoassay protocols that had 
been considered in theory were studied in practice.
One protocol involved the use of multi-enzyme systems in order 
to simultaneously quantitate more than one component of a biological 
fluid. A model dual hapten method was developed in which alkaline 
phosphatase was conjugated to thyroxine, and p-galactosidase was linked 
to triiodothyronine. The choice of these two enzymes enabled each to be 
measured in the presence of the other without cross detection and 
provided the means for the determination of both thyroid hormones in a 
single ' tube. The assay compared well with existing radioimmunoassay 
techniques and confirmed that the theoretical advantages of the method, 
in time and cost saving, could be achieved in practice.
The other new protocol investigated involved the use of an 
enzyme inhibitor as a label in an homogeneous system. Homogeneous assays 
possess the features of rapidity and ease of automation which can be of 
significant advantage in a routine laboratory. Enzymes have been used 
directly as labels in homogeneous methods but the use of an enzyme 
inhibitor label would, in theory, be a simpler process. A series of 
problems prevented the development of a model method based on this 
principle although the experimental work carried out did enable a better 
appreciation of the essential requirements of the proposed system to be 
gained.
A final evaluation concludes that both protocols have potential 
for future use.
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CHAPTER ONE
A REVIEW OF PUBLISHED IMMUNOASSAY METHODOLOGY
1.1 PRINCIPLE OF IMMUNOASSAY
Immunoassays are a group of protein-binding assays which make 
use of the antigen-antibody reaction as an analytical tool. The 
technique, which has an inherent high specificity, can be very sensitive 
and has allowed the measurement of a variety of biologically active 
compounds present in nanogram to picogram amounts in biological systems. 
This has enabled much progress to be made in the understanding of many 
physiological processes, particularly with regard to endocrinology. 
Another important use of these assays has been the monitoring of blood 
drug levels, so making it possible for safe but effective therapy to be 
given.
In immunoassay techniques a label is attached to one component 
of the immunological reaction, most frequently to the antigen. In such a 
reaction system the labelled antigen competes with the antigen present 
in the sample under investigation for a limited number of binding sites 
on the antibody. If the level of antigen is low then the majority of the 
antibody sites will be occupied by labelled antigen. Thus the 
distribution of labelled antigen between the antibody-bound and the non 
antibody-bound (i.e. free) fractions depends on the unlabelled antigen 
concentration in the sample under study. By using a standard curve, 
obtained with solutions of known antigen content, the antigen content of 
the sample under test can be determined. Usually the bound and free 
fractions must be separated before measurement of the label present in 
one of the two phases can take place. Either of the phases (i.e. bound 
or free) can be used for the measurement of label and the choice between 
the two is often determined by the separation method involved in the 
immunoassay procedure being used.
The technique described above, which uses labels attached to 
the antigen, is often referred to as the ’classical’ immunoassay system. 
It is illustrated diagramatically in Figure 1.1
However this is not the only immunoassay configuration 
possible, and assays have been developed in which the label has been 
attached to either the first or second antibody.
One such antibody-labelled system is illustrated in Figure 1.2. 
In this procedure antigen from the sample is reacted with labelled first
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FIGURE 1.1
t h e  a n t i g e n l a b e l l e d 'CLASSICAL* IMMUNOASSAY
SYSTEM
>
Antigen i 
from sample '
Antibody
+
>
Labelled antigen
Antigen from sample 
bound to antibody
Labelled antigen 
bound to antibody
FIGURE 1.2
LABELLED ANTIBODY USED WITH SOLID PHASE ANTIGEN
>
Antigen “|“
from sample
Labelled
Antibody
Antigen from sample bound 
to labelled antibody
Solid phase 
antigen
Solid phase antigen bound 
to labelled antibody
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antibody. The non-reacted labelled antibody is then removed with 
insolubilised antigen and quantified. The amount of this unreacted 
antibody is inversely related to the antigen concentration in the
sample. When the label is a radioactive isotope, this system is referred 
to as an immunoradiometric assay.
Labelled first antibodies can also be used in a 'sandwich'
assay for antigen detection. In this system insolubilised antibody is 
incubated with the sample which contains the antigen, and then with 
labelled antibody. The amount of label bound to the solid phase is
proportional to the amount of antigen in the sample. This method, which 
is shown diagramatically in Figure 1.3, can only be used for antigens 
that are sufficiently large to bind with two antibody molecules.
Labelled second antibodies can be used in a 'sandwich' assay
for the detection of antibodies. In this system insolubilised antigen is 
incubated with sample containing the antibody to be measured, and then 
with labelled second antibody (i.e. antibody to the immunoglobulins of 
the species from which the sample originates). The amount of label bound 
to the solid phase is proportional to the amount of antibodies present 
in the test sample that were directed against the insolubilised antigen. 
Figure 1.4 illustrates this immunoassay system of antibody detection.
In some assay systems the antibodies are replaced by naturally 
occurring receptor proteins. Strictly speaking, these assays should be 
referred to as competitive protein-binding (CPB) assays rather than 
immunoassays. Although there are many similarities between the two types 
of assay, the use of antibodies does have distinct advantages over the 
use of natural receptor molecules (Van Vunakis, 1980). Antibodies are, 
for example, stable, soluble proteins with known physical and chemical 
properties. Procedures for the purification of antibodies are available, 
but in the majority of fluid phase assays the antisera is simply diluted 
for use. It has been estimated that an individual animal has the
potential to produce antibodies for approximately 10^ diverse 
immunodominant moieties (Kabat, 1980). These molecules may possess 
binding constants for individual antigens of the order of 10“^ to 
lO-l^M.
Over the last twenty years a wide range of atoms and molecules 
have been employed as immunoassay labels. The first assays developed
used radioactive isotopes in a technique which has become known as
radioimmunoassay. This group of methodologies is still the most widely 
employed immunoassay procedure, and as such, the advantages and
disadvantages of the technique deserve detailed consideration.
n
FIGURE 1.3
SANDWICH ASSAY FOR ANTIGEN DETECTION
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FIGURE 1.4
SANDWICH ASSAY FOR ANTIBODY DETECTION
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1.1.1 ADVANTAGES AND DISADVANTAGES OF RADIOIMMUNOASSAY
Radioimmunoassay (RIA) was first described by Yalow and Berson 
(1959, 1960) who developed an assay for insulin. The detailed procedure 
published in 1960 has become a 'citation classic* having been cited over 
one thousand times in the period 1961 to 1975. The work of Yalow and
Berson evolved from the authors' previous studies of I^^^-labelled 
insulin binding to insulin antibodies generated in insulin treated 
diabetics. An attempt to publish that work in the mid 1950's was 
rejected by the first journal to which it was submitted when the editor 
accepted the referee's comment that 'everyone knows that insulin does 
not elicit antibodies' (Yalow and Berson, 1971). The development of RIA 
from its modest genesis to its current state of maturity is a tribute to 
the wide applicability, sensitivity, specificity, accuracy and precision 
of this powerful technique.
Several different radioactive nucleides have been used to label 
antigens to a high specific activity. The most commonly used isotopes 
are (tj=2.3 years, approximately 30 Ci/milliatom at 100% isotope 
enrichment), or 1^25 (^-^=60 days, approximately 2200 Ci/milliatom). Less 
often used are I^^l (ti=8 days, approximately 6000 Ci/milliatom) and C^^ 
(ti=5100 years, approximately 62mCi/milliatom). The short half life of 
1^31 and the low specific activity of C^ '^  has limited their use in 
immunoassay procedures (Van Vunakis, 1980).
The value of RIA as an analytical technique is without
question; the Nobel Prize for Physiology or Medicine was awarded for it 
in 1977. However, despite its clearly recognised advantages over earlier 
methods, and the length of time that it has been in use, it suffers from 
some serious drawbacks. Both the advantages and the drawbacks of the 
technique are derived from the radioactive nature of the label.
Table 1.1 shows the advantages of radioimmunoassay as listed by 
Ekins (1978). The particular advantages of isotope methods are that the 
measurement of radioactivity (given even a simple counter) is extremely 
easy and reliable, and that the activity of the label is entirely
unaffected by changes in the physical or chemical environment in which 
the isotope is situated. Moreover, no significant radioisotopic
'background' is normally present in assay samples so implying that assay 
measurements are not affected by any spurious activity unrelated to the 
labelled molecules under observation.
Ekins (1978) also considered the disadvantages of 
radio-labelled assays and these are listed in Table 1.2. The particular
14
disadvantages are the health hazard posed by the radiation, the cost of 
radioisotopic manipulation and counting equipment, the limited shelf 
life of some isotopes and the fundamental requirement that free and 
bound fractions must be separated before the amount of label residing in 
each phase can be determined.
The action of ionizing radiation on living tissue is a subject 
of much debate, and an assessment of the risks caused by 'low-dose'
exposure is difficult to carry out. It appears at present that the risk 
to persons carrying out routine radioimmunoassays using pre-prepared 
reagents is of a lower order than other risks encountered in a clinical 
laboratory, such as the possible presence of hepatitis virus in the
samples under test. However, for those involved in the production of the 
raw isotopes, and for those who prepare their own radio-labelled 
compounds, there can be no doubt that the risks are real and cumulative. 
These dangers have prompted very restrictive laws and regulations for 
the distribution, use and disposal of radioactivity.
One feature of RIA listed in Table 1.2 which is not generally 
appreciated, is that in a reasonable counting time only a very small 
fraction of the labelled molecules are responsible for radioactive 
decay. The figure quoted in Table 1.2 for 1^25 means that for every 100
disintegrations that occur in a minute, 1.25 x 10^ atoms do not decay.
This is, in theory at least, a limiting factor with regard to 
sensitivity.
Other drawbacks include the chemical instability of some 
labels. This is caused by radioactive transmutation and by the 
degradative effects that decay emanations have on nearby molecules.
15
TABLE 1.1
ADVANTAGES OF RADIOACTIVE LABELS
1. Measurement of radioactivity is extremely simple and is 
unaffected by the chemical composition of the reaction milieu, 
or other environment factors.
2. Measurement of the magnitude of the radioactive signal does 
not limit assay sensitivity or precision in any contemporary 
technique.
3. Relatively simple and reliable radiolabelling procedures are 
now available. Many labelled compounds are commercially 
available.
4. Manual radioactive counters are relatively inexpensive. 
Automatic counters are efficient, simple and reliable.
5. Labels are of relatively small atomic dimensions and do not 
normally affect reaction kinetics.
(From: Ekins, 1978)
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TABLE 1.2
DISADVANTAGES OF RADIOACTIVE LABELS
1. Limited shelf life; variation of labelled compound from batch 
to batch.
2. A very small fraction of labelled molecules are observed 
during a count-time of acceptable duration (0.00008%/min for 
1^25), This could limit the sensitivity of some assays.
3. Separation of reacted and unreacted labelled compound is 
essential.
4. Real and imaginary health hazards and legal problems 
associated with the use of radioisotopes.
5. Unfamiliarity of staff with radioisotopes and counting 
equipment.
(From: Ekins, 1978)
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1.1.2 HOMOGENEOUS AND HETEROGENEOUS SYSTEMS
In radioimmunoassay, the label obeys the physical and
statistical laws of nuclear decay, and it is virtually unaffected by its 
physico-chemical environment. It is for this reason that RIA has always 
required a separation step to distinguish between the free and the bound 
phases. Systems in which the signal generated by the label is unaffected 
by its environment and which therefore require a separation step are 
referred to as 'heterogeneous* assays. The separation process usually
involves centrifugation after the addition of a reagent which will
selectively precipitate one of the two phases. The supernatant is then
removed by aspiration or décantation. Such a separation process is 
difficult to automate and has limited the development of 
radioimmunoassay. (In recent years various 'non-centrifugation* 
separation methods have been developed for use in heterogeneous assays 
such as RIA (Mattiasson and Ling, 1980; Mattiasson, 1980; Mattiasson and 
Eriksson, 1982; Cais and Shimoni, 1981 (a) and (b); Thorell, 1981; Smith 
and Gehle, 1980; Guesdon and Avrameas, 1981) but at the present time
none of these systems has been widely applied.)
Some labels, however, do respond to their chemical or physical 
environment, being affected by influences such as pH, ionic strength, 
the presence of quencher or potentiator substances, temperature and
magnetic fields. Various methods have been devised to modulate the
properties of these labels in order to produce non-separation or 
'homogeneous* immunoassays. Such a system is possible when the signal
generated by the labelled compound present free in solution can be
distinguished from the signal produced when the compound is antibody
bound. Homogeneous assays can be automated with relative ease, and the 
introduction of labels suitable for use in non-separation systems has 
been a major step forward in immunoassay development. The homogeneous
assays do have some disadvantages, particularly with regard to
sensitivity. These problems will be discussed later with particular 
reference to the homogeneous enzyme immunoassay methods.
1.1.3 NON-RADIOISOTOPIC IMMUNOASSAY
Alternatives to the use of radioisotopes for labelling in
immunoassay have been aggressively sought for many years. Miles and
Hales (1968) suggested that the sensitivity of an immunoradiometric
procedure for measuring insulin could be improved if the iodine label
was replaced by a compound which was capable of taking part in cycling
reactions. The authors listed enzymes, co-enzymes and viruses as 
possible candidates for this cycling role. The theoretical possibility
18
of increased sensitivity is one of the factors listed in Table 1.3 which 
shows in general terms the advantages of non-radioactive labels.
One of the fundamental advantages of such labels is that the 
labels themselves are relatively long lived. Provided that the molecules 
to which they are linked are stable, then the labelled reagents formed 
potentially possess a much longer shelf-life than those labelled with 
the shorter lived isotopes such as
Most labels possess no known health hazard, and this is a 
significant advantage, particularly in those countries in which 
regulations relating to the use of radioisotopes are especially 
stringent.
However, the use of non-radioactive labels is not without its 
disadvantages and some of these are listed in Table 1.4. The main 
disadvantage is that the activity of the label is vulnerable to 
environmental effects such as temperature and the chemical milieu in 
which the label is placed. It is also possible that other substances 
present in the assay incubation mixtures may stimulate or inhibit the 
signal generated by the label. In practice such effects set a lower 
limit to the amount of label that can successfully be employed, and 
render the measurement of the label itself a more difficult arid 
technically vulnerable operation than the measurement of radioactivity. 
The combined effect of these factors is implicitly a loss of assay 
sensitivity.
Such problems are most severe with homogeneous systems in which 
the signal generated by the label is measured in the presence of the 
biological fluid under test. The assay depends on the signal generated 
by the label being changed by specific antibody binding, but it is 
possible that non-specific actions due to the presence of the biological 
fluid will also influence the signal produced.
19
TABLE 1.3
ADVANTAGES OF NON-RADIOACTIVE LABELS
1. Long shelf life of label (though not necessarily of labelled 
reagent). This offers the possibility of wide distribution 
and assay standardisation.
2. Eliminates the need for radioisotopic processing facilities 
and equipment.
3. Some techniques permit the elimination of the need for 
physical separation of free and bound phases.
4. All labelled molecules may contribute to the signal so 
implying increased efficiency of label detection. With some 
labels cycling processes can allow 'amplification' of the 
primary signal.
5. Manual equipment for signal measurement is cheap and 
relatively familiar to staff. Some techniques are suitable 
for visual reading of results.
(From: Ekins, 1978)
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TABLE 1.4
DISADVANTAGES OF NON-RADIOACTIVE LABELS |
      : 1
1. Non-specific effects on the signal can arise in the incubation 
medium and lead to a loss of sensitivity, precision and 
accuracy.
2. Additional steps are required in some techniques for signal 
detection. This can make the systems more complex, 
time-consuming, expensive and liable to error than radioactive 
measurement.
3. Labelling and purification steps may be complex.
4. Some labels require detection equipment of high complexity and 
cost.
(From: Ekins, 1978)
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Interference from non-specific factors is less of a problem in 
heterogeneous systems as the measurement of the signal generated by the 
label takes places in a milieu from which the original biological sample 
has been removed.
Two more general limitations on the use of non-isotopic labels 
should be noted in this section. Firstly, the homogeneous techniques 
have only been widely applied to the assay of substances of small 
molecular size where the binding of the test substance to the specific 
antibody is most likely to affect the activity of the label to which it 
is linked. Recently homogeneous assays for macromolecules have been 
described (e.g. Gibbons e^ al. 1979 and 1980) but at the present time 
such assays are in the minority. Secondly, difficulties can arise in the 
use of non-radioactive labels because of their relatively large 
molecular size. Large labels can impede the reaction between the ligand 
and the specific antibody and may contribute in this way to a loss of 
both sensitivity and precision.
This introduction has discussed in general terms the advantages 
and disadvantages of radiosotopic and non-radioisotopic immunoassay 
procedures. The following section will consider in more detail some of 
the more frequently used non-radioisotopic labels.
1.2 NONISOTOPIC IMMUNOASSAY
The practical investigations carried out in this project 
concerned the development of new enzyme, and enzyme based, immunoassay 
systems. In order to evaluate the potential usefulness of the systems 
under development it is essential that the advantages and disadvantages 
of other available non-radioisotopic immunoassay techniques are 
considered.
1.2.1 BACTERIOPHAGES
Bacteriophages are viruses that infect living bacterial cells, 
replicate in them, and ultimately cause their lysis and death. 
Bacteriophages lose their capacity to infect cells when they are bound 
to specific antiphage, a process referred to as 'neutralisation*. It is 
also possible to neutralise bacteriophages by chemically coupling 
molecules to their surfaces and by reacting the resulting coupled 
product with an antibody that is specific for the attached molecules. It 
is this latter feature which has enabled use to be made of 
bacteriophages in a technique which has become known as viroimmunoassay.
When suitable bacteria are cultured in the absence of 
bacteriophages, they will grow on culture medium in a petri dish to form 
a dense carpet. In a culture infected by bacteriophages holes appear in
the carpet where the bacteria have been killed by lysis. The number of 
such holes, called 'plaques', is proportional to the severity of the 
infection by the bacteriophages and will be altered if some 
bacteriophages have been neutralised by antibody. Viroimmunoassays 
exploit these microbiological events to measure the concentration of 
haptens by competitive neutralisation of bacteriophage-hapten labels 
with antibody to the hapten.
Bacteriophage labels have been employed for some time, having 
been first used by Haimovich and Sela (1969) to measure both antibodies 
and antigens. Considerable sensitivity has been claimed for the 
technique. Andrieu ejt al. (1975) developed viroimmunoassays for the 
steriods oestradiol and progesterone and found that these assays were 
three times more sensitive than radioimmunoassays using tritiated 
steriods. The authors claimed that with such sensitivity, and with the 
use of automated counting of plaque formation, viroimmunoassay would
find application in both research and routine investigations.
However, when compared to other immunoassay systems available, 
the viroimmunoassay would appear to be excessively laborious, requiring 
a large number of manual manipulations even when automatic counting is 
employed. The technique is far from rapid, as incubations of twelve or 
more hours are required. It would seem that the disadvantages of this 
method outweigh any slight increase in sensitivity that can be obtained 
and it would appear unlikely that the technique will be widely used.
1.2.2 CHEMILUMINESCENCE LABELS
Luminescence immunoassays have been developed in which
luminogenic molecules are employed directly as labels or indirectly to 
quantify enzyme conjugates. Luminescence may be defined as the emission 
of light from a molecule following its electronic excitation through the 
absorption of any form of energy. The source of that energy 
distinguishes the categories of luminescent phenomena. Photon emission 
from a molecule that has undergone excitation as a result of absorbing 
energy derived from a chemical reaction is defined as chemiluminescence.
Bioluminescence is one special form of chemiluminescence in
which certain highly specialised proteins act as catalysts in the 
luminescent reaction. A notable example of this is the firefly 
luciferin-luciferase reaction in which ATP serves as the energy source.
Both chemiluminescence (Pratt et al., 1978; Velan and Halmann,
1978; Pazzagli et al., 1981 (a) and (b)) and bioluminescence (Schroeder
ejt al., 1976 (a); Wannlund e_t al., 1980) have been, and are being, used 
in the development of immunoassay procedures,
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The two papers published almost simultaneously in 1978 by Pratt 
et al. and Velan and Halmann each claimed to be the first demonstration 
of chemiluminescence immunoassay. However a study of the two 
publications reveals that the assays are based on fundamentally 
different principles.
Pratt al. (1978) developed a method which employed a
luminogenic molecule directly as a label by linking a luminol derivative 
to testosterone. In this assay system competition for antibody binding 
occurred between the labelled testosterone and testosterone in the 
sample under study.
The chemiluminescence of luminol has been known for some time 
(Albrecht, 1928) and a general scheme for the reaction of luminol is 
shown in Figure 1.5. Under the alkaline conditions typically employed in 
luminol assays, luminol exists in the form of a monoanion. However, 
primary catalysts such as hydrogen peroxide do not react appreciably 
with this form and therefore another catalyst or co-oxidant is required 
to convert luminol to a more reactive state. Such co-oxidants include 
free iron ions (Fe^*^), ferricyanide ions, or chelated iron in hematin 
compounds (Ewetz and Thore, 1976). Hydrogen peroxide then reacts with 
the luminol to form an unstable intermediate which readily decays to an 
electronically excited anion. This then relaxes to its ground state with 
concomitant photon emission,
Velan and Halmann (1978) used the ability of ckelated iron in 
hematin compounds to act as a catalyst in the luminol reaction scheme 
described above to develop the alternative approach to chemiluminescence 
immunoassay. This approach initially appears to be an enzyme immunoassay 
with a luminol based detection system, as the hapten to be læasured is 
labelled with a peroxidase enzyme. The technique has, in fact, been 
referred to as chemiluminescent enzyme immunoassay by some workers 
(Wilson, 1980; Arakawa et al., 1981). In this system it is the hapten 
enzyme conjugate which is involved in the immunological reaction, and 
the luminol is only present at a later stage, being used as a detection 
system to quantitate the peroxidase present after separation of the free 
and bound phases. Although in the immunological reaction the 
hapten-enzyme conjugates play the same role in both enzyme immunoassay 
and chemiluminescent immunoassay, there is a fundamental difference in 
the ultimate function of the peroxidase molecule as used in the two 
techniques. In enzyme immunoassay the conjugates are detected on the 
basis of the reaction between chromogenic substrates and active enzyme 
conjugates. In chemiluminescence enzyme immunoassay however, the
24
FIGURE 1.5
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peroxidase conjugates are employed merely to provide a source of haem as 
a catalyst in the chemiluminescence reaction. This is an important 
distinction since up to half of the enzyme activity of peroxidase may be 
lost during conjugate preparation (Boorsma et al., 1976). Destruction of 
enzyme activity will have an adverse effect on the sensitivity of enzyme 
immunoassay but this is not a problem in the chemiluminescence linked 
system since even if the peroxidase molecule is not enzymically active, 
the haem is still present to act as catalyst in the luminol reaction. In 
fact the haem is probably solubilised by the alkaline conditions 
employed during the luminol reaction (Neufeld _e£ al., 1965). This may 
account for the greater sensitivity of some chemiluminescence enzyme 
immunoassays as compared to corresponding enzyme immunoassay methods in 
which the enzyme activity is measured (Olsson et al., 1979). The number 
of such direct comparisons of the two methods is limited but one recent 
study showed that the chemiluminescence detection improved the 
sensitivity of peroxidase labelled immunoassay for antigens and 
antibodies by 16 to 95 fold as compared to absorptiometric end point 
methods (Pronovost and Baumgarten, 1982).
In the system in which chemiluminescence precursors are used 
directly as labels both heterogeneous and homogeneous methods have been 
described. Separations in heterogeneous systems, in which the signal 
generated by the label was not affected by the antibody binding, have 
been achieved by filtration or by the use of solid phase antibody (e.g. 
Pratt ejt al., 1978; Schroeder et al., 1978; Schroeder al., 1979;
Simpson et al., 1979; and Kim et al., 1982).
A system referred to as antibody-enhancement has been used to 
develop homogeneous chemiluminescence immunoassays. Schroeder _e£ al., 
(1976(b)) produced a method in which the activity of a biotin-isoluminol 
conjugate was enhanced about ten fold when bound to avid in. Such an 
enhancement in chemiluminescent intensity obviates the necessity of 
removing unbound conjugate. A four fold enhancement was found sufficient 
to develop a homogeneous assay for plasma progesterone (Kohen ejt al., 
1979).
One disadvantage of chemiluminescence is that chemiluminescent 
substrates often have low quantum efficiences (i.e. the number of quanta 
emitted/the number of molecules reacting). Typical values are from 1 to 
5% (Isaacsson and Wettermark, 1974). The modern bialkali photomulipliers 
can detect chemiluminescence from reactions which have quantum 
efficiencies as low as 1 x 10“^^% but the cost of such equipment is
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significantly higher than that of a simple photometer suitable for 
colorimetrically monitored enzyme immunoassays.
The advantages of chemiluminescence immunoassay include the 
stability of the labels and the fact that because few chemiluminescent 
substances occur in biological materials, the method encounters little 
interference. The additional advantages of homogeneous systems have 
already been discussed but even with the advantages of non-separation 
protocols, the cost of the hardware required to detect the emitted light 
may, in many laboratories, prevent the introduction of chemiluminescence 
based assay systems.
1.2.3 FLUORESCENCE LABELS
The use of fluorescent labels is one of the most active areas 
of non-radioisotopic immunoassay research. This activity arises, in 
part, from the fact that, like enzymes, fluorescent compounds can be 
incorporated into an immunoassay system in many different ways. 
Fluoroimmunoassay was reviewed by Soini and Hemmila (1979) and Visor and 
Schulman (1981), and both sets of reviewers subdivide fluoroimmunoassay 
in similar ways.
As for chemiluminescent labels, both heterogeneous and 
homogeneous assay systems have been developed.
The majority of the research and development effort has been 
concentrated in the area of homogeneous assays in which separation is 
not required because of the effects exerted upon the label by the 
different micro-environments in which the free and bound ligands 
reside. In the aqueous environment, the free labelled antigen 
experiences strong polarising forces as a result of interactions with 
the water molecules, and the rotation of certain functional groups on 
the fluorophore is possible subsequent to the fluorescent emission. 
However, in the hydrophobic environment of an antibody binding site, the 
dielectric strength is low, and the rotation of functional groups on the 
fluorophore is severely restricted. Generally speaking, the binding of 
the antibody causes the label to fluoresce at a shorter wavelength. The 
weak solvation and restricted rotational freedom can also cause the 
label to fluoresce more intensely than the free label because the 
antibody shields it from internal and external conversions which compete 
with fluorescence for deactivation of the excited state. These effects 
of antibody binding have been used to develop a variety of homogeneous 
systems.
The three major types of homogeneous fluoroimmunoassay involve
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the measurement of fluorescence enhancement, quenching or polarisation. 
A fourth technique, known as reactant labelled fluoroimmunoassay, will 
be discussed later in section 1.3.4.
(i) Fluorescence Enhancement Methods. In many instances, as was 
described above, the binding of a labelled hapten to the antibody 
enhances the fluorescence because the label enters a less polarised 
environment. Such environment sensitive probes are widely used, for 
instance in the measurement of conformational changes in enzymes. 
Although fluorescence enhancement has been used to develop immunoassay 
methodologies (e.g. Smith, 1977) it is not suited to situations in which 
the excitation and emission wavelengths of the labels employed are
similar to those producing background fluorescence in the presence of 
serum (Visor and Schulman, 1981). This problem limits the sensitivity of 
such methods.
(ii) Fluorescence Quenching Methods. In these systems the 
binding of the labelled antigen to the antibody results in a quenching 
of the fluorescence emitted by the label. This quenching may simply be 
due to antibody binding (e.g. Shaw et al., 1977), or may be due to the 
presence of a chemical quencher in the antibody. In the method described 
by Ullman e_t al. , (1976) the quenching compound joined to the antibody 
was a dye called rhodamine. The rhodamine was used to absorb the
emission from the fluorescein labelled hapten. This method is also
referred to as fluorescence excitation transfer immunoassay and in the 
direct method the antigen present in the sample under study prevents 
quenching of the fluorescence by occupying antibody binding sites. In a 
variation of the method, half of the antibodies are labelled with 
fluorescein and half with rhodamine. This technique, also developed by
Ullman e_t al. (1976), is only suitable for polyvalent antigens capable 
of binding to two antibodies, but it does not require the production of 
labelled antigen. When the antigen binds both antibodies, the
fluorescein and the rhodamine are held so that energy transfer, and
hence fluorescence quenching, can occur. The use of fluorescein and
rhodamine has some disadvantages including the instability of
rhodamine-antibody conjugates (Lim e£ al., 1980(a)), and it has been 
suggested that fluorescamine and fluorescein would be a better pair of 
labels for an energy transfer immunoassay (Miller e_t , 1980).
As with all homogeneous assays, such fluorescence quenching 
methods are suitable for automation (e.g. Lim et al., 1981(b)) but the 
method does require two conjugation or labelling reactions and, like all
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homogeneous fluorescence systems, the background interference resulting 
from the presence of the biological material may limit the sensitivity,
(iii) Fluorescence Polarisation Methods. Fluorescence 
polarisation methods were first described by Dandliker (1964),
and are suitable for the measurement of both antigens and antibodies. In 
this technique the sample under test is excited with polarised light 
after being mixed with a solution containing the labelled compound, and 
the degree of polarisation of the emission is measured. As the labelled 
antigen binds to the antibody its rotation slows down and the degree of 
polarisation of the emitted light increases. The method requires a 
fluorescent label with a relatively long lifetime (>20ns) so that the 
rotation can be measured. Most fluorescence polarisation methods have 
employed fluorescein as the label (e.g. Watson al. , 1976) but
recently a derivative of umbelliferone has also been used (Li e^ al., 
1981). The major disadvantage of the polarisation method is that it has 
a narrow dynamic range of polarisation values over which the standard 
curves are obtained. The conditions of the assay therefore require 
careful optimisation. Polarisation measurement is not as straightforward 
as fluorescence intensity measurement and laborious manipulation can be 
involved if the equipment used is not specifically designed for the task 
(Li e^ al., 1981). As with other fluorescence methods, background
interference may place a limitation on the sensitivity that can be 
obtained.
There is one other homogeneous system which deserves mention 
but which does not fit into any categories described above. This is the 
use of antibodies against the label itself. The technique was developed 
by two groups almost simultaneously and was referred to as * indirect 
quenching fluoroimmunoassay* by one group (Nargessi al., 1979) and
"fluorescence protection immunoassay" by the other (Zuk al., 1979). 
Both groups labelled an antigen with fluorescein in such a way that 
binding of the labelled antigen to antibodies raised to the antigen did 
not affect the fluorescent activity of the fluorescein. This activity 
was inhibited by anti-fluorescein antibodies, but these could not bind 
to labelled antigens which were already bound to antibodies raised to 
the antigen. Competition from antigen in the sample under test for 
antibody binding released more of the labelled antigen for quenching by 
the anti-fluorescein antibodies.
In all of the homogeneous fluoroimmunoassay methods described 
above the sensitivity is limited by the high background signal generated
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by the presence of proteins in the biological fluid being examined. 
Therefore, despite the speed and simplicity of the homogeneous methods, 
it is occasionally desirable to carry out fluoroimmunoassays in a 
heterogeneous manner. In such cases the separation of free and bound 
phases can be achieved by using methods commonly employed with other 
labels, such as precipitation of the bound form using ammonium sulphate 
or second antibodies, or the use of solid phase linked reagents.
In conclusion it is clear that fluoroimmunoassay is one of the 
more fruitful areas of non-radioactive immunoassay development. 
Homogeneous systems have been developed which are based on a variety of 
principles, but all suffer to some extent from background interference 
which may limit the sensitivity that can be obtained. Many of the 
techniques require only a simple fluorimeter and this has been an 
important factor in their increasing use. This use may be expected to 
increase further if the development of improved labels and automated 
techniques continues.
1.2.4 PARTICULATE LABELS
The majority of immunoassay labels are soluble in the assay 
media in which they are used. However, a number of systems have been 
devised in which the labelling component is either a solid particle or a 
hollow microsphere. Some particulate labels provide assay systems of 
high sensitivity and some are suitable for use in homogeneous protocols.
Hollow particulate vessels that have been used in immunoassay 
procedures include liposomes (Brinkley e^ ^ . , 1979), microspheres
(Rembaum and Dreyer, 1980), and erythrocytes (Nakane, 1980). The hollow 
vessels are filled with reagents such as fluorescein or haemoglobin. The 
process of antigen-antibody binding affects the particulate vessel in 
some way so producing a change which can be measured. This change may be 
in the fluorescent activity of the contents or it may involve lysis of 
the vessel and the release of the contents.
The most important particulate labels however, are not hollow 
but solid. The two types most frequently employed are sols and latex 
particles.
Sol particles are colloidal or near colloidal suspensions of 
elemental metals or inorganic compounds. The sol suspensions often have 
an intense colour. The colour, and the intensity of that colour, is 
dependent upon the particle size of the sol suspension. This feature is 
utilised in the colorimetric detection methods that can be employed in 
sol particle immunoassay. Provided that the sol particles are prepared
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from elements not found in biological specimens (e.g. gold, silver or 
barium) the sols may also be detected using atomic absorption 
techniques. This detection method can provide assays of high 
sensitivity.
Quantitative immunoassay using sol particles was described by 
Leuv^ing ^  al. (1980) who used sol particles in a heterogeneous system 
with both colorimetry and atomic absorption employed as detection 
methods. The sensitivity using atomic absorption was equal to that of 
radio-labelled techniques and the colorimetric assay, while being four 
times less sensitive was still an improvement on available enzyme 
immunoassay methods. In the same publication Leuvering ^  al. referred 
to the development of a simultaneous dual assay. In this system, which 
was much less sensitive than single hormone methods, 
anti-choriomammotropin was labelled with silver sol, and anti­
choriogonadotropin with gold sol. Both metal labels were measured in a 
single sample incubation using atomic absorption. The same workers later 
developed a homogeneous colorimetric sol particle immunoassay for human 
choriogonadotropin (Leuvering et al., 1981). The use of sol particles is 
an interesting recent development in immunoassay and may increase in 
importance in the future. The homogeneous system seems a candidate for 
automation, and, providing adequate sensitivity can be achieved without 
the need to employ the expensive atomic absorption detection system, 
then this technique may soon compete with more established næthods.
Latexes have also found application in immunoassay. Polystyrene 
latex particles are used in particle counting immunoassay (FACIA), a 
technique first described by Cambiaso e^ al. (1977). The method is 
suitable for the quantitation of both antibodies and antigens and 
involves the use of a blood cell counter to measure the reduction in the 
number of particles which results from particle agglutination. The FACIA 
system has been adapted to the Technicon automated assay equipment 
(Collet-Cassart et al., 1981) (a) and (b); Limet et al., (1982)). The 
sensitivity of the assay method is however limited by serum interference 
(Schall and Tenoso, 1981). High sensitivities have been reported for 
latex based systems in which the earliest stages of agglutination were 
detected using anisotropic light scattering techniques (Von Schulthess 
et al., 1980).
Both latexes and sols would seem to hold potential for the 
future of immunoassay. Both are suitable for automation in that 
homogeneous systems have been developed. However, if high sensitivity is 
required, then both of the techniques demand the use of relatively
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sophisticated detection methods, and this may prove a limitation on the 
use of these particles as immunoassay labels.
1.2.5 METAL ATOMS
The use of metal atoms as labels has been described by Cais
et al., (1977). The atoms are used in the form of organo-metallic or
co-ordination compounds and are detected by atomic absorption after 
separation of the free and bound phases. The assay has been used to 
measure both antigens and antibodies, but, as the process of 
antigen-antibody binding has no effect on the signal generated by the 
label, the technique can only be used in the heterogeneous mode. This is
a serious disadvantage of the method, and, together with the cost of
atomic absorption equipment, may set a limit to the use of this 
technique.
1.2.6 STABLE FREE RADICALS
Electrons possess a rotational property called spin, and in 
both atoms and compounds, the electrons tend to associate themselves in 
pairs, such that their spins neutralise each other. However some atoms 
and compounds possess unpaired electrons and when held in a suitable
magnetic field and excited by the right frequency of radio waves, then 
these absorb and scatter energy by resonance. The resonant absorption of 
unpaired electrons may be altered by changes in the immediate chemical 
environment, such as occur when antibodies bind to nearby antigenic 
determinants. These changes can be detected by electron spin resonance 
spectroscopy and have been used as the basis for homogeneous 
immunoassays (Leute et al., 1972 (a) and (b)).
Assays involving direct measurement of spin labelled compounds 
were adequate only for haptens present in relatively high concentrations 
(0.1 to 1 pmol/litre) and the labels tended to be rather insoluble. This 
led to the development of a modification of the technique \diich combined 
the features of spin labelled and liposome immunoassays. The method, 
which was developed by Chan ^  al., (1978), is called spin membrane
immunoassay and involves the production of liposome labels containing 
compounds with unpaired electrons. When the liposome labelled antigen 
binds to the specific antibody in the presence of complement, the 
liposome is lysed and the contents are released. This produces a greatly 
amplified spin signal, and in the work of Chan e^ £l. (1978) it was
found that antibody affinity rather than label detection was the factor
which limited the sensitivity of the assay.
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The cost of the equipment required for the detection of spin 
labels, and the limited sensitivity of the direct measurement techniques 
have been factors limiting the widespread use of spin labels in 
immunoassay.
1.2.7 CONCLUSIONS
In the last 20 years many non-radioisotopic immunoassay labels 
have been developed, and the brief discussion above is far from 
comprehensive. However, the few examples given do indicate the variety 
of methodology that has been produced. Many of the labels mentioned in 
this section have the potential for automation in that a separation step 
is not required, but such homogeneous methods often are prone to 
interference from the biological material present in the final assay 
mixture and in many cases this interference sets a limit to the 
sensitivity that can be achieved. Many of the labels require only simple 
detection equipment which would be found in all clinical chemistry 
laboratories, while others would require capital investment for 
specialised detection devices. In situations where finance is limited, 
it is the labels that can be measured with existing available hardware 
that will find the most widespread use. In some laboratories the
technical expertise available may be limited, and this may also prevent 
the introduction of new methodologies.
If enzyme immunoassay techniques are to play a significant role 
in the future then they must be shown to have advantages not only over 
the use of radio labels, but also over the other available
non-radioisotopic labels, such as those discussed above. It is in this 
context that the advantages and limitations of enzyme immunoassay, and 
enzyme-based immunoassay methodologies will now be considered.
1.3 ENZYME IMMUNOASSY
1.3.1 INTRODUCTION
The use of enzymes as labels in what is known as enzyme
immunoassay, or EIA, is one of the more promising of the 
non-radioisotopic techniques. The subject has been extensively reviewed 
(Sharpe al., 1976; Wisdom, 1976; Schuurs and Van Weemen, 1977 and 
1980; Belanger, 1978; Voiler ^  al., 1978; O'Beirne and Cooper, 1979; 
O'Sullivan ^  al., 1979; Van Weemen ^  al., 1979; Oellerich, 1980;
earlier ^  , 1981; Yolken, 1982).
In section 1.1.3 the advantages and disadvantages of 
non-radioisotopic labels were discussed in general terms. Considering
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EIA in more detail now, more specific comments can be made. Tables 1.5 
and 1.6 list these more specific advantages and disadvantages.
Both heterogeneous and homogeneous EIA systems are possible. As 
for the other labels, the homogeneous methods have the advantage of ease 
of automation but tend to suffer from restricted sensitivity.
The enzyme chosen as a label in EIA should ideally possess the 
qualities shown in Table 1.7. In practice, few, if any, enzymes possess 
all these properties. The choice of enzyme is dictated by the nature of 
the assay. For instance, in heterogeneous assays the enzyme activity is 
measured on the washed bound phase, and therefore endogenous enzyme 
activity and interfering factors derived from the biological sample 
under test will be removed prior to measurement of the bound enzyme 
label, and the absence of such influences from the biological fluid is 
not an absolute requirement. However, homogeneous methods will be more 
susceptible to this type of interference and therefore it is desirable 
that the enzyme selected for use in such systems is absent from, and 
unaffected by factors present in, the biological fluid to be studied. 
The sensitivity required also affects the choice of enzyme. Lysozyme has 
been used as a label to detect a number of drugs present in the urine in 
the mg/litre range (Rubenstein jet al., 1972; Schneider e£ al., 1973), 
but owing to the low specific activity of the enzyme, it would not be 
suitable for assays which required greater sensitivity.
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TABLE 1.5
ADVANTAGES OF ENZYME LABELS
1. Sensitive assays can result from the amplification effect of
the enzyme.
2. Reagents are relatively cheap and can have a long shelf life.
3. A variety of enzymes can be used as labels. In consequence:
(a) multiple simultaneous assays should be possible
(b) labels may be prepared using a wide variety of 
conjugation techniques
(c) a number of systems for detecting enzyme activity 
may be used
4. Equipment can be inexpensive and is widely available.
5. No radiation hazards occur during labelling or disposal of
wastes
6. Homogeneous assays are readily automated and can be rapid. 
(From: O'Sullivan et al., 1979)
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TABLE 1.6
DISADVANTAGES OF ENZYME LABELS
1. Measurement of enzyme activity can be more complex than the
measurement of the activity of some types of radioisotopes
2. Enzyme activity may be affected by plasma constituents.
3. At present the homogeneous systems have only limited
sensitivity
(From; O'Sullivan et al., 1979)
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TABLE 1.7
CRITERIA FOR CHOICE OF AN ENZYME-LABEL
1. Availability of purified low-cost homogeneous enzyme 
preparations
2. High specific activity,
3. Presence of residues through which the enzyme can be cross- 
linked to other molecules with minimal loss of both enzyme and 
antigen activity.
4. Stable enzyme conjugates.
5. Enzyme absent from biological fluid.
6. Assay method that is simple, cheap, sensitive, precise and not
affected by factors present in biological fluids.
7. Enzyme, substrate, co-factors etc., should not pose a
potential health hazard
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1.3.2 HETEROGENEOUS ENZYME IMMUNOASSAY
Heterogeneous EIA as an analytical technique originated more 
than ten years ago in the work of Van Weeman and Schuurs (1971) and 
Engvall and PerImann (1971). The principles behind the various assay 
protocols are identical to those in which other labels are employed, and 
EIAs have been developed using each of the four systems illustrated in 
Figures 1.1 to 1.4 .
Competitive EIA for antigen (Figure 1.1) is analogous to the 
classical radioimmunoassay and involves competition between labelled and 
unlabelled antigen for a limited amount of specific antibody (e.g. 
Engvall et al., 1971). As with the radioimmunoassay system, a
sequential addition variation of this method is possible in which the 
addition of the labelled antigen is delayed until the binding between 
the antibody and unlabelled antigen is complete (e.g. Berlanger et al., 
1976).
Figure 1.2 shows the principle of the immunoenzymometrie assay 
in which the enzyme labelled antibody is reacted with antigen from the 
sample and then excess solid phase antigen is added. The enzyme 
activity bound to the solid phase is inversely proportional to the 
concentration of free antigen (e.g. Maiolini et al., 1975).
In the sandwich assay for antigen, solid phase antibody is 
incubated with the antigen to be measured. The solid phase is then 
washed and enzyme labelled antibody is added. The enzyme activity 
attached to the solid phase is proportional to the concentration of 
antigen (e.g. Clark and Adams, 1977). The principle of this method is 
shown in Figure 1.3.
The sandwich assay for antibody detection (Figure 1.4) has also 
been employed with enzyme labels (Engvall and PerImann, 1972). In this 
technique the amount of enzyme activity bound to the solid phase is 
proportional to the amount of an antigen-specific antibody present in 
the sample.
As well as the four techniques detailed above, an heterogeneous 
EIA for antigen has been demonstrated using enzyme labelled second 
antibody. In this method free antigen prevents antigen-specific 
antibody from binding to solid phase antigen. Thus the amount of enzyme 
labelled second antibody bound to the solid phase is inversely 
proportional to the quantity of free antigen in the sample (Gnemmi et 
al., 1978). This method has the advantage that one label can be used to 
measure any antigen for which a suitable first antiserum is available.
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The choice of separation method in heterogeneous EIA is limited 
by the large size of the enzyme label. This precludes the use of 
methods such as charcoal separation which are based on differences in 
molecular weight. Separation methods which have been employed include 
the use of second antibodies (e.g. Miyai al., 1976), covalent
chromatography (Yamamoto e£ al., 1981), polyacrylamide-agarose beads
impregnated with iron oxide and linked to either antigen or antibody 
(Guesdon and Avrameas, 1977; Guesdon et al., 1978 (a) and (b)) and solid 
phases. A variety of solid phases have been used. Some, such as 
cellulose, agarose and polyacrylamide particles require centrifugation 
and as such have little advantage over the use of second antibodies. It 
is, however, in the use of solid supports in which no centrifugation is 
needed that the heterogeneous EIA methods have made most impact.
The use of such solid supports in both competitive and 
non-competitive techniques has been given the name Enzyme Linked 
Immunosorbent Assay (ELISA) by Engvall and PerImann (1971). ELISA has 
been used with enthusiasm, particularly by those working on infectious 
diseases, where the need is often for the measurement of antibodies. 
The indirect sandwich assay illustrated in Figure 1.4 has proved 
particularly applicable. The solid support most frequently used in the 
large scale screening work required in the study of infectious diseases 
has been the microtitration plate (Voiler et al., 1974). These plates
are cheap, require only small volumes of reagents and can be used 
directly with suitable colorimeters (Clem and Yolken, 1978). An 
inexpensive, portable, battery operated photometer for reading ELISA 
tests in microtitration plates has been developed by Rook and Cameron 
(1981). Antigens and antibodies have also been absorbed to the walls of 
spectrophotometric cuvettes and used in single tube ELISA methods in 
which the enzyme activity was determined directly using reaction rate 
analysis (Chooi, 1980; Tsang et al., 1980).
One novel approach to heterogeneous EIA recently described is
the use of tagged enzyme-ligand conjugates (Ngo and Lenhoff, 1981). In
this assay the insoluble phase is provided by a receptor to the tag 
which has been linked to the enzyme-ligand conjugates. The receptor is 
insolubilised by being joined to Sepharose.
Competition for antibody binding occurs between free ligand
from the sample under test and the tagged enzyme-ligand conjugates. 
Antibody binding serves to mask the tag on the conjugates so that it can 
no longer bind to the insolubilised receptor. Accordingly, the amount 
of enzyme activity associated with the insoluble fraction is
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proportional to the amount of free ligand in the sample under test. The 
model system used biotin as the tag and immobilised avidin as the 
receptor. The major advantage of this system is that the insolubilised 
receptor is a 'universal* separation reagent and can be used for any 
ligand or enzyme provided the enzyme is linked to the same tag. The use 
of a solid phase receptor would eliminate the centrifugation process and
be an additional advantage of the technique.
A novel separation method for use in a heterogeneous EIA was 
reported by Monji and Castro (1979) and Castro and Monji, (1981). These 
workers used (3-galactosidase as a label and an insoluble pseudosubstrate 
of the enzyme, agarose-aminocaproyl-p-galactosylamine, to separate the 
phases, in assays for human choriomammotropin and thyroxine. Monji and 
Castro referred to their assay as Steric Hindrance Enzyme Immunoassay 
(SHEIA). The system begins with the liquid phase incubation of enzyme 
labelled hormone, sample containing the free hormone to be measured, and 
antibody. When the incubation is complete, the insolubilised 
pseudosubstrate is added. The hormone-enzyme conjugate which is
antibody bound, is prevented from binding to the pseudosubstrate by
steric hindrance, whereas the conjugate which is not antibody bound can 
reversibly attach to the pseudosubstrate. Either the bound or free 
enzyme activity can be measured and used for the quantitation of the 
hormone being studied.
One other variation of the solid phase technique which deserves 
mention is the Thermometric Enzyme Linked Immunosorbent Assay (TELISA). 
In this method the enzyme reaction is monitored not by substrate-product 
colour change but by measuring the heat produced by the reaction in a 
continuous flow system (Borrebaeck et al., 1978).
Too many variables are involved to allow general statements as 
to the sensitivity of heterogeneous EIA in comparison with other 
immunoassay techniques (Schuurs and Van Weemen, 1977). The importance 
of some such variables has been investigated in the EIA of steroids 
(Joyce e^ al., 1978). These workers found that the sensitivity was 
influenced both by the separation method used and the molar ratio of 
steroid to enzyme in the conjugate employed.
Statements have been made that radioimmunoassay is always more 
sensitive than EIA (e.g. Watson, 1976; EJcins, 1976) but much of the 
experimental data reviewed by Schuurs and Van Weemen in 1977 showed that 
such a generalisation was not justified. Indeed, with the use of 
fluorescent detection methods, the potential sensitivity of EIA is 
high. Using |3-galactosidase, one group of workers have been able to
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measure one attomole (10”^® mol.) of ornithine- S -aminotransferase by 
careful assay (Kato ££ al., 1977; Ishikawa and Kato, 1978). Another 
group of workers used a fluorogenic substrate with alkaline phosphatase 
and were able to detect attograms of antigen (Shalev ^  al., 1980),
while Hosli ^  al. (1978) used an ultra-micro scale method to determine
1,000 antigenic determinants in single cells. Of course, many EIAs 
described in the literature are less sensitive than the corresponding 
radioimmunoassays but it does not seem that this difference is caused by 
factors inherent in the two types of assay (Schuurs and Van Weemen,
1980). Certainly for large molecules the two techniques are comparable 
in performance, and even for small molecules, where the attachment of a 
label of high molecular weight, such as an enzyme, would theoretically 
influence the reactivity of the molecule more than the presence of the 
smaller radioisotope, the observed sensitivity is not always less than 
that seen for radioimmunoassay.
One final point should be made in reference to heterogeneous 
EIA, and this is that although serum factors are removed prior to the 
measurement of enzyme activity and cannot therefore interfere in that 
reaction, interference in the immunological process of an heterogeneous 
EIA system has been noted (Kato et al., 1979). The inclusion of
digested gelatin in the reaction buffer was found to remove this
interference (Kato e£ ad., 1980) but the two publications by Kato et 
al., serve as a useful reminder that even in heterogeneous systems, the 
presence of serum factors may produce undesirable non-specific effects.
1.3.3 HOMOGENEOUS ENZYME IMMUNOASSAY
The Enzyme Multiplied Immunoassay Technique (EMIT) is the most 
widely used homogeneous enzyme immunoassay system. The assay principle 
is shown in general terms in Figure 4.1. The technique was introduced 
by Rubenstein al., (1972) and depends upon a change in the specific
enzyme activity when antibody binds to enzyme labelled antigen. The
activity of the unseparated assay mixture corresponds to the proportion 
of enzyme labelled antigen to which antibody is bound.
Three distinct variants of the EMIT principle have been devised 
and applied commercially. The earliest EMIT systems (Rubenstein et al., 
1972) employed lysozyme as the enzyme label. The natural substrate for 
this enzyme is the peptidoglycan of the cell wall of certain bacteria. 
When lysozyme acts on a suspension of Micrococcus luteus the turbidity 
of the suspension is reduced, thus providing a convenient measure of 
enzyme activity. Lysozyme-hapten conjugates are active with the
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bacterial suspension but when hapten antibodies bind to an enzyme-hapten 
conjugate, a steric barrier is presented to the bulky substrate. 
Antibody binding in this way can inhibit up to 98% of the enzyme 
activity (Growl ^  al., 1980), This effect is employed in the EMIT
assays for drugs of abuse (Schneider et al., 1973).
Enzymes with small substrates have also been successfully used 
in EMIT assays. Hapten conjugates of glucose-6-phosphate dehydrogenase 
and malate dehydrogenase were found to be inhibited up to 80% by excess 
hapten antibodies. The mechanism in the case of malate dehydrogenase 
was investigated by Rowley je£ al. (1975) who concluded that the 
inhibition was due to conformational effects. It is most likely that an 
inhibitory conformational change is induced by the antibody binding to 
haptens linked to certain active groups on the enzyme surface, although 
an alternative explanation would be that a conformational change 
required for activity is prevented as a result of the antibody binding 
(Growl et al., 1980). The dehydrogenase enzymes are used in this way in 
the EMIT assays for therapeutic drugs (e.g. Pippenger et al., 1975).
In the lysozyme and dehydrogenase based assays described above, 
antibody binding results in an inhibition of the activity of enzyme 
hapten conjugates. There is one EMIT assay, however, in which antibody 
binding stimulates the activity of the conjugate. This in the assay for 
thyroxine. In this method, the conjugation of thyroxine to malate 
dehydrogenase results in a substantial inhibition of enzyme activity. 
The binding of the thyroxine antibodies to the conjugate can, in certain 
circumstances, partly reverse the inhibition.
These complex phenomena have been studied in detail by Ullman 
et al., (1979), and have been used as the basis for the assay for
thyroxine ( Jaklitsch ^  , 1976).
Until recently the EMIT system had only been applied to small 
molecules, but Gibbons et al. (1979) investigated the use of the 
technique to measure proteins. They realised that the conformational 
effects of the binding of the antibody to the enzyme-linked antigen (as 
utilised in the dehydrogenase based systems) were likely to be much 
smaller when the antigen was a protein rather than a small molecule. 
Steric considerations restricted the number of protein molecules that 
could be attached to an enzyme molecule. Using a conformational change 
based system, the antibody binding to the protein would need to exert 
effects across the bulk of the antigen. Preliminary experiments with 
dehydrogenase protein conjugates confirmed the expectation that antibody 
binding would cause only weak inhibition (Growl et al., 1980). It
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seemed more likely that the steric exclusion of a macromolecular 
substrate (as utilised in the lysozyme based systems) would be of use in 
the measurement of proteins provided that the presence of the antigen 
proteins attached to the enzyme did not prevent the substrate reaching 
the active site. The enzyme [3-galactosidase was selected for use 
because of the absence of serum activity at the pH optimum of the 
bacterial enzyme used for conjugation, and because the enzyme has been 
shown to retain its activity even after conjugation to protein (Kitagawa 
and Aikawa, 1976). The substrate o-nitrophenyl-galactoside was 
converted to a macromolecular form by attachment to a dextran carrier 
via a hydrophobic spacer. Inhibition of enzyme activity was observed up 
to a maximum of about 80% as a result of the addition of excess antibody 
and this provided the basis for the homogeneous assay of free antigen. 
The expansion of the EMIT system to enable large molecules to be
measured is a significant improvement in its usefulness.
Another novel assay recently produced by the same group of
workers is 'enzyme enhancement immunoassay* (Gibbons al., 1981).
This is an assay specifically for polyvalent ligands and antibodies and 
avoids the need to label the antigen. The technique involves antibodies 
labelled with p-galactosidase, succinylated antibodies, and a
macromolecular form of the o-nitrophenyl-galactoside substrate.
The enzyme-labelled antibody and the succinylated antibody form an
immune complex in the presence of sample antigen. An enzyme within this 
negatively charged microenvironment forms a product that gives a second 
light-scattering phase, whereas the product formed by free enzyme 
remains soluble. Thus the amount of antigen in the sample under test 
modulates the rate of increase of light-scattering.
Two other variations of the EMIT system are * enzyme channelling 
immunoassay* and the use of an *end-point* approach. In enzyme 
channelling immunoassay, glucose-6-phosphate dehydrogenase and 
hexokinase are placed adjacent to each other by the immune reaction. 
The conversion of NAD and NADH will occur (in the presence of glucose 
and ATP) when the two enzymes are in solution, but the overall reaction 
rate is greatly increased when the two enzymes are bound in close 
juxtaposition. (Litman et al., 1980). The end-point approach to the 
EMIT assays (Yoshida ^  al., 1980) involves the use of antibodies
against the enzyme label to completely inhibit enzyme activity. The 
assay was published only in abstract form and the details of the method 
cannot be determined, but it is possible that a system similar to the 
use of antibodies against fluorescent labels (Nargessi et al., 1979; Zuk 
et al., 1979) has been developed.
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The major advantage of the EMIT system is that it can be 
automated with relative ease. The commercially available 'kit' method 
has been adapted for use with centrifugal analysers (Lasky et al., 1977; 
Finley £t al., 1977 and 1980(a); Lâcher e£ al., 1980(a) and (b);
Izquierdo et al. , 1982), continuous flow systems (Nolan et al., 1981), 
and automated kinetic reaction equipment (Galen and Forman, 1977; 
Eriksen and Anderson, 1978; Finley and Williams, 1978; Cruse, 1979, 
Bhatia, 1980; Dietzler et al., 1980).
As with other homogeneous immunoassays, the EMIT method is 
prone to interference from non-specific factors present in the 
biological fluid under test. Interference has been shown to occur due 
to the presence of hyperlipidaemia (Ying ^  al., 1981), myeloma
immunoglobulin (Alexander ^t al., 1980) and excess sodium chloride in 
urine samples (Kim and Cerceo, 1976; Anderson and Eriksen, 1977). This 
last effect is due to an increase in ionic strength and produces false 
negative results. Salt has been added to urine samples by drug addicts 
wishing to avoid detection by the EMIT drugs of abuse assays (Kim and 
Cerceo, 1976).
1.3.4 ENZYME-BASED IMMUNOASSAY
The various ways in which enzymes have been employed directly 
as immunoassay labels have been discussed above. However, molecules 
acting with or upon enzymes (often referred to collectively as 'enzyme 
associated substances' or EAS) have also been used as immunoassay 
labels. Such assays depend on the steric hindrance caused by antibody 
to the hapten-EAS conjugate modulating the enzyme activity by altering 
the natural function of the EAS with the enzyme.
Enzyme cofactors, prosthetic groups and substrates have all 
been shown to be suitable for use as enzyme associated substance labels 
in the development of homogeneous immunoassay systems.
The use of enzyme cofactors was introduced in two consecutive 
publications (Carrico al., 1976; Schroeder ^  al., 1976(a)). The 
technique takes advantage of the amplifying effects of enzymic cycling. 
The method requires that the ligand-cofactor conjugate be active in 
enzyme catalysed reactions, and that the activity be modified when the 
ligand is bound to a specific protein. In the published methods, 
ligands were conjugated to nicotinamide 6-(2-aminoethylamino)purine 
dinucleotide (AENAD), a derivative of nicotinamide adenine dinucleotide 
(NAD). The conjugate was active with dehydrogenases with a reduced form 
of the confactor conjugate being produced (i.e. ligand-AENADH). The 
ligand-AENADH was then recycled, its oxidation being responsible for the
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formation of either reduced thiazolyl blue (Carrico ^  al., 1976), or 
bioluminescence via a luciferase reaction (Schroeder e^ al., 1976(a)). 
The publication of Schroeder e£ al. detailed the development of both 
competitive protein binding and antibody based immunoassay systems. The 
cofactor cycling system employed in the initial studies gave about 200 
cycles per hour with the conjugates (Carrico et al., 1976). The use of 
cycling systems with higher cycling rates would improve the sensitivity 
of the assay, and alcohol dehydrogenase, which has been used to cycle 
NAD at 30000 cycles/hour, was used in the later studies (Schroder ^  
al., 1976(a)).
The assay is homogeneous, rapid (using bioluminescence 
incubations of only one minute were required) and has the potential for 
the production of sensitive assays. '
Use of a prosthetic group as a label in immunoassay could also 
lead to the development of sensitive systems, again because of the 
amplifying effect of the enzyme. Such a method for the detection of 
haptens was reported by Morris ^  al. (1981). In their method the 
prosthetic group was joined covalently to the ligand in such a way that 
the conjugate was able to combine with inactive apoenzyme to form the 
active holoenzyme. The assay can be carried out without the need for 
separation because the ability of the prosthetic group-ligand conjugate 
to regenerate active holoenzyme is substantially inhibited when the 
labelled ligand is completed with its antibody.
The model system used flavine adenine dinucleotide (FAD) as the 
prosthetic group, and glucose oxidase as the enzyme, in a colorimetric 
immunoassay for theophylline. All of the reagents required were well 
defined and readily prepared. The assay was rapid and required only Ipl 
of sample for assays in the therapeutic range of theophylline. The 
system has also been applied to the measurement of protein molecules 
(Morris et al., 1981) but the details of that method have not yet been
published. The prosthetic group label system has also been adapted to a
reagent strip format (Tyhach et al., 1981).
Enzyme substrates have also been employed as immunoassay 
labels, particularly in a method which combines features of both 
enzyme-based and fluorescence immunoassay techniques. The method has 
been given the name 'substrate labelled fluorescent immunoassay' 
(SLFIA). It was developed by Burd et al. (1977(a) and (b)) and has been
used in a variety of assay systems (e.g. Wong _e^  al. , 1979; Ngo ^  al. ,
1981). In the method neither the labelled ligand or the antibody bound 
ligand is fluorescent. However, the labelled ligand can be cleaved by
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enzyma^c hydrolysis to release a part of the label molecule which is 
then able to fluoresce. Cleavage of the labelled ligand is sterically 
prevented when it is bound to the specific ligand antibody. Competition 
for antibody binding sites by ligand from the sample under test makes
more of the labelled ligand available to act as an enzyme substrate.
The extent of the fluorescence is proportional to the amount of free 
ligand in the test sample. In the assay for gentamicin (Burd jet al., 
1977(b)), galactosidase was used as the enzyme and the synthetic 
fluorogenic substrate was a p-galactosylumbelliferone-gentamicin 
conjugate. The sensitivity of the assay was comparable to that of
radioimmunoassay.
The assay method is homogeneous, rapid, and simple to perform. 
Only lyl of sample is required, and linear standard curves are obtained. 
The SLFIA system has also been adapted to a dry-strip format (Greenquist 
et al., 1981) in which the results obtained compare well with those 
found using established methods.
One other enzyme associated substance which has potential for 
use in an enzyme immunoassay system is an enzyme inhibitor. This fact 
was noted by Wisdom (1976) but when the experimental work presented in 
this thesis was commenced, no investigations into the use of inhibitors 
in this way had been published.
The development of such an inhibitor based system was one of
the aims of this project, and the theoretical requirements of such a
I
system are discussed in detail in the introduction to Chapter Four. 
During the last three years, two publications have considered the use of 
inhibitor based immunoassay methods. Ngo and Lenhoff (1980) developed a 
method in which antibodies were used to modulate enzyme activity. In 
the discussion section of their paper they considered how more 
conventional enzyme inhibitors could be used in similar methods, but 
they did not present any experimental evidence to support their claims. 
Finley je^  al. (1980(b)) evaluated a model inhibitor based system to 
measure serum thyroxine. The method has been used to produce a 
commercial 'kit' assay despite the fact that the system studied by 
Finley et al. was not without its difficulties.
The final chapter of this thesis discusses the publications of 
Ngo and Lenhoff, and Finley et al. in the light of the experimental work 
carried out during this project, and tries to assess the future 
potential of such inhibitor based methods.
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1.3.5 THE USE OF COMBINED TECHNIQUES
There has been in recent years an increasing interest in the
use of combinations of two techniques, as the basis for immunoassay
protocols. These methods do not easily fit into any classification of 
the methods available, but as such techniques may play an important role 
in the future they deserve to be discussed. Mention has already been 
made of spin-membrane immunoassay (Section 1.2.6.), a method which 
combines the use of liposomes and stable free radicals. In this 
section, three examples of combination techniques in which enzymes are 
involved will be given.
One such combination technique is the viroenzymoimmunoassay for 
penicillin which was developed by Mamas and Dray (1979). The classical 
viroimmunoassay (e.g. Haimovich and Sela, 1969) has already been 
described (Section 1.2.1.). It involves the counting of plaques 
produced by bacterial lysis. In viroenzymoimmunoassay the bacterial 
lysis is monitored not by plaque formation but by the measurement of the 
release from the bacteria of the endocellular enzyme, (3-galactosidase. 
The combination method is similar to virommunoassay in all other
respects in that competition for antibody binding occurs between 
bacteriophage labelled hapten and free hapten from the sample under 
test. The performance of the assay is better than EIA methods and 
comparable to classical viroimmuoassay techniques. However, the 
viroenzymoimmunoassay is much quicker than the classical plaque counting 
method and is also more suitable for automation.
Enzyme enhanced luminescence immunoassay is a combined method 
that has only recently been developed (Fricke ^  ^ . , 198^). Mention
has already been made of 'chemiluminescence enzyme immunoassay' in which 
the enzyme activity as such is not utilised and the peroxidase functions 
only as a haem containing catalyst molecule. However, in enzyme 
enhanced luminescence immunoassay the true activity of the enzyme is 
employed. The model system involved transferrin labelled with pyruvate 
kinase. After the antibody-antigen reaction and subsequent bound/free 
separation, the enzyme was used to generate adenosine triphosphate (ATP) 
from adenosine diphosphate (ADP) and phosphoenolpyruvate. The ATP was 
then monitored using a firefly luciferin-luciferase reagent. The assay 
for transferrin compared well with an established radioimmunoassay 
procedure. The authors point out that for hapten assays, enzymes with a 
lower molecular weight than pyruvate kinase would appear to be more 
suited. The method is not limited to the ATP/ADP system as other 
enzymes with high turnover rates could be linked to a bacterial 
NADP/NADPH dependent luciferin-luciferase.
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The third, and in some ways most promising, combination 
technique discussed in this section is radio-enzyme immunoassay. The 
method involves the use of tritium, and hence does not possess all the 
advantages of a non-radioactive system, but it does allow the 
development of assays of very high sensitivity without the use of the 
potentially more hazardous radioactive iodine.
The principle was initially discussed in a short publication by 
Van Der Waart and Schuurs (1976). These workers prepared conjugates 
between human chorionic gonadoptropin (hCG) and acetylcholinesterase. 
Competition between free and labelled antigen for binding to anti-hCG 
antibodies that had been adsorbed to microtitre wells, was allowed to 
take place. After washing of the solid phase, the bound enzyme activity 
was measured using tritiated acetylcholine as substrate. The contents 
of the wells were transferred to glass tubes and extracted with 
toluene/isoamylalcohol and the radioactivity present in the non-aqueous 
phase was determined. The authors of this short paper stated that their 
assay was not optimised but claimed that it was more sensitive than 
either radioimmunoassay or enzyme immunoassay for hCG.
The first detailed use of this system was described by Harris 
and coworkers who refer to the technique as 'ultra sensitive enzymatic 
radiommunoassay' (USERIA) (Harris ^  al., 1979; Hsu _et al., 1980).
These workers used both competitive and non-competitive assay protocols 
but in all systems the final stage was the addition of a alkaline 
phosphatase-goat-anti IgG conjugate (either anti-guinea pig IgG or 
anti-rabbit IgG depending upon the source of the first antiserum). 
After washing of the solid phase, the bound alkaline phosphatase 
activity was measured by the conversion of tritiated adenosine 
monophosphate to tritiated adenosine. Product and substrate were 
separated using small DEAE-Sephadex columns and the enzyme activity 
observed was used to calculate the antigen concentration in the sample 
under test.
The USERIA for cholera toxin was claimed (Harris et al., 1979) 
to be 100 to 1000 fold more sensitive than either of its two parent 
assays. The detection limit was 10~^^g of cholera toxin. This is 
equal to approximately 600 molecules. When applied to the assay of 
acetylaminofluorine-DNA adducts (Hsu ^  al., 1980) the detection limit 
was 2 femtomoles. This was a 60 fold increase in sensitivity over 
available radiommunoassay methods.
The USERIA system is recognised as having potential for the 
future (e.g. Ekins, 1980), particularly if simpler methods of
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substrate/product separation could be developed.
1.3.6 MULTIPLE SIMULTANEOUS ENZYME IMMUNOASSAY
Ever since the development of immunoassay, systems have been 
sought in which two or more components could be determined 
simultaneously in a single sample. The principle has been investigated 
using both radioactive (e.g. Mitsuma al., 1972; Ljunggren al., 
1976; Haynes and Goldie, 1977) and non-radioactive (Leuvering eJC al., 
1980) components as labels. It has been recognised for some time that 
enzymes could possibly be used in such a system (Wisdom, 1976; 
O'Sullivan _et a^, 1979), but when this project was commenced no methods 
involving enzymes had been published.
The development of a model dual enzyme immunoassay and a study
of the feasibility of producing a system for measuring more than two
components simultaneously were two of the aims of the practical work
undertaken in this project.
The published literature, and the theoretical considerations
relating to the production of multiple simultaneous immunoassays is
reviewed in more detail in the introduction to Chapter Two of this
thesis.
1.3.7 CONCLUSIONS
In general, the use of enzyme labels and enzyme associated
labels in immunoassay systems has provided assays which are specific, 
potentially sensitive and relatively inexpensive to set up and run. The 
reagents involved are stable and for that reason are particularly well 
suited to assay systems that are used only infrequently. In the
majority of instances, the enzyme sytems are much safer than the
techniques in which radioisotopes are used. However, it should not be 
assumed that the enzyme systems are completely free of health hazards. 
It has, for instance, been shown that some substrates used in EIA can 
exert a mutagenic action (Voogd al., 1980) and as many mutagenic
compounds are also carcinogenic, the selection of EIA substrates needs 
some care.
The presently available homogeneous systems have a limited
sensitivity, but this disadvantage is balanced, and possibly outweighed, 
by their convenience and ease of automation. The heterogeneous methods 
can be very sensitive and are relatively unaffected by interfering
factors.
Despite the plethora of publications on the subject, it must be 
remembered that EIA is still a relatively new technique and much of the
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methodology involved has not yet been fully evaluated. One particular 
area where research would be valuable is in the direct comparison of 
different EIA techniques. Some publications have directly compared 
different substrates (e.g. Groome, 1980; Porstmann et al., 1981;
Labrousse et al., 1982; Yolken and Leister, 1982) or different enzymes 
(Johnson et al., 1980) but the greater availability of such information 
would be a significant aid to enzyme immunoassay development.
Areas of methodology suitable for further improvement include 
the examination of new enzyme labels, the production of more sensitive 
methods of enzyme assay, the discovery of better cross-linking reagents 
and the introduction of rapid and reproducible separation procedures for 
the heterogeneous assays.
Improvements are also possible in the intrinsic design of the 
immunoassay techniques and many of the theoretical possibilities have 
yet to be explored. Two such possibilities are investigated in this 
thesis. Chapters Two and Three are concerned with the development of 
heterogeneous multiple simultaneous enzyme immunoassays, while Chapter 
Four considers the production of an homogeneous inhibitor labelled 
enzyme based immunoassay system.
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CHAPTER TWO
THE DEVELOPMENT OF AN HETEROGENEOUS ENZYME IMMUNOASSAY FOR THE 
SIMULTANEOUS QUANTITATION OF TWO HAPTENS
2.1 INTRODUCTION
The use of enzymes as immunoassay labels has several advantages 
which could theoretically lead to the development of more efficient 
immunoassay methodologies. The modulation of enzyme activity by 
environmental factors and steric hindrance has been utilised in the 
production of homogeneous assays. Enzyme labels could also increase the 
efficiency of heterogeneous methods by allowing the simultaneous 
quantitation of more than one hapten. The theoretical possibility of 
using enzymes in this way has been noted by at least two reviewers 
(Wisdom, 1976; O'Sullivan ejt al., 1979) but until the work presented 
here was commenced, no practical investigations into the development of 
such simultaneous systems had been carried out. The advantages of 
simultaneous multiple-hapten systems when compared to single-hapten 
methods, include savings on reagent cost and sample volume required, and 
a reduction in overall assay time.
One or two other labels have been employed in the development 
of dual assay systems but at the present time each would seem to have 
significant limitations.
The use of the two iodine isotopes I^^^ and has been the
most widely used approach. Simultaneous methods based on the use of 
these two isotopes have been used to measure thyroxine and 
triiodothyronine (Mitsuma et al., 1972; Ljunnggren et al., 1976; Haynes 
and Goldie, 1977) thyroxine and thyroid-stimulating hormone (Bluett 
et al., 1977) and Group A and Group B meningococcal polysaccharides
(Gruss et al., 1978). The assay for the two polysaccharides was carried 
out in microtitre plates and involved the use of a third isotope (Na^^) 
as a volume marker in a method in which an arbitrary amount of 
supernatant was removed for counting. The methods involving the use of 
the two iodine isotopes vary in details such as the sample volume 
required and the separation method employed, but all have two major 
limitations in common. One is the 8.1 day half-life of 1^31 which 
requires that counting must take place before the counts due to the 1^31 
fall below the activity necessary for accurate results to be obtained
51
and thus results in the need for frequent synthesis of the labelled 
compound. The other is the maximum number of counts allowed per
sample. It has been found that samples containing more than 0.05 pCi of 
ll31 result in spillovers into the lower energy I^^S channel that are 
not directly related to the content of I^^^, and hence a linear 
correction factor cannot be used in this range. (If such a situation is 
produced then waiting for a few days will allow the to decay until
it is within the range where spillover is a linear function of 1^31 
counts (Gruss ^  al., 1978)). These two limitations are factors which 
have prevented the widespread introduction of any of the dual-hapten 
methods which employ the two iodine isotopes.
The problems with the use of have been avoided by some
workers who have labelled more than one component with I^^^. This 
approach has been used by Kaul al. (1977) in the development of a 
screening procedure for drug abuse. Polyvalent antiserum was produced 
capable of binding various combinations of drugs of abuse. Depending on 
the antiserum used, two or three il25 labelled drugs were incubated with 
the antiserum in the presence of the sample under test. The bound 
fraction was precipitated and an aliquot of the supernatant counted. A 
high level of counts in the supernatant aliquot would indicate a 
positive result, although it would not reveal which of the combination 
of drugs tested for, was in fact present in the subject's serum.
A quantitative dual hapten assay in which both components are 
labelled with 1^25 recently been published by Vihko and Koskinen
(1981). In their method two types of antibody are immobilised on 
different sections of small test tubes which are then joined to produce 
a single multicomponent tube. By using this ingenious, but complex, 
technique a simultaneous assay for human pregnancy cho r iomammo t r op in and 
pregnancy-specific glycoprotein was developed. The two components 
were quantified using a multi-detector gamma counter. The assay tubes 
used in the development of the technique were produced manually and the 
authors state that the variation in tube performance may account for 
much of the overall assay variation observed. The commercial manufacture 
of the multicomponent tubes may reduce this variation and render the 
method useful in laboratories which routinely use 'kit' 
radioimmunoassays, but the system would appear to have few advantages 
for workers experienced in the use of 'in-house' immunoassay 
techniques. One important positive feature of the multi-component tube 
method is that the system could be expanded to measure three or more 
haptens simultaneously provided that the commercial preparation of the 
required tubes was possible and suitable multi-detector counters were
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available.
In recent months a more conventional dual radioimmunoassay for 
vitamin 8^2 and folic acid has been developed by Corning Limited. The 
method has only recently become commercially available and has not, as 
yet, been fully evaluated in independant laboratories. The method uses 
1^25 labelled folate and Co^? labelled vitamin ^12» Competition occurs 
between the labelled antigens and those from the sample under test for 
binding to immobilised binding proteins (folate binding protein and 
intrinsic factor). The amount of bound radioactivity is measured after 
separation of the free and bound phases. The gamma emissions of the two 
isotopes used in this method can be more easily distinguished from each 
other than can the gamma emissions of the two iodine isotopes. The 
half-life of Co^^ is 270 days, and this is a further advantage when 
compared to the use of I^^^.
One non-radioisotopic immunoassay has been developed to erasure 
two components simultaneously (Leuvering et al., 1980). In this method 
gold and silver sol particles were used to label human placental 
lactogen and human chorionic gonadotropin. The sensitivity of the dual 
method was significantly less than that observed in the single-hapten 
methods even with the use of atomic absorption as the detection method. 
(The use of sol particles in single-hapten methods is discussed more 
fully in Section 1.2.4). The use of atomic absorption in the dual 
component system means that the amounts of the two bound labels can only 
be determined sequentially.
The simultaneous enzyme immunoassay avoids the need to use 
radioisotopes, and as such has the general advantages previously 
detailed. More specifically the use of enzymes is to be preferred over 
the use of the two iodine isotopes because of the stability of the 
enzyme conjugates (particularly compared to 1^31 q label) and the 
potential for ease of distinction between the two (or more) signals 
produced.
To investigate in a practical way the feasibility of developing 
multiple-hapten simultaneous enzyme immunoassay systems, it was decided 
to attempt to produce a dual assay for the two thyroid hormones, 
thyroxine and triiodothyronine.
The selection of the two enzymes to be employed is obviously an 
important step in the development of a dual assay. The ideal criteria 
for the selection of the enzymes are shown in Table 2.1.
The enzymes p-D-galactosidase (EC 3.2.1.23) and alkaline 
phosphatase (EC 3.1.3.1) were selected as satisfying the majority of the
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TABLE 2.1
IDEAL CRITERIA FOR THE SELECTION OF ENZYMES TO BE USED 
AS LABELS IN SIMULTANEOUS DUAL-HAPTEN IMMUNOASSAYS
- I
1. Both enzymes should be readily available, inexpensive, 
and have high turnover numbers.
2. Each must be stable under the simultaneous assay 
conditions and not susceptible to interference from 
the other enzyme or its substrate.
3. Each enzyme must have a similar optimum pH, and belong
to the same group of enzymes.
4. The final assay method for each enzyme should be 
simple, sensitive, rapid and cheap.
5. Neither enzyme should occur in the biological fluid 
to be assayed and interfering factors should be 
absent.
6. Each enzyme should contain potentially reactive 
groups which allow linking of enzymes vdiile retaining 
a substantial part of the enzyme activity.
7. The spectra of the products of the enzyme activity 
should not overlap with each other.
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requirements shown in the Table. The proposed method involved a
heterogeneous system in which the bound enzyme activity was to be
determined using the following colour forming reactions.
phenolphthalein monophosphate alkaline phenolphthalein + inorganic
phosphatase phosphate
o-nitrophenyl-p-galactoside P~D~galactosidas^ o-nitrophenol + galactose
The phenolphtalein is measured at 540nm and the o-nitrophenol 
at 420nm. The measurements at these two wavelengths did not produce 
significant cross-detection of the two reactions. It was found that the 
absorbance of phenolphtalein at 420nm was only 1.7% of its absorbance at 
540nm and o-nitrophenol had only 0.7% of its maximum absorbance when 
studied at 540nm. The spectral overlap was therefore assumed to be 
negligible. Alkaline phosphatase is an enzyme which is present in serum 
but this did not prevent its use as it was shown that the washing 
procedures adopted in the heterogeneous protocol completely removed 
endogeneous enzyme before the detection of bound enzyme activity took 
place.
Although the method which was developed was for thyroxine and 
triiodothyronine, the real aim of the experimental work was not so much 
to develop an assay which would compete with the well established 
single-hapten methods for these two particular hormones, but to discover 
and evaluate in general terms the potential usefulness of simultaneous 
multiple-component enzyme immunoassays.
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2.2 MATERIALS
Alkaline phosphatase and p-D-galactosidase (both from 
Escherichia coli), L-thyroxine and 3,3 *,5-triiodo-L-thyronine (free 
acids), dimethyl adipimidate hydrochloride, bovine albumin fraction V, 
tris (hydroxymethyl) aminomethane, phenolphthalein monophosphate (sodium 
salt) and o-nitrophenyl-p-D-galactoside were obtained from Sigma 
Chemical Company Limited, Fancy Road, Poole, Dorset, BH17 7NH. Sephadex 
G-25 (fine grade) was obtained from Pharmacia Fine Chemicals, Uppsala, 
Sweden, and 8-anilino-l-naphthalene sulphonic acid from Eastman Kodak, 
Rochester, NY 14650. Rabbit anti-thyroxine (Batch HP/R/142-I), sheep 
anti-triiodothyronine (Batch HP/S/60-IF), donkey anti-rabbit IgG (Batch 
HP/D/15-IIB) and donkey anti-sheep IgG (Batch HP/D/14-VIII) were all 
obtained from Guildhay Antisera, Division of Clinical Biochemistry, 
Department of Biochemistry, University of Surrey, Guildford, GU2 5XH. 
All other chemicals were obtained from British Drug Houses Chemicals 
Limited, Poole, Dorset, BH12 4NN. All chemicals were of the highest 
grade or purity available.
All absorbance measurements were carried out using a Cecil CE 
292 Digital Spectophotometer fitted with micro-Sipette and digital 
printer (Cecil Instruments Limited, Milton, Cambridge, CB4 4AZ).
2.3 METHODS
2.3.1 PREPARATION OF REAGENTS
(a) Preparation of buffer solutions
The following five buffers were prepared for use in the 
various studies.
Buffer A : Sodium carbonate buffer (lOOmM, pH 9.9) containing 
lOmM MgCl2
Buffer B : Tris-acetic acid buffer ( 50mM, pH 7.5) containing
lOmM MgCl2
Buffer C : Buffer A also containing lOmM 2-mercaptoethanol
Buffer D : Buffer B also containing lOOmM NaCl and 20mM
2-mercaptoethanol
Buffer E ; Tris-HCl buffer (lOOmM, pH 8.5) containing
lOmM MgCl2
(b) Preparation of hormone free plasma
Norit A charcoal was added at a concentration of 20g/100ml
of human plasma. The charcoal suspension was stirred overnight at 4°C
and then the charcoal precipitated by centrifugation at 2500 x ^  for 30 
minutes. The supernatant was filtered through a Sietz filter (Model EK)
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and then frozen until required.
2.3.2 PREPARATION OF HORMONE-ENZYME CONJUGATES
(a) Thyroxine-alkaline phosphatase conjugate
Alkaline phosphatase was coupled to thyroxine using the 
cross-linking bi-functional imidoester dimethyl adipimidate. The 
structure of this compound is shown in Figure 2.1(a). Both ends of the 
dimethyl adipimidate molecule react with amino groups as shown in Figure 
2.1(b) with the release of methanol. The conjugation method used was 
adapted from that employed by O'Sullivan et al. (1978).
Thyroxine (lOmg, 12.5jimol) was dissolved in specially dried 
methanol (2ml) containing 25% w/v N-ethy Imorpholine. Dimethyl 
adipimidate (6mg, 25pmol) was added and the solution maintained at room 
temperature for 30 minutes. The solution was then added to 2ml of buffer 
A containing alkaline phosphatase (0.5mg, 7.5nmol). The reaction mixture 
was left at room temperature for a further 90 minutes with occasional 
mixing. After this time all of the solution was applied to a column of 
Sephadex G25 (fine grade), and the products eluted with buffer B. The 
column was 2cm^ x 26cm in size and the flow rate was approximately 
0.5ml/minute. Seventy fractions of 1ml volume were collected and tested 
for enzyme activity in the following way. Aliquots (lOpl) of alternate 
elution fractions were incubated at 30°C with 1ml of a 2.5mM solution of 
phenolphthalein monophosphate in buffer E. After 2 hours 0.5ml of 0.1 M 
sodium hydroxide was added and the absorbance measured at 540nm. The 
fractions containing significant enzyme activity were pooled. After the 
addition of sodium azide and bovine serum albumin (each to a 
concentration of 0.1% w/v), the pooled fractions were stored at 4°C 
until required.
(b) Triiodothyronine-|3-galactosidase conjugate 
The conjugation reaction again followed the method of 
O'Sullivan et al. (1978) which involves the use of dimethyl adipimidate.
Triiodothyronine (6.5mg, lOymol) was dissolved in 1.4ml of a 
mixture of specially dried methanol and N-ethylmorpholine (1:1 v/v). 
When the triiodothyronine had dissolved, dimethyl adipimidate (3.9mg, 
16ymol) was added and the mixture left at room temperature for 10 
minutes. After this time a lOOyl aliquot was taken and mixed with 1ml of 
Buffer C containing lOOyg (0.2 nmol) of p-D-galactosidase. The solution 
was left for 90 minutes at room temperature with occasional mixing. The 
reaction products were purified as described above for the 
thyroxine-alkaline phosphatase conjugate, except that buffer D was used
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FIGURE 2.1(a)
THE STRUCTURE OF DIMETHYL ADIPIMIDATE
+ + Cl"
C — CH _— C H ,— C H r — CH„— c  
/ ^ ^ \
C H f °  "CH3
FIGURE 2.1(b)
THE REACTION OF DIMETHYL ADIPIMIDATE
WITH AMINO GROUPS
" 2 %  _
R— NH, +
1
4-R— T  CH3-O-H
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to elute the products. The enzyme activity of the fractions was assessed 
in the following way. Aliquots (lOyl) of alternate fractions were 
incubated with 1ml of a 2.5mM solution of o-nitropheny1-(3-D-galactoside 
in buffer B. After 2 hours, 0.5ml of 0.1 M sodium hydroxide was added 
and the absorbance of the solutions at 420nm was measured. The fractions 
containing significant enzyme activity were pooled. After the addition 
of sodium azide and bovine serum albumin (each to a concentration of 
0.1% w/v), the pooled fractions were stored at 4°C until required.
2.3.3 SINGLE-HAPTEN ENZYME IMMUNOASSAYS FOR THYROXINE AND
TRIIODOTHYRONINE
The protocol for the antiserum dilution curves and standard
curves for the thyroxine single-hapten assay is shown in Table 2.2. The 
thyroxine standards were prepared as follows; 37.3mg of L-thyroxine 
(free acid) was dissolved in a few drops of 0.1 M sodium hydroxide and 
the volume made up to 100 ml with distilled water. This solution was 
diluted a further 1 in 100 in distilled water and then 0.1 ml aliquots 
of this dilution were taken and stored at -20°C. On the day of assay an 
aliquot was diluted with buffer E to a volume of 1 ml to provide a 
standard solution containing 480nmol of thyroxine per litre. This 
solution was double diluted to prepare the range of standards required 
for the assay.
The protocol for the antiserum dilution curves and standard
curves for the triiodothyronine single-hapten assay is shown in Table 
2.3. The triiodothyronine standards were prepared as follows; 10.4mg of 
L-triiodothyronine (free acid) was dissolved in a few drops of 0.1 M 
sodium hydroxide and the volume made up to 10ml with distilled water. 
This solution was diluted 1 in 100 in,distilled water and a further 1 in 
200 in saline containing bovine serum albumin (0.1% w/v). Aliquots (0.1 
ml) of this second dilution were taken and stored at -20°C. On the day
of assay, an aliquot was diluted with buffer B to a volume of 1 ml to
provide a standard solution containing 8nmol of triiodothyronine per 
litre. This solution was double diluted to prepare the range of 
standards required for the assay.
Both single-hapten methods were carried out with aqueous 
reagents only, and the effects of plasma on the curves was not 
considered.
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TABLE 2.2 METHOD PROTOCOL FOR THE SINGLE-HAPTEN ENZYME
IMMUNOASSAY OF THYROXINE
All volumes in pi Total Enzyme Non-specific Antiserum Dilution Standard
Activity Binding Curve Curve
Buffer E
Thyroxine Standard 
Thyroxine Antiserum 
Thyroxine label
Second antiserum 
(Donkey anti­
rabbit IgG-)
Buffer E
500 400
Phenolphthalein 
monophosphate 
dissolved in 
buffer E
Sodium hydroxide 
(0.1 M)
300
—  —  —  100
-  100 100
100 100 100 100
Mix and leave for three hours at room temperature 
100 100 100
Mix and leave overnight at 4°C
1000 1000 1000
Mix, centrifuge (2500g for 10 minutes) and aspirate 
the supernatant. Repeat the washing process.
500 500 500 500
Mix and leave for 2 hours at 30°C 
750 750 750 750
Centrifuge (as above) and measure the absorbance 
of the supernatant at 540nm
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TABLE 2.3 METHOD PROTOCOL FOR THE SINGLE-HAPTEN ENZYME
IMMUNOASSAY OF TRIIODOTHYRONINE
All volumes in pi Total Enzyme Non-specific Antiserum Dilution Standard
Activity Binding Curve Curve
Buffer E
Triiodothyronine
Standard
Triiodothyronine
Antiserum
Triiodothyronine
Label
Second antiserum 
(Donkey anti­
sheep IgC)
500 400
100 100
100
100
300
100
100
100
Mix and leave for three hours at room temperature 
100 100 100
Buffer E
Mix and leave overnight at 4°C
1000 1000 1000
Mix, centrifuge (2500g for 10 minutes) and aspirate 
the supernatant. Repeat the washing process.
Nitrophenyl-3- 
galactoside 
dissolved in 
buffer E or buffer 
B (see text for 
details)
Sodium hydroxide 
(0.1 M)
500 500 500 500
Mix and leave for 2 hours at 30°C 
750 750 750 750
Centrifuge (as above) and measure the absorbance 
of the supernatant at 420nm
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2.3.4 DUAL-HAPTEN SIMULTANEOUS ASSAY FOR THYROXINE AND
TRIIODOTHYRONINE 
The protocol for the simultaneous technique was revised in 
various ways during the development of the method. The details and 
effects of these revisions are discussed in the results section of this 
chapter. The protocol initially followed is shown in Table 2.4, while 
Table 2.5 shows the final form of the assay method.
The dual method was carried out initially in a totally aqueous 
system, but once the method had been optimised for this situation, the 
effect of hormone free plasma on the assay was determined. The plasma 
(lOOpl/tube) was added in the presence and absence of 8-anilino-l- 
naphthalene sulphonic acid (200pg/tube). The presence of the 8-anilino- 
l-naphthalene sulphonic acid prevents binding of the hormones to 
endogeneous binding proteins present in the plasma.
When the performance of the simultaneous assay in the presence 
of hormone free plasma had been determined, a method comparison study 
was carried out. Thirty-four patients' samples were examined for 
thyroxine and triiodothyronine by the simultaneous enzyme immunoassay 
and by two single-hapten radioimmunoassay techniques. (Ratcliffe et al., 
1974 (a) and (b)). The radioimmunoassays were carried out by staff at 
St. Luke's Hospital, Warren Road, Guildford, Surrey, GUI 3NT. The study 
was carried out in a double-blind manner. When all measurements and 
calculations had been completed the correlation between the methods was 
determined.
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TABLE 2.4 INITIAL METHOD PROTOCOL FOR THE SIMULTANEOUS ENZYME
IMMUNOASSAY OF THYROXINE (T4) AND TRIIODOTHYRONINE (T3)
All volumes in Total Non- Antiserum 
Enzyme specific Dilution 
Activity binding Curve
Standard
Curve
Zero
Standard
, . 1
Buffer E 400 300 100 200
Combined T4 and 
T3 standard — — - 100 -
Combined T4 and 
T3 antiserum — . — 100 200 200
Combined T4 and 
T3 labels 200 200 200 200 200
Mix and leave and 3 hours at room temperature
Combined second 
antibody (i.e. 
anti-rabbit and 
anti-sheep IgG)
200 200 200 200
Mix and leave overnight at 4°C
Buffer E 1000 1000 1000 1000
Mix, centrifuge (2500g for 10 minutes) and 
the supernatant. Repeat the washing process
aspirate
T3 sustrate in 
buffer B 500 500 
Mix and leave for 2
500
hours at 30°C
500 500
T4 substrate in 
buffer A 500 500 
Mix and leave for 2
500
hours at 30°C
500 500
Sodium hydroxide 
(0.1 M) 750 750 750 750 750
Centrifuge all tubes (as above) and measure the 
absorbance of the supernatant at 540 and 420nm
(Unless stated, all dilutions were made in buffer E)
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TABLE 2.S FINAL METHOD PROTOCOL FOR THE SIMULTANEOUS ENZYME
IMMUNOASSAY OF THYROXINE (T4) AND TRIIODOTHYRONINE (T3)
All volumes in ;il
Buffer E
Combined T4/T3 
Standard
Unknown samples
Hormone free 
plasma 
(containing 
200jigANS/100pl)
Buffer E
(containing
200pgANS/100pl)
Combined T4/T3 
Antiserum
Combined T4/T3 
enzyme labels
Combined Second 
Antibody
Buffer E
T3 substrate 
in Buffer B
T4 substrate in 
Buffer A
Sodium Hydroxide 
(0.1 M)
Total Non- Antiserum Standard Zero Unknowns
Enzyme specific Dilution Curve Standard
Activity binding Curve
300 200 100
100
100
100 100 100 100
100 200 200
100
200
Mix and leave for 1 hour at room temperature 
200 200 200 200 200 200
Mix and leave for 2 hours at room temperature
200 200 200 200 200
Mix and leave overnight at 4°C
1000 1000 1000 1000 1000
Mix, centrigufe (2500g for 10 minutes) and aspirate 
the supernatant. Repeat the washing process.
500 500 500 500
Mix and leave for 2 hours at 30°C
500 500 500 500
Mix and leave for 2 hours at 30°C
500 500
500 500
750 750 750 750 750 750
Centrifuge all tubes (as above) and measure the 
absorbance of the supernatant at 540 and 420nm
(Unless stated, all dilutions were made in buffer E)
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2.4 RESULTS
2.4.1 PREPARATION OF HORMONE-ENZYME CONJUGATES
Figures 2.2 and 2.3 show the enzyme activity recovered from the 
Sephadex columns after the fractionation of the reaction products 
resulting from the two conjugation procedures.
The purification of the thyroxine-alkaline phosphatase
conjugate is shown in figure 2.2. A pool of fractions 21 to 29 inclusive 
was taken and stored as detailed previously. On the day of assay an 
aliquot of this pool was diluted for use as appropriate.
The purification of the triiodothyronine-{3-galactosidase
conjugate is shown in figure 2.3. A pool of fractions 16 to 23 inclusive 
was taken and stored as detailed previously. On the day of assay an 
aliquot of this pool was diluted for use as appropriate.
2.4.2 SINGLE-HAPTEN ENZYME IMMUNOASSAYS
(a) Thyroxine
In the initial studies using the protocol shown in Table 
2.2, single-hapten thyroxine antiserum dilution curves were prepared 
with the thyroxine-alkaline phosphatase diluted initially 1/10 or 1/50
in buffer E before addition to the assay tubes. Figure 2.4 shows the two
antiserum dilution curves that were obtained. The experiment using the 
label initially diluted 1/10 was carried out first and the range of 
antiserum dilutions employed did not allow the maximum level of binding 
to be determined. Therefore, when the experiment was repeated with an 
initial label dilution of 1/50, the antiserum dilution range was 
extended to ensure that a value for the maximum binding would be 
obtained.
Standard curves for the thyroxine single-hapten method were 
prepared using the same two initial dilutions of the thyroxine-alkaline 
phosphatase label. The titre of the antiserum when the label was 
initially diluted 1/50 was determined from Figure 2.4 as being 1/250, 
and the antiserum was used at this dilution for the preparation of the 
standard curve. With the label initially diluted 1/10, a true titre 
could not be determined from the antiserum dilution curve, but as the 
gradient of the curve was steep at an antiserum dilution of 1/50, this 
antiserum dilution was used for the preparation of the standard curves. 
The two standard curves obtained are shown in Figure 2.5.
The antiserum dilution curves shown in Figure 2.4 indicate that 
the initial label dilution of 1/50 is more economical in the use both of 
the antiserum, and of the label itself. However Figure 2.5 reveals that 
the standard curve produced with initial dilutions of 1/50 for the label
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FIGURE 2.4
THYROXINE SINGLE-HAPTEN ANTISERUM DILUTION CURVES
USING THE LABEL AT TWO DIFFERENT INITIAL DILUTIONS
50
■ Label diluted initially 1 in 10
Label diluted initially 1 in 50
45
40
35
•H
I-1
15
1:1600 1:32C1:2001.100 1:400 1:8001:25 1:50
INITIAL DILUTION OF THYROXINE ANTISERUM 
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FIGURE 2.5
THYROXINE SINGLE-HAPTEN STANDARD CURVES USING
THE LABEL AT TWO DIFFERENT INITIAL DILUTIONS
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and 1/250 for the antiserum is far too sensitive for use (the reference 
range for thyroxine being commonly 55 to 155 nmol/litre (Houston et al., 
1975)). There are various ways in which the assay could be made less 
sensitive such as the use of more antiserum, the use of more label or 
the use of a shorter incubation time for the immunological reaction.
At this stage of the experimental work it was not known what 
alterations (if any) in assay performance would result from the use of 
the simultaneous dual-hapten system. For this reason, further 
optimisation of the thyroxine single-hapten method was not carried out.
(b) Triiodothyronine
A triiodothyronine antiserum dilution curve was prepared 
as indicated in Table 2,3. The triiodothyronine-p-galactosidase 
conjugate was used at an initial dilution of 1/10. This antiserum 
dilution curve is shown in Figure 2.6. Although this curve would appear 
to be satisfactory and indicate an antiserum titre of 1/2000, the 
absorbance change was much lower than that observed* in the thyroxine 
studies. At the maximum binding obtained, the colour change was only 
about 0.1 of an absorbance unit after 3 hours incubation with substrate 
solution.
The enzymes alkaline phosphatase and p-galactosidase were 
selected for use after a brief study carried out previously (Al-Bassam, 
1979). They have significantly different pH optima (10.4 for alkaline 
phosphatase and 7.3 for p-galactosidase) but both are active at the 
proposed assay pH of 8.5. However, while the alkaline phosphatase 
retains the majority of its activity at the intermediate pH, the 
activity of the p-galactosidase is reduced to unacceptable levels. 
Further studies using a range of buffers of different pH, revealed that 
lowering the pH to a point where the p-galactosidase activity was 
suitably higher resulted in a large decrease in phosphatase activity.
One solution to this problem would be to change the pH of the 
enzyme reaction medium during the incubation. Preliminary studies 
indicated that a shorter overall assay time would be needed for a two 
stage colour forming reaction than for a system which used the 
intermediate pH and which was incubated with the substrate solutions 
until sufficient coloured products had been formed to allow accurate 
measurements to be obtained. It was decided to employ this approach in 
the development of the dual-hapten system.
Once this decision had been taken, the triiodothyronine 
antiserum curve was repeated but with buffer B (pH 7.5) used as the 
diluent. The curve obtained was similar to that shown in Figure 2.6, but
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FIGURE 2.6
TRIIODOTHYRONINE SINGLE-HAPTEN 
ANTISERUM DILUTION CURVE
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INITIAL DILUTION OF TRIIODOTHYRONINE ANTISERUM
the absorbance changes observed were approximately five times higher 
than those seen with the use of the pH 8.5 buffer. These larger 
absorbance changes made it possible for a triiodothyronine standard 
curve to be obtained. Figure 2.7 shows such a standard curve. The label 
was diluted 1/10 initially and the antiserum was used at a dilution of 
1/1000, for the production of this curve. The use of the antiserum at a 
dilution higher than the observed titre was found to produce larger 
absorbance changes without reducing the sensitivity of the standard 
curve.
As with the thyroxine assay, it was not known what alterations 
(if any) in assay performance would result from the use of the 
simultaneous dual-hapten system and so once again, further optimisation 
of the single-hapten method was not carried out,
2,4.3 DUAL-HAPTEN ENZYME IMMUNOASSAY
The dual-hapten assay protocol shown in Table 2.4 was used to 
obtain simultaneous antiserum dilution curves with various initial 
dilutions of the two labels. The curves observed are shown in Figures 
2,8 and 2,9,
In order to economise on the use of both antisera and labels, 
and also to obtain maximum sensitivity from the assay system, both of 
the labels were used at an initial dilution of 1/40 in all further 
studies.
The effect of hormone free plasma, both in the absence and 
presence of 8-anilino-l-naphthalene sulphonic acid, is shown in Figure 
2,10, It can be seen that the addition of the hormone free plasma had a 
significant effect on the thyroxine antiserum dilution curve. This 
effect was totally reversed by the presence of 200yg/tube of 
8-anilino-l-naphthalene sulphonic acid which prevents the hormones 
binding to proteins in the serum sample. Figure 2,10 also indicates that 
the hormone free plasma, with or without the presence of 
8-anilino-l-naphthalene sulphonic acid, produced only minimal changes to 
the shape of the triiodothyronine antiserum dilution curve.
As a result of the information obtained from the dual-hapten 
antiserum dilution curves the triiodothyronine antiserum was used at an 
initial dilution of 1/1500 (final dilution 1/9000) and the thyroxine at 
an initial dilution of 1/20 (final dilution 1/120) in all further 
experiments.
Dual assay standard curves are shown in Figure 2,11, It can be 
seen that the addition of hormone free plasma decreased the sensitivity
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FIGURE 2.7
TRIIODOTHYRONINE SINGLE-HAPTEN STANDARD CURVE
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FIGURE 2.8
THYROXINE DUAL-HAPTEN ASSAY ANTISERUM DILUTION CURVES
USING THREE DIFFERENT INITIAL DILUTIONS OF LABEL
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FIGURE 2.9
TRIIODOTHYRONINE DUAL-HAPTEN ANTISERUM DILUTION CURVES 
USING THREE DIFFERENT INITIAL DILUTIONS OF LABEL
A Label diluted initially 1 in 10
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FIGURE 2.10
EFFECT OF HORMONE FREE PLASMA (HFP) ON THE SIMULTANEOUS DUAL 
ANTISERUM DILUTION CURVES FOR THYROXINE (T4) AND
TRIIODOTHYRONINE (T3) WITH AND WITHOUT 8-ANILINO- 
1-NAPHTHALENE SULPHONIC ACIDI O O 1
• Totally aqueous T4 assay 
A T4 assay with HFP 
■ T4 assay with HFP and ANS
OTotally aqueous T3 assay
AT3 assay with HFP
□T3 assay with HFP and ANS
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of both curves. The addition of 8-anilino-l-naphthalene sulphonic acid 
reduced, but did not remove, the effect exerted by the hormone free 
plasma on the two standard curves. It was found that the sensitivity of 
both curves was further improved by including a one hour preincubation 
of the antisera with the samples and standards before the addition of 
the two enzyme labelled hormones. The standard curves obtained with the 
use of the preincubation stage are also shown in Figure 2.11. Table 2.5 
shows the final assay protocol including the preincubation and the 
addition of hormone free plasma and 8-anilino-l-naphthalene sulphonic
acid.
The protocol shown in Table 2.5 was used in the method 
comparison study. The correlation between the results obtained using the 
dual enzyme immunoassay and those determined by the two single-hapten 
radioimmunoassays is shown in Figure 2.12. The correlation line was
calculated by the method of Brace (1977). This method is recognised 
(e.g. Smith et al., 1980) as being a simplified method of obtaining the 
'true* slope and intercept as defined by Deming (1943). The study 
included both jaundiced and haemolysed samples but these did not show 
unusually large discrepancies.
2.5 DISCUSSION
The method in its present form is not meant to be a serious 
challenge to the well established assays for the two thyroid hormones, 
but was developed to demonstrate the general principle upon which the
assay method is based. This aim has been achieved and it has been shown 
that the use of the simultaneous dual-assay system does not entail a
significant compromise of the accuracy or precision of the measurement 
of the individual components.
However, the model system presented here could be improved in
several ways. One major problem was that the use of the single
intermediate pH for the enzyme reaction incubation did not produce
sufficient enzyme activity. This resulted in a situation in which the
required assay sensitivity could not be achieved with an enzyme reaction 
incubation of reasonable length. The reason for this has already been 
discussed. The use of the two stage colour reaction meant the
introduction of an extra pipetting stage but produced a system in which 
suitable colour changes were obtained within a four hour total
incubation time. The use of two enzymes with more similar pH optima than 
those of the enzymes used in this study would enable a one-stage 
incubation to be achieved in a shorter time.
Two further problems resulted from a limitation on the antisera
available. All antisera were obtained within the University of Surrey
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FIGURE 2.12
COMPARISON BETWEEN THE THYROID HORMONE LEVELS AS 
MEASURED IN THE NEW DUAL ENZYME IMMUNOASSAY
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from Guildhay Antisera, and the only thyroxine antiserum available was 
of a low titre, and was raised in a rabbit. The titre of this antiserum 
was only 1/750 (final) when used in a radioimmunoassay procedure. The 
titre of the antiserum when used in the dual assay system was found to 
be 1/120 (final) an observation not unexpected, as due to the large size 
of the enzyme label, the titres seen with enzyme immunoassays are
frequently lower than when the same antiserum is used in a radiolabelled 
technique. However although this result was expected it was very 
uneconomical regarding the use of the antiserum as it required an
initial dilution of only 1/20. The fact that the antiserum was raised in 
a rabbit whereas the triiodothyronine antiserum was raised in a sheep 
introduced a further complication in that two different second 
antibodies were required. The use of a thyroxine antiserum raised in a 
sheep, and having a higher titre would simplify the assay procedure and 
reduce the costs involved.
Further savings in overall cost would also be achieved if the
method could be expanded so that three, four or more compounds could be
measured simultaneously. The problems encountered with the dual-hapten 
method were due to faults of the model system, rather than of the assay 
principle itself, and there would appear to be no reason why such an 
expansion of the simultaneous method would not be possible. Apart from 
financial considerations, an expansion of the simultaneous method would 
also increase savings in total assay time and total sample volume 
required. This last consideration is particularly important when the 
sample volume is limited, for example, in paediatric investigations.
The principle of simultaneous enzyme immunoassay could also be 
applied to enzymes whose activity is measured in other ways, for 
example, using fluorogenic substrates. The most sensitive enzyme 
immunoassays so far produced have been those in which the enzyme 
activity is measured using fluorimetric detection systems (e.g. Kato et 
al., 1975) and the use of such a detection system would possibly be 
useful in increasing the sensitivity of the dual assay as it would 
enable smaller amounts of the two hap ten-enzyme conjugates to be used.
The model dual-hapten system presented here is not without its 
limitations, but despite these faults, the principle has been 
demonstrated to be valid. The principle could be widely applied and 
simultaneous multi-hapten assays may provide a significant advance in 
the future exploitation of enzymes as labels in immunoassay systems.
The details of the model system presented here, together with a 
discussion of the limitations of the model system, have recently been
80
published (Blake et al., 1982).
The next chapter of this thesis will briefly consider ways in 
which the model system could be improved, and discuss the feasibility of 
expanding the system so that three haptens could be determined 
simultaneously.
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CHAPTER THREE
POSSIBILITIES FOR IMPROVEMENT AND EXPANSION OF THE SIMULTANEOUS 
MULTI-HAPTEN ENZYME IMMUNOASSAY SYSTEM
3.1 AIMS OF THIS STUDY
The development of the dual-hapten model enzyme Immunoassay 
detailed in the previous chapter, clearly demonstrated that such
simultaneous assays are possible. This chapter will consider ways in 
which that model system could be improved and discuss how these
improvements could be incorporated in the production of a system capable 
of quantitating three haptens simultaneously.
The model dual-hapten method has several undesirable features 
which have already been discussed. These difficulties can be divided 
into two main areas, problems with the antisera available, and problems 
concerning the choice of enzymes. This chapter will consider these 
problems in turn.
3.2 IMPROVEMENTS IN THE ANTISERA EMPLOYED IN THE MODEL SYSTEM
3.2.1 INTRODUCTION
The problems in this area arose from the thyroxine antiserum 
that was employed. This had been raised in a rabbit and was of a low 
titre. At the time that the initial work was carried out on the model 
system, this antiserum was the only one available from Guildhay Antisera 
for the measurement of thyroxine. However, the low titre of this 
antiserum when used in radioimmunoassay (1 in 750 final dilution), and 
its consequently very low titre when used in the dual enzyme immunoassay 
method (1 in 120 final dilution), together with the resulting need to 
use high concentrations of the donkey anti-rabbit antiserum to ensure 
that full separation was achieved, made the model system relatively 
uneconomical in financial terms. The use of an anti-thyroxine serum 
raised in a sheep, and of a higher titre, would improve this situation 
considerably. Such an antiserum was obtained, and its interaction with 
the enzyme label used in the previous studies was examined.
3.2.2 MATERIALS
Anti-thyroxine antiserum, raised in sheep, was obtained from 
the Scottish Antibody production Unit, Law Hospital, Carluke, 
Lanarkshire, Scotland, ML8 5ES. The batch obtained was number 0052A, 
which had been shown to have a final dilution titre of 1 in 10000 when 
used in a radioimmunoassay method with double antibody separation. The 
antiserum was obtained in a lyophilised form and was reconstituted and 
stored as detailed on the package insert supplied. The sources of all
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other reagents employed have already been described in section 2,2,
3.2.3 METHODS
Single-hapten antiserum dilution curves were prepared using the 
method protocol shown in Table 2.2. The composition of the buffer 
solutions employed has been detailed in section 2.3. The thyroxine- 
alkaline phosphatase enzyme label that was used was from the same batch 
as was used in the initial studies reported earlier. The stock label 
solution was diluted 1 in 20 initially for use in the preparation of the 
antiserum dilution curves. Two curves were prepared, one with the sheep 
anti-thyroxine described above (Batch 0052A) and the other with the 
rabbit anti-thyroxine previously used (Batch HP/R/142-I).
3.2.4 RESULTS
The two antiserum dilution curves obtained are shown in Figure 
3.1. The titre of the sheep anti-thyroxine is approximately 1 in 1000 
while that for the rabbit antiserum is in the region of 1 in 100.
3.2.5 DISCUSSION
Sufficient of the original thyroxine-alkaline phosphatase 
conjugate was not available to permit the sheep anti-thyroxine antiserum 
to be used in further studies involving the dual-hapten assay protocol. 
However, if the ten-fold difference in antiserum performance observed in 
the single-hapten system was repeated in the dual assay method, then it 
might be expected that the sheep anti-thyroxine would have a final titre 
of 1 in 1200. This would equate to an initial dilution of 1 in 200 and 
would produce financial savings by requiring lower concentrations of 
both first and second antibodies. The need for only one form of second 
antibody would also result in a slight simplification of the assay 
protocol.
One interesting result obtained as a by-product of this study 
concerns the stability of the thyroxine-alkaline phosphatase label. The 
experiment reported here was carried out fifteen months after the 
preparation of the labelled hormone. During that time the label was 
stored at 4°C in the presence of sodium azide (0.1% w/v) and bovine 
serum albumin (0.1% w/v). A comparison of the antiserum dilution curve 
obtained in this study using the rabbit anti-thyroxine with antiserum 
dilution curves obtained soon after the synthesis of the label indicated 
that the thyroxine-enzyme label had not greatly deteriorated during its 
period of storage. The maximum binding was found to have decreased from 
47% to 41% (compare Figures 2.4 and 3.1) while the non-specific binding 
was unchanged at 1.5% of the total activity added. The absorbance 
changes were not significantly different from those obtained previously
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FIGURE 3.1
COMPARISON OF THE ANTISERUM DILUTION CURVES OBTAINED 
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indicating that no detectable change in the activity of the enzyme label 
had taken place since it had been prepared fifteen months before. (A 
label prepared with the use of 1^25 ^ould retain less than 0.8% of its 
initial activity after a similar period of storage).
This evidence is somewhat anecdotal but it does serve as an 
indication of the stability of enzyme labels, even when stored in 
solution.
This brief study has shown that the use of the sheep anti­
thyroxine would be a significant improvement in the dual-hapten method 
previously developed, both in terms of method simplicity and financial 
economy. Care should be taken in any expansion of the simultaneous 
method so that the choice of a third hapten to be measured is limited to 
those for which high-titre antisera evoked in sheep are available.
3.3 IMPROVEMENTS IN THE SELECTION OF ENZYMES FOR USE AS LABELS
3.3.1 INTRODUCTION
The need to change the pH of the enzyme reaction medium during
the colour forming incubation was a major disadvantage of the model 
dual-hapten system. It resulted in a longer assay time than would 
otherwise have been required, and introduced an extra reagent addition 
step and consequently an extra potential source of error. In considering 
ways of improving and expanding the model system, it was decided that 
combinations of enzymes with more similar pH optima should be sought. 
Although the two enzymes used in the original system were both active at 
a common pH, their activity under these intermediate conditions was too 
low for suitable sensitivity to be achieved in a reasonable time.
In order to investigate the possibility of using two or three
enzymes of near identical pH optima in a multi-hapten immunoassay
system, preliminary studies of enzymes and colo^genic substrates were
carried out. The choice of substrates is an important feature of any
expansion of the model dual-hapten simultaneous method. That method used
phenolphthalein monophosphate as the substrate for alkaline phosphatase
and o-nitrophenyl-p-galactoside as a substrate for p-galactosidase.
There is practically no overlap of the spectra of the two products,
phenolphthalein and o-nitrophenol. To expand the system to incorporate a
third product is not so simple. It is, of course, possible to use
fluorogenic compounds or substrates which form products opaque to
ultra-violet radiation, but neither of these approaches is ideal. The
use of a fluorogenic compound as the third marker would entail the use
of two different detection methods for the final measurement. This would 
prevent maximum advantage, in terms of time saving, to be obtained from
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the simultaneous principle of the assay. The use of the ultra-violet 
range for the quantitation of enzyme activity could produce difficulties 
due to interference and cross-detection of other components of the 
reaction mixture, such as phenolphthalein, which also absorb strongly at 
ultra-violet wavelengths. With these considerations in mind, the 
theoretical and experimental investigations carried out investigated the 
feasibility of using three colour forming reactions with products 
detectable in the visible range. From an appraisal of enzymes and
substrates available, it was decided to investigate the use of three 
enzymes active at pH 5.0, p-glucosidase, arylsulphatase and acid 
phosphatase.
3.3.2 MATERIALS
Acid phosphatase (type III) from potatoes, P-glucosidase from
almonds, arylsulphatase from limpets, o-nitrophenyl-p-D-glucoside, 
thymolphthalein monophosphate and para-nitrocatechol suplhate were 
obtained from the Sigma Chemical Company Limited, Fancy Road, Poole, 
Dorset, BH17 7NH. Citric acid monohydrate and trisodium citrate were
obtained from British Drug Houses Chemicals Limited, Poole, Dorset,
BH12 4NN. The sources of all other reagents employed have already been
described in section 2.2. Unless stated, all reagents were of the
highest grade or purity available.
Citrate buffer (pH 5.0, 0.1 M) was prepared by the combination 
of citric acid and trisodium citrate as described by Dawson et al. 
(1969).
3.3.3 METHODS
The two triads of enzyme/substrate combinations that were 
considered are detailed below.
System A
o—nitrophenyl-p—glucoside _P~glucosidase ^ o-nitrophenol (420nm)
p-nitrocatechol sulphate sulphatase ^ p-nitrocatechol (515nm)
thymolphthalein TnonoipVstQ^ W^^ re acid phosphatas^ thymolphthalein (600nm) 
System B
o-nitrophenyl-p-glucoside p-glucosidase ^ o-nitrophenol (420nm)
phenolphthalein disulphate —  sulphatase ^  phenolphthalein (540nm)
thymolphthalein m o n o p h o s &cid phosphatas^ thymolphthalein (600nm)
(The figures in parentheses indicate the wavelengths at which 
the products exert maximum absorbance under alkaline
conditions)
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Absorbance spectra of the four products were obtained using the 
scanning facility of a Unicam SP 1800 spectrophotometer. To form the 
products, enzyme incubations were carried out in which each of the four 
substrates was reacted with its apropriate enzyme. The substrates were 
present in citrate buffer (pH 5.0, 0.1 M) at an initial concentration of 
400ymol/litre and approximately 0.1 U of enzyme activity was added to 
each incubation. After one hour at 30°C the reactions were stopped by 
the addition of 0.5 ml of 0.5M sodium hydroxide. Blank substrate 
solutions were prepared in which the alkali was mixed with the substrate 
prior to the addition of the enzyme. The absorbance spectrum of each 
product was obtained with the use of the appropriate substrate blank.
3.3.4 RESULTS
Figures 3.2 to 3.5 show the SP 1800 scans produced. The optimal 
wavelengths for the measurement of each of the other three products is 
indicated on each of the Figures.
The spectra reveal that system A, as detailed above, would not 
be a suitable combination of reactions to use, as the p-nitrocatechol is 
strongly coloured at 420nm, the optimal wavelength for the measurement 
of o-nitrophenol.
System B, as shown above, would seem to have more potential for 
use. Phenolphthalein is transparent at 420nm and 600nm, and
o-nitrophenol is transparent at both 540nm and 600nm. The only problem 
with system B is the absorbance at 540nm resulting from 
thymolphthalein. This would interfere with the measurement of the
phenolphthalein. This effect could be minimised by measuring the
absorbance of the phenolphthalein at 510nm. At this wavelength, the 
phenolphthalein retains 45% of its maximum absorbance but the 
thymolphthalein has only about 5% of its maximum absorbance. This 
situation is not ideal but it would appear to be the best compromise 
possible with the use of the three particular enzymes that were chosen 
for study.
3.3.5 DISCUSSION
The use of the three enzymes with identical pH optima that were 
chosen for study, would seem to entail a compromise in the detection 
wavelengths employed. The use of system B with the detection of
phenolphthalein at 510nm would need to be investigated further so that 
the consequences of measuring this product at a wavelength different 
from that at which it has maximum absorbance could be evaluated. The use 
of such a wavelength would obviously decrease the potential sensitivity 
of the measurement of the hapten for which a sulphatase conjugate was
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prepared but studies would need to establish if this factor was 
compensated for by the increased sensitivity possible as a result of the 
use of a single pH for the colour forming reaction incubation.
To investigate the sensitivities possible, it was proposed that 
a three hapten simultaneous method, involving the use of the reactions 
detailed in system B, should be developed.
3.4 INITIAL STUDIES INTO THE DEVELOPMENT OF A SIMULTANEOUS THREE-
HAPTEN ENZYME IMMUNOASSAY
3.4.1 INTRODUCTION
The use of the three enzyme systems detailed previously to 
develop a three-hapten immunoassay method was considered. Cortisol was 
chosen as the third hapten to be added to the two thyroid hormones in 
the model system. Sheep anti-cortisol antiserum was available and was of 
a suitable titre (1 in 6000 initial dilution when used in 
radioimmunoassay). The measurement of cortisol would serve as a useful 
addition to a simultaneous assessment of endocrine function. Cortisol 
has been linked to enzymes by the use of hemisuccinate derivative of the 
hormone (e.g. Ogihara et al., 1977) and a similar approach was proposed 
for the conjugation of cortisol for use in this study.
The planned triad of reactions in the new model is detailed
below.
o-nitrophenyl-p-glucoside —  thyroxine-p—glucosidase ^ o-nitrophenol
phenolphthalein disulphate _  cortisol-arylsulphatase ^ phenolphthalein
thymolphthalein monophosphate triiodothyronine—aci(^- thymolphthalein
- phosphatase
The time available for the development of the system detailed 
above was very limited, and only the first of the three conjugates 
listed was successfully prepared. Attempts to produce the 
cortisol-sulphatase using the method of Ogihara et al. (1977) failed to 
form an enzymically active conjugate which was capable of binding to the 
cortisol antiserum.
The production of the thyroxine-j3-glucosidase label is detailed
below.
3.4.2 MATERIALS
The sources of all materuvls employed have previously been 
described in sections 2.2 and 3.3.2. The preparation of the buffer 
solutions used is detailed in sections 2.3 and 3.3.2.
3.4.3 METHODS
The thyroxine-p-glucosidase conjugate was prepared in the
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following manner. Thyroxine (lOmg) was dissolved in 2 ml of specially 
dried methanol containing 25% w/v N-ethylmorpholine. Dimethyladipimidate 
(6mg) was added and the solution maintained at room temperature for 30 
minutes. The solution was then added to 2 ml of buffer A containing 
p-glucosidase (1 mg). The reaction mixture was left at room temperature 
for a further 2 hours with occasional mixing. After this time, all of 
the solution was applied to a column of Sephadex G25 (fine grade) and 
the products eluted with buffer B. The column was 2 cm^ x 34 cm in size 
and the flow rate was approximately 0.5 ml/minute. Seventy fractions of 
1 ml volume were collected and tested for enzyme activity in the 
following way. Aliquots (lOpl) of alternate elution fractions were 
incubated at 30°C with a 1 ml of a 2.5 mM solution of o-nitrophenyl-p- 
glucoside in citrate buffer (pH 5.0, 0.1 M). After one hour, 1.0 ml of 
0.1 M sodium hydroxide was added and the absorbance measured at 420nm. 
The fractions containing significant enzyme activity were pooled and 
stored at 4°C after the addition of sodium azide (0.1% w/v) and bovine 
serum albumin (0.1% w/v). The stored label was diluted for use on the 
day of assay.
Single-hapten antiserum dilution curves were prepared using the 
protocol shown in Figure 2.2 except that the substrate employed was 
o-nitrophenyl-p-glucoside, and that the pH 5.0 citrate buffer was used 
as diluent throughout. Two curves were obtained, both with the label at 
an initial dilution of 1 in 10. One curve was for the rabbit 
anti-thyroxine, while the other was for the antiserum that was raised in 
sheep.
3.4.4 RESULTS
Figure 3.6 shows the enzyme activity recovered from the 
Sephadex column after the fractionation of the thyroxine-p-glucosidase 
conjugation products. A pool of fractions 15 to 21 inclusive was taken 
and stored as detailed previously.
The antiserum dilution curves obtained using an initial
dilution of 1 in 10 of the label are shown in Figure 3.7. The difference 
between the two antisera observed previously (Figure 3.1) was again seen 
in the curves obtained with the use of the new thyroxine label. The
titre of the sheep antiserum is approximately 1 in 1 0 0 initial dilution 
(i.e. 1 in 600 final dilution). The titre of the rabbit antiserum could 
not be accurately determined as a maximum binding level was not
obtained.
3.4.5 DISCUSSION
The experimental work carried out in this section was
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FIGURE 3.7
COMPARISON OF THE ANTISERUM DILUTION CURVES OBTAINED 
WITH THE TWO DIFFERENT ANTI-THYROXINE ANTISERA AND 
THE THYROXINE--GLUCOSIDASE LABEL
100
90
•Rabbit anti-thyroxine 
(Batch HP/R/142-I) 
■Sheep anti-thyroxine 
(Batch 0052A)80
70
^  40“
20
10-
OJ
CM
INITIAL ANTISERUM DILUTION
unfortunately severely restricted by the time available* As a result of 
this, only one of the labels planned was successfully prepared, and 
therefore it is not possible to make any specific comments on the 
proposed system.
Further experiments that were planned involved the synthesis of 
the two other enzyme labels required for the three-hapten method, an 
assessment of the sensitivity that could be achieved, and an evaluation 
of any cross-detection that occurred between the various products.
The final chapter of this thesis will consider in general terms 
the important principles and future potential of simultaneous 
multi-hapten enzyme immunoassays.
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CHAPTER FOUR
THE DEVELOPMENT OF A HOMOGENEOUS INHIBITOR-BASED ENZYME IMMUNOASSAY
4.1 GENERAL INTRODUCTION
Over the last two decades, much of the improvement in the 
methodology available to the clinical chemist has involved the 
introduction of automated techniques. Such automation has improved the 
efficiency of clinical biochemistry laboratories by reducing the time 
taken to produce a result, by increasing the number of samples that can 
be studied per unit time, by decreasing the possibility of human error 
and by lowering the financial cost of the investigation.
Until recently immunoassays have proved difficult to adapt to 
automated systems; the major problem being that immunoassays depend on 
the ability to distinguish between the label present in the free form in 
the reaction mixture, and the label which is antibody bound. In 
radioimmunoassays, and in many non-radioisotopic immunoassay techniques, 
this distinction can only be made after phase separation. Most 
immunoassay phase separation methods involve either the linking of one 
component of the reaction mixture to a solid phase (for example in the 
use of particulate immunosorbents (Wide, 1981) or antibody coated 
plastic tubes (Parsons, 1981) or centrifugation of a precipitate 
produced by the addition of charcoal (Odell, 1980), second antibody 
(Midgley and Hepburn, 1980), or a non-specific protein precipitant 
(Chard, 1980), Neither phase separation technique is easy to automate, 
and at present such methods are not widely used in non-manual systems. 
The most promising area of automated separation immunoassay development 
has been in the use of magnetic supports for the immobilisation of 
antigen or antibody (Smith and Gehle, 1980; Guesdon and Avrameas, 1981) 
so allowing automation or semiautomatation of the separation step.
Phase separation is necessary in such immunoassays because the 
signal generated by the label (e.g. B or ^ emmission or enzyme activity) 
is not affected by the binding of the antibody to the labelled 
compound. However, this need for phase separation is avoided if a label 
is produced in which the emitted signal is modified as a result of the 
process of antibody binding. Various non-isotopic labels which possess 
the property of signal modification have been produced and this has 
resulted in the development of a range of non-separation, or 
*homogeneous *, immunoassays.
97
The relative merits of these various homogeneous systems have 
already been discussed in Chapter One but it is useful at this stage to 
outline again the principle of the homogeneous enzyme immunoassay.
The first report of such a system was by Rubenstein, Schneider 
and Ullman (1972), and in the last ten years this group has been 
responsible for the development of many other homogeneous enzyme 
immunoassays. Their system has been given the trade name EMIT (Enzyme 
Multiplied Immunoassay Technique). The mode of action of the EMIT system 
is shown in Figure 4.1.
As can be seen from Figure 4.1, the EMIT assays involve the 
production of an enzyme-hapten conjugate in which the activity of the 
enzyme is unaffected by the conjugation, but is inhibited by the binding 
of the hapten to its specific antibody. Enzyme molecules are large 
complex proteins, often with a very labile and yet very critical 
conformational structure, and the production of hapten-enzyme conjugates 
which conform to the requirements of the EMIT assay may have limited the 
development of a wider range of homogeneous systems.
This section of the research project investigated the 
possibility of avoiding the need to produce hapten-enzyme conjugates by 
linking the hapten instead to an enzyme inhibitor. If a homogeneous 
system were to be developed then the hapten-inhibitor conjugate would 
need to exert its inhibitory action while present free in the reaction 
solution, but be sterically hindered from interacting with the enzyme 
when the antigenic portion of the conjugate was antibody bound. In such
a system no conjugation involving the enzyme would be required, and yet
the advantages of a homogeneous system would be retained. As the enzyme 
inhibitor would be a much smaller molecule, having a more stable and
less complex structure than the enzyme itself, the linking of the hapten
to the inhibitor should, in theory at least, be a simpler and more 
reliable process than that involving the enzyme. The principle of action 
of the proposed * inhibitor-based' homogeneous enzyme immunoassay is 
shown in Figure 4.2.
In selecting the enzyme and inhibitor to study in a model
system, many different factors need to be considered.
Criteria important for the choice of enzyme include the
turnover number (i.e. the activity), the availability, purity, stability 
and cost of suitable enzyme preparations, the availability, sensitivity, 
and ease of the assay method, and the absence of interfering factors and 
enzyme-like activity in the test fluid.
With regard to the choice of inhibitor, a consideration of the
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FIGURE 4.1
THE COMPETING REACTIONS INVOLVED IN THE EMIT 
SYSTEM OF HOMOGENEOUS ENZYME IMMUNOASSAY
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f i g u r e 4.2 THE COMPETING REACTIONS INVOLVED IN THE PROPOSED 
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bound to antibody
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equilibria involved (see Figure 4,2) indicates that a very potent 
inhibitor is required. This is because firstly the inhibitor should 
produce significant inhibition at the concentration at which the antigen 
is present in the test fluid, and secondly, the affinity of the 
inhibitor for the enzyme should be of the same order as the affinity of 
the antigen for the antibody. Both of these considerations suggest that 
an inhibitor with a dissociation constant for the enzyme-inhibitor 
complex (Kj^ ) of around 10""% is needed. This is a considerably higher 
affinity than is found in most enzyme/inhibitor systems.
Table 4,1 shows brief details of some enzymes and inhibitors 
for which the published information indicates that the inhibitor acts 
with sufficient potency to be potentially useful in an inhibitor based 
system.
As well as the classic enzyme-inhibitor systems shown in Table 
4,1, it is possible to contemplate variations of the proposed system in 
which other high affinity interactions could be utilised. The most 
promising of these would seem to be the use of the exceptionally strong 
interaction between avid in and biotin (dissociation constant; 1 0”^%) to 
inhibit biotin dependent enzymes. This interaction has already been
exploited in other assay systems (e.g. Schroeder e_t , 1976 (b), and 
Guesdon et al., 1979),
In considering the choice of hapten a number of factors also
have to be considered. Firstly the hapten must be suitable chemically
for conjugation to the chosen inhibitor, secondly a specific antiserum 
raised to that hapten must be available (as this project aimed to 
improve methodology generally rather than to measure a particular hapten 
the production of new antisera was not considered), and thirdly the 
hapten should be one for which an improved assay technique would be of 
value in the clinical laboratory.
As a result of the above considerations various enzymes,
inhibitors and haptens were chosen for experimental investigation. The 
two enzymes studied in detail were glucose-6-phosphate dehydrogenase and 
dihydrofolate reductase. Initial studies with both of these enzymes were 
carried out to obtain kinetic and inhibition information for the 
particular enzyme preparations used under the reaction conditions 
employed. The experimental readings obtained were subjected to both 
manual and computer analysis. The manual procedure of drawing reciprocal 
plots was carried out to ensure that the assumptions made in the 
computer program as to the linear nature of the reciprocal plots were 
valid, and also served as a check that no operational errors were made
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TABLE 4.1 LITERATURE REPORTS OF POTENT ENZYME INHIBITORS
ENZYME I INHIBITOR INHIBITION
CONSTANT
NOTES AND REFERENCES
N-acetyl-D- 
glucos eaminidase
2 -acetamido-
2-deoxy-D-
gluconolactone
5x10“% Assay monitors paranitro- 
phenol production from 
synthetic substrate. Would 
need to synthesise inhibitor 
Enzyme is found in serum. 
(Leaback, 1968)
Adenosine
deaminase
Coformycin
Erythro-9-(2 
hydroxynonyl) 
adenine (EHNA)
2 .2x 1 0“! %
1 0“%
Can measure reaction 
directly at 265nm or link to 
a second enzyme and measure 
at 340nm. Enzyme available 
but not inhibitor.
(Cha, 1976)
EHNA is not commercially 
available.
(Snyder et al., 1978)
Adenylate kinase Diadenosine 
pentaphos phate
4x10“% Measurement of activity very 
complex. Enzyme but not 
inhibitor available. Some 
serum enzyme activity. 
(Lienhard and Secemski,1973)
Carbonic
anhydrase
Acetazolamide 4x10“% Best detection method is to 
follow esterase reaction, 
but (i) this is not 
inhibited as strongly as the 
main reaction and (ii) 
esterase method also detects 
some non-enzymic hydrolysis. 
Lindskog , 1971)
Cholinesterase Various e.g. 
Eserine
5x10“% Need two step reaction to 
measure activity. Enzyme 
activity found in serum.
Dihydrofolate
reductase
Amethopterin
(Methotrexate)
2 x1 0“%
to
5x10“! %
Methods available for 
convenient assay. Potency 
of inhibition varies with 
source of enzyme. Enzyme and 
inhibitor are available. 
Enzyme not found in extra­
cellular space.
(Williams et al., 1980; 
White, 1979)
Glucose-6-
phosphate
dehydrogenase
Aurine tri­
carboxylic 
acid (ATA)
1 .6x1 0“%
(NADP)
2.5x10“%
(G6P)
Measure at 340nm. Enzyme and 
inhibitor available. Need to 
use NAD form to prevent 
interference from human 
enzyme. Not known if ATA 
inhibits the NAD form. (Hsu 
and Joshi, 1977)
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TABLE 4.1 LITERATURE REPORTS OF POTENT ENZYME INHIBITORS
ENZYME INHIBITOR INHIBITION
CONSTANT
NOTES AND REFERENCES
Glyceraldehyde
3-phosphate
dehydrogenase
D-threose
diphosphate
2x1 0“% Measure at 340nm. Would need 
to synthesise inhibitor. 
Enzyme found in serum.
Xanthine oxidase Allopurinol
Alloxanthine
6.3x10“! %
5.4x10“! %
Measure uric acid formation 
at 295nm. Enzyme and 
allopurinol available but 
not alloxanthine. Time 
dependent reaction. 
Allopurinol is given for 
gout. (Cha et al., 1975; 
Spector and Johns, 1970).
Various kinases 
and
dehydrogenases
Cibracon 
Blue 3GA
.
1 0 “ 6 to 
1 0“%
Detection methods available. 
Inhibitor interacts with 
many different enzymes.
(Apps and Gleed, 1976, 
Beissner and Rudoplh, 1978)
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Iin the actual use of the computer method. The program employed was
written in Fortran, and has only recently been described (Cornish-Bowden
and Endrenyi, 1981). It is a robust weighted regression program for 
fitting equations to kinetic enzyme data which requires minimal
assumptions about the error structure of that data. The dependence of 
the variances on the velocities is not assumed, but is deduced from 
internal evidence in the data itself. The effect of very bad
observations ('outliers') is mitigated by decreasing the weight of 
observations that give large deviations from the fitted equation.
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4.2 GLUCQSE-6-PHOSPHATE DEHYDROGENASE
4.2.1 ENZYME STUDIES
4.2.1.1 INTRODUCTION
The literature survey of enzyme systems of possible use in an 
inhibitor based enzyme immunoassay revealed that there were two 
inhibitors, aurine tricarboxylic acid and Cibacron Blue 3GA, which might 
be useful in conjunction with glucose-6-phosphate dehydrogenase (G6PDH).
Aurine tricarboxylic acid (ATA) has the structure shown in 
Figure 4.3. Hsu and Joshi (1977) demonstrated that ATA strongly 
inhibited the NADP-linked G6PDH obtained from yeast (see Table 4.1). In 
the proposed homogeneous system the enzyme used for the assay should be 
absent from the test fluid. Human serum contains a NADP-linked G6PDH and 
therefore this form of the enzyme is not suitable for use in the assay. 
However if ATA also inhibits the NAD-linked form of the enzyme then the 
problem of interference would be overcome. To this end studies were 
carried out using the NAD linked G6PDH obtained from Leuconostoc 
mesenteroides.
The compound known as Cibacron Blue F 3GA (or more recently, 
since the renaming of dyes produced by Ciba, as Cibacron Blue 3GA) has 
the structure shown in Figure 4.4, and is known to be a potent inhibitor 
of several enzymes including kinases and dehydrogenases (e.g. Apps and 
Gleed, 1976; Beissner and Rudolph, 1978(a): Boehme et al., 1978; Ashton 
and Polya, 1978). Cibacron Blue 3GA and related compounds have been 
widely used in the preparation of affinity columns for the purification 
of such proteins (Boehme et al., 1972; Beissner and Rudolph, 1978(b)). 
The precise nature of the interaction between Cibacron Blue and the 
enzymes is not fully understood and is still the subject of much debate 
(see Stellwagen, (1977) and Grazi et al. (1978) for opposing views and 
Beissner and Rudolph, (1979) for a more recent investigation).
The theories proposed suggest that the interaction may be 
hydrophobic, a combination of hydrophobic and electrostatic, 
nucleotide-specific, or "dinucleotide-fold" specific, but as yet the 
mode of action is not clear. One further problem with Cibacron Blue 3GA 
is that the commercially available dye is by no means pure, and after 
the dye was examined using preparative column chromatography, many minor 
components were obtained (Weber et al. 1979).
No literature relating to the use of Cibacron Blue with 
glucose-6-phosphate dehydrogenase was uncovered and therefore 
experimental investigations were carried out to determine whether or not 
the dye would be a useful inhibitor of this enzyme.
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FIGURE 4.3
THE STRUCTURE OF AURINE TRICARBOXYLIC ACID
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FIGURE 4.4
THE STRUCTURE OF CIBACRON BLUE 3GA
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4.2.1.2 MATERIALS
D-Glucose-6-phosphate (monosodium salt), |3-nicotinamide adenine 
dinucleotide (grade III), glucose-6 -phosphate dehydrogenase (type XXIV
from Leuconostoc mesenteroides), aurine tricarboxylic acid (ammonium 
salt) and tris (hydroxymethy1) aminomethane ('Tris') were purchased from 
Sigma Chemical Company Limited, Fancy Road, Poole, Dorset, BH17 7NH. 
Hydrochloric acid (concentrated) was obtained from Fisons Scientific
Apparatus, Loughborough, Leicestershire. The Cibacron Blue 3GA was a
gift from Ciba-Geigy (UK) Limited, Dyestuffs and Chemicals Division,
Clayton, Manchester, Mil 4AR,
Unless specified, all reagents were of the highest grade or purity
available.
4.2.1.3 METHODS
An initial experiment was carried out to determine the
Michaelis constant (Kj^ ) values for glucose-6-phosphate and NAD using the
enzyme preparation from Leuconostoc mesenteroides. The initial velocity
(v^) of the enzyme reaction was monitored at 340nm using a Bauch and
Lomb spectrophotometer holding cuvettes of a 1 cm pathlength. All
c
reagents and the rea^ion cuvette were maintained at 20°C throughout the 
experiment. The final concentrations of the components of the reaction 
cuvette were as follows: Tris-HCl buffer pH 7.5 (50mM),
Glucose-6-phosphate (varied from 12pM to 300pM), NAD (varied from 20pM 
to 500pM), and Glucose-6-phosphate dehydrogenase (0,46mU/ml).
The concentrations of each of the two substates were varied in 
turn in five stages through the ranges given above. Measurements were 
therefore made at 25 different combinations of substrate 
concentrations. The reaction was started by the addition of the enzyme, 
and the formation of NADH was followed by the increase in absorbance at 
the above wavelength. Each reaction was monitored for three minutes, 
with readings of absorbance taken every minute. The reaction was 
observed to be linear over this time period.
Inhibition experiments studied the effect of the addition of 
ATA and Cibacron Blue to the reaction mixture.
In these invesitgations glucose-6-phosphate was maintained at 
300pM (fixed substrate) while the concentration of NAD was varied in 
five stages as before. At each of the five levels of varying substrate, 
measurements of initial velocity were taken in the absence of inhibitor 
and in the presence of four different inhibitor concentrations. The 
inhibitor concentrations used were lOpM, 50pM, lOOyiM and 150pM for ATA
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and 0,5pM, IpM, 2.5pM and 5pM for Cibacron Blue. The experiment was 
repeated with glucose-6-phosphate as the varying substrate with NAD 
maintained at 500pM throughout. As before the reaction was monitored by 
following the increase in absorbance at 340nm for the first three 
minutes of the reaction.
All enzyme rate measurements were carried out in duplicate.
4.2.1.4 RESULTS
The mean of the duplicate observations of the first three 
minutes of the reactions was taken to be a measurement of initial 
velocity (v^). The manual determination of the kinetic constants 
involved the plotting of 1/v^ against reciprocal substrate concentration 
in the manner of Lineweaver and Burk (1934). This plot has been the 
subject of some criticism (Wilkinson, 1961; Dowd and Riggs, 1965), but 
it can be defended (Engel, 1977), and with careful use it is a quick and 
simple way of determining the kinetic constants. The computer program 
used in conjunction with the manual method allowed an objective analysis 
of the error distribution within the data, and the results reported 
below are those calculated using this program. In all cases only minor 
differences were found between the computer calculated kinetic constants 
and those obtained by the drawing of secondary plots (slope or intercept 
of the primary plots are plotted against reciprocal concentration of the 
'fixed' substrate, in the determination of Kj^ , and against inhibitor 
concentration in the determination of K^). Figure 4.5 shows a typical 
primary plot. The points shown are the experimental values observed, and 
the lines drawn represent the computer calculation using the weighted 
regression analysis.
Summary of Kinetic Constants Determined
Glucose-6 -phosphate NAD
Km 253yM 489yM
Glucose-6 -phosphate
varied
NAD
varied
ATA Ki 19.4yM 13.7yM
Cibacron %i
1
1.50yM 1.40yM
Blue
4.2.1.5 DISCUSSION
The values tabulated above are both approximately 4,7 times 
higher than the values reported by Olive et al. (1971) in their studies 
on the G6FDH from Leuconstoc mesenteroides (quoted values being; Kj^(G6P) 
42.7yM and K^CNAD) 106yM). The conditions used in this present study are
FIGURE 4.5
A TYPICAL PRIMARY PLOT SHOWING EXPERIMENTAL POINTS 
AND COMPUTER FITTED REGRESSION LINES
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at [NAI^  = O.OlmM are not included)
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comparable to those used by Olive ^  al. (the only significant 
difference being that of temperature), and the reason for the variation 
between the published and the experimental values is unknown. This 
difference, however, meant that the experimental design was less than 
ideal as the range of substrate concentrations used was calculated on 
the assumption that the values observed would be close to the
published values. A better range of substrate concentrations would have 
been from 50pM to 1.25mM for G6P and from lOOpM to 2.5mM for NAD. 
Despite the differences seen, however, both published and experimental 
Kjq values for the interaction of NAD with the Leuconostoc enzyme are
much higher than the values found for the association of NADP and the 
yeast G6PDH that were used in the studies of Hsu and Joshi (1977).
This may explain the low potency of inhibition seen in the
experimental studies using ATA. Hsu and Joshi found values of the 
order of 10-^M using ATA and the NADP-linked yeast enzyme (i.e. 
approximately 1 0 0 times lower than observed in this present study) but
this result could possibly have been predicted from a consideration of
the differing affinities of the two enzymes for their respective 
coenzymes.
No published investigations involving the inhibition of the 
Leuconostoc G6PDH by Cibacron Blue 3GA were discovered. However, the Kj^  
values obtained were of the order of 1 0”^  and this is within the range 
of values published for the inhibition of other enzymes by the dye.
The study of the action of the two inhibitors indicated that 
Cibracon Blue 3GA is the more potentially useful of the two in the 
development of a model homogeneous inhibitor-based enzyme immunoassay 
system. Although the interaction between the enzyme and the inhibitor is 
not as potent as was hoped, it was thought that it would be sufficient 
for a model system to be produced, although such a system would, 
theoretically, be lacking in sensitivity.
4.2.2 CONJUGATION STUDIES USING CIBRACON BLUE 3GA
4.2.2.1 INTRODUCTION
Haptens for conjugation were selected using the criteria 
discussed earlier of chemical suitability, antiserum availability and 
clinical usefulness. The two haptens initially selected for study were 
digoxin and methotrexate.
Digoxin is a cardiac glycoside derived from naturally occurring 
compounds found in plants of the species Digitalis. Digoxin is taken 
orally by patients with congestive heart failure and can maintain such 
patients in a reasonably active state of health for many years (Walton
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and Gazes, 1971). However digoxin has a relatively low therapeutic index 
and as the correlation between oral dose and serum concentration has 
been shown to be poor, the regular monitoring of blood levels is 
required, particularly when the maintenance dose is being established.
The measurement of serum methotrexate levels is also very 
important in clinical terms. Methotrexate is a folate analogue and is an 
effective agent in the treatment of leukaemia and other tumours. It is 
one of the most versatile antineoplastic agents because its toxicity at 
high dose regimens can be largely prevented by the reduced folate, 
leucovorin (5-formyltetrahydrofolate). Toxic effects are seen in 
patients who have a delayed clearance of the drug, and can be fatal, so 
again the regular monitoring of blood levels is required (Stoller 
et al., 1977).
Both digoxin and methotrexate possess chemical groups suitable 
for conjugations to be carried out (see Figure 4.6), and antisera raised 
to both of these hatpens were available.
4.2.2.2 MATERIALS
Isobutylchloroformate, l-ethyl-3-(3-dimethylaminopropyl
hydrochloride) carbodiimide, ethylene glycol, Norit A charcoal, and 
bovine serum albumin (fraction V) were purchased from the Sigma Chemical 
Company Limited, Fancy Road, Poole, Dorset, BH17 7NH. Bio-gel P2 
(200-400 mesh) was obtained from Bio-Rad Laboratories, 32nd and Griffin, 
Richmond, California, USA. Methotrexate was from the American Cyanamid 
Company, Pearl River, NY 10965, USA. Gelatin (L8 grade) was purchased 
from the Oxoid Company, Southwark Bridge Road, London, SEl. Dextran T-70 
was from Pharmacia Fine Chemicals AB., Uppsala, Sweden. Digoxin and 
radio-labelled digoxin were obtained from as a gift from Mr. B. A. 
Morris and the radiolabelled methotrexate was donated by Dr. G. W. 
Aherne. Mr. Morris and Dr. Aherne are both members of the Department of 
Biochemistry, University of Surrey, Guildford. Anti-digoxin serum 
(G/S/5IIIA) and anti-methotrexate serum (G/S/261 20/3/75) were obtained 
from Guildhay Antisera, Division of Clinical Biochemistry, Department of 
Biochemistry, University of Surrey, Guildford. Absolute ethanol was 
obtained from James Burrough Limited, Fine alcohols division, 60 
Montford Place, London, SEll. Dioxane was from the Aldrich Chemical 
Company, Gillingham, Dorset, SP8 4JL. 'Tris', hydrocholoric acid, and 
Cibacron Blue were from the sources described previously. All other 
chemicals were purchased from British Drug Houses Chemicals Limited, 
Poole, Dorset, BH12 4NN.
Unless specified, all reagents were of the highest grade or 
purity available.
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FIGURE 4.6
THE STRUCTURES OF DIGOXIN AND METHOTREXATE
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4.2.2.3 METHODS
(a) Conjugation of Digoxin to Cibacron Blue
The procedure used was that of Butler and Chen (1967) who 
linked digoxin to amino groups in bovine serum albumin, in order to 
produce an antiserum to digoxin. As Cibacron Blue has a free amino 
group, this method, which involves the use of periodate to open the 
sugar ring of the digoxin molecule, was attempted. The reaction scheme 
is outlined in Figure 4.7.
Digoxin (lOmg) was added to 6 ml of O.IM sodium periodate, 8 ml 
of absolute ethanol and 2ml of dioxane. The reaction mixture was stirred 
for 30 minutes at room temperature using a magnetic stirrer. After 30 
minutes 1.8ml of IM ethylene glycol was added followed by lOmg of 
Cibacron Blue 3GA dissolved in 2ml of distilled water adjusted to pH 9.3 
with 5% potassium carbonate. The solution was stirred for one hour at 
room temperature with the pH being maintained in the range 9.0 to 9.5 by 
the further addition of 5% potassium carbonate. After this time 60mg of 
sodium borohydride was added and the solution left at room temperature 
for 24 hours.
The reaction products were separated using a Bio-gel P2 
(200-400 mesh) column (18cm x Icm^) equilibrated in Tris-HCl buffer O.IM 
pH 7.5. The fractions were eluted using the equilibration buffer and a 
flow rate of 0.4ml/minute. The fractions obtained were studied in 
various ways.
The absorbance of the fractions at a wavelength of 622nm was
measured as a monitor of the presence of Cibacron Blue, while the
inhibitory effect of the fractions on G6PDH was studied to determine if 
the dye had retained its inhibitory action. The inhibition studies were 
carried out using the system used for obtaining kinetic information 
which has already been described. The digoxin content of the fractions 
was measured using the radioimmunoassay method described below.
(b) Digoxin Radioimmunoassay
The method employed was that currently in use at the University 
of Surrey. It is based on the Burroughs Wellcome 'Lanoxitest-V and 
'Lanoxitest-p* kits using the 1^25 labelled digoxin of the * y  kit in 
conjunction with the single antibody of the *3’ kit. Phase separation
was effected using albumin coated charcoal. Glass apparatus was used
throughout as digoxin binds appreciably to plastic tubes. The assay 
protocol is shown in Figure 4.8. The reagents used were prepared as 
follows :
Phosphate buffer. A stock buffer solution was prepared to a
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FIGURE 4.7
THE CONJUGATION METHOD OF BUTLER AND CHEN (1967)
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FIGURE 4.8 THE ASSAY PROTOCOL FOR THE RADIOIMMUNOASSAY OF DIGOXIN
All volumes in jil Total Non- Maximum
Tubes specific binding
binding
Zero Standard Test
Standard Curve Sample
Assay Buffer
Digoxin Antiserum 
(Initial dilution 
of 1 in 5000)
Digoxin Antiserum 
(Initial dilution 
of 1 in 2 0 0 0 0 )
Digoxin Standard
Test Sample
Radiolabelled
Digoxin
Charcoal
Suspension
100
200 100
100
100 50
100
100 100 100
100
50
100
Incubate for 30 minutes at 4°C 
100 100 100 100
50
100
50
100
100
Leave for ten minutes. Centrifuge, aspirate the 
supernatant and count the radioactivity 
remaining in the pellet.
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concentration of 40mM and adjusted to pH 7.4. The stock buffer contained 
1% sodium azide. Immediately prior to use, 1% bovine serum albumin was 
added to the required volume of stock buffer.
Digoxin standards. l.Omg of digoxin was dissolved in 10ml of
warmed ethanol. Once the solid was dissolved, phosphate buffer was added
to a final volume of 100ml. This stock solution of lOpg/ml was diluted 
on the day of use to provide a range of standards from 0.38ng/ml to 
6 .0 ng/ml.
Labelled digoxin. The il25 labelled digoxin obtained
commercially was diluted as recommended by the manufacturers so that 
lOOpl of the diluted reagent added to the assay tubes contained 40 pg of 
digoxin.
Digoxin antiserum. A stock solution was prepared by diluting 
lOpl of neat antiserum (Guildhay G/S/5-IIIA) to 50ml with buffer. On the 
day of use the required volume of stock solution was diluted in buffer 
in the ratio of 1ml of stock made up to a volume of 8ml.
Coated charcoal suspension. Barbitone (3.68g), sodium barbitone 
(20.68g), bovine albumin (2.0g), sodium azide (l.Og) and Norit A
charcoal (25g) were added to a beaker, distilled water added to a volume 
of 1 litre, and the suspension stirred on a magnetic stirrer at 4°C 
overnight.
In view of the short period of incubation all reagents were
cooled to 4°C before use. After addition of the charcoal suspension, the
tubes were vortexed and then stood for a further 10 minutes at 4°C
before being centrifuged (again at 4®C) for 15 minutes at lOOOg. The
supernatant was removed by aspiration and radioactivity present in the 
charcoal pellet was measured using LKB *Rackgamma* counter.
(c) Conjugation of Methotrexate to Cibacron Blue
Two different methods were investigated in this study, but both 
act by aiding the formation of a peptide bond. The first was the mixed 
anhydride method of Marks et al. (1978) in which the link is achieved by 
the use of isobutylchloroformate, while the second, basically that of 
Dray ^  al. (1975), involved the use of the water soluble l-ethyl-3- 
(3-dimethylaminopropyl) carbodiimide. An outline of the reactions 
involved in these two methods is shown in Figure 4.9.
(i) Mixed Anhydride method.
Methotrexate (6 .8mg) and tri-n-butylamine (lOpl) were added 
sequentially to 0 .1ml of dimethylformamide and the solution was cooled 
to 10°C. Isobutylchloroformate (20pl) was added and the mixture was 
maintained at 10°C for 10 minutes with occasional vortex mixing, A
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FIGURE 4.9(a)
AN OUTLINE OF THE REACTIONS INVOLVED IN THE 
MIXED ANHYDRIDE CONJUGATION METHOD
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FIGURE 4.9(b)
AN OUTLINE OF THE REACTIONS INVOLVED IN THE 
CARBODIIMIDE CONJUGATION METHOD
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solution of Cibacron Blue (7mg in 2ml distilled water adjusted to pH9 
with sodium hydroxide) was added and the reaction mixture was stirred 
for 3 hours at 10°C. After overnight storage at 4°C, the reaction 
products were separated using a Bio-gel P2 column as described for the 
digoxin conjugations.
(ii) Carbodiimide method.
A solution of 5mg methotrexate in 2ml of Tris-HCl buffer O.IM 
pH 7,5 was mixed with 0.4ml of IM l-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide and allowed to stand for 30 minutes at room temperature. 
After this time 1ml of distilled water containing 5mg of Cibacron Blue 
was added. The solution was mixed and left overnight at 4°C before being 
separated using a Bio-gel P2 column as previously described.
Both sets of fractions were examined spectrophotometrically at 
622nm (to measure Cibacron Blue), and at 360nm (to measure 
methotrexate). Methotrexate was also measured by radioimmunoassay as 
described below.
(d) Methotrexate Radioimmunoassay
This was carried out in the manner employed in the clinical
biochemistry laboratories of the University of Surrey as part of the
Supra-Regional Assay Service. A detailed assay protocol is given in
Figure 4.10. The reagents required were prepared as follows
H
Assay buffer. Phosnate buffer 0.5M pH 7.4 was prepared 
containing 0.172g merthiolate, 6g sodium chloride, and Ig gelatin per 
litre.
Methotrexate antiserum. Guildhay antiserum (G/S/261 20/3/75)
was obtained neat and diluted in assay buffer to an initial dilution of 
1 in 5000.
Radioactive methotrexate. This was obtained as the kind gift of 
those carrying out the assay in a routine manner within the Department. 
It was prepared by them by the method of Kamel and Gardner (1978) and 
was diluted in assay buffer to give total counts of 10000 counts per 
minute per tube.
Methotrexate standards. A Img/lOml stock solution of 
methotrexate in assay buffer was prepared. This was used to prepare a
range of working standards from 0.5 to lOng/ml. These were prepared by 
dilution in assay buffer on the day of use.
Dextran-coated charcoal. Norit A charcoal (25g) and dextran
T-70 (2.5g) were suspended in 1 litre of assay buffer and allowed to 
stir overnight at 4°C. The fines were removed after centrifugation and 
the charcoal resuspended in assay buffer to a volume of 1 litre.
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FIGURE 4.10 THE ASSAY PROTOCOL FOR THE RADIOIMMUNOASSAY OF METHOTREXATE
All volumes in pi Total
Tubes
Non- Maximum 
specific binding 
binding
Zero Standard 
Standard Curve
Test
Sample
Assay Buffer - 500 400 300 300
Methotrexate
Standard
- — — - 100 -
Test Sample - — — - - 100
Methotrexate
Antiserum
- 500 100 100 100
Radiolabelled
Methotrexate
100 100 100 100 100 100
Incubate for 50 minutes at room temperature and then 
for 10 minutes in ice.
Dextran Coated 
Charcoal
- 100 100 100 100 100
Leave for fifteen minutes. 
supernatant and count 
remaining in
Centrifuge, aspirate the 
the radioactivity 
the pellet.
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(e) Antiserum Dilution Curves
The separation fractions, which appeared to contain the 
required conjugate, were mixed with various dilutions of the specific 
antiserum to see if the desired effects could be observed. In the 
proposed assay system the addition of antiserum should, by binding to 
the inhibitor-hapten conjugate, regenerate the enzyme activity that is 
inhibited when the conjugate is acting in the absence of antiserum. To 
see if this situation existed, the fraction under test was mixed in a 
reaction cuvette containing: Tris-HCl buffer 50mM pH 7.5,
glucose-6-phosphate (300jiM), NAD (500pM), anti-methotrexate antiserum 
diluted in the range 1/200 to 1/18000, and glucose-6-phosphate 
dehydrogenase (0.46mU/ml).
Sufficient of the conjugate was added to produce a measurable 
degree of inhibition in the absence of antiserum. To confirm that any 
effect seen was due to the presence of the specific antibodies, the
experiment was repeated with the antiserum replaced by the same range of 
dilutions of normal sheep serum. Also to confirm the specific nature of 
any effect the experiment was repeated using pure Cibacron Blue instead 
of the conjugate fraction under test.
4.2.2.4 RESULTS
(a) Digoxin-Cibacron Blue Conjugation
The first Bio-gel separation of the reaction products gave the 
absorbance and inhibition pattern shown in Figure 4.11(i). This was an 
encouraging result with two peaks of absorbance and inhibitory activity 
being seen. However, it had not been shown that the larger molecule
eluting in fractions 12 to 14 was in fact a conjugate of Cibacron Blue 
and digoxin. To investigate this a second separation of the same 
reaction products was carried out, and the fractions examined for 
absorbance at 622nm and for digoxin by radioimmunoassay. The result of 
these investigations is shown in Figure 4.11(ii). (N.B. In the digoxin 
radioimmunoassay each fraction was studied at several dilutions and 
therefore in order to restrict the assay to a reasonable size, the 
elution fractions taken in the second separation were of a larger 
volume.)
As can be seen from Figure 4.11(ii), only one peak of digoxin
was seen and this did not coincide with either of the two Cibacron Blue
peaks observed.
(b) Methotrexate-Cibacron Blue Conjugations
Both of the conjugation methods employed gave what appeared to 
be suitable products, both showing a first peak containing both
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FIGURE 4.12
THE SEPARATION OF THE METHOTREXATE/CIBACRON BLUE 
MIXED ANHYDRIDE CONJUGATION PRODUCTS
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FIGURE 4.13
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methotrexate and Cibacron Blue. The mixed anhydride products were 
studied in most detail and the results of the investigations made of the 
Bio-gel elution fractions of these products are shown in Figure 4.12.
Figure 4.13(i) and (ii) show the antiserum dilution curves seen
when various dilutions of anti-methotrexate antiserum or normal sheep
serum were added to an enzyme reaction mixture containing an aliquot (a)
of a pool of fractions 3 and 4 of the mixed anhydride conjugation, or
(b) of unreacted Cibacron Blue.
4.2.2.5 DISCUSSION
“  BLjlA«L
The results of the digoxin-Cibacronj^ conjugation attempt
appeared to be encouraging when fractionation with a Bio-gel column 
revealed two peaks of the dye, both of which exerted inhibitory action. 
However, the digoxin radioimmunoassay showed only one peak of 
immunoassayable digoxin, and indicated that this peak did not coincide 
with either of the two Cibacron Blue peaks. The nature of the peak 
eluted first in Figure 4.11(i) was not determined, but it would seem 
probable that the reaction conditions produce some form of 
polymerisation of the dye so yielding the higher molecular weight 
compound seen.
Figure 4.12 shows the results of the mixed anhydride 
conjugation between methotrexate and Cibacron Blue. As can be seen from 
Figure 4,12(i) the spectrophotometric studies indicated that the first 
peak contained both methotrexate and Cibacron Blue. This observation was 
confirmed by the results of the methotrexate radioimmunoassay shown in 
Figure 4.12(ii), From these results four observations can be made, (i) 
two peaks of immunoreactive methotrexate are present, (ii) the position 
of the methotrexate peaks by radioimmunoassay correspond closely with 
those found by measuring at 360nm, (iii) the relative size of the peaks 
is different in the two methods - if the 360nm values are taken as the 
* total methotrexate* and the radioimmunoassay values as *immunoreactive 
methotrexate*, it can be seen that the methotrexate in the first peak 
only cross reacts by about 5%, and (iv) the very high dilutions of the 
fractions required for the radioimmunoassay, bearing in mind that the 
elution fractions are not diluted further for inhibition studies, is an 
indication of the eventual insensitivity of the proposed method using 
Cibacron Blue. This insensitivity is due to the relatively *weak* 
interaction of the dye with the enzyme G6PDH, but this in itself would 
not prevent the use of Cibacron Blue in a model system.
The next stage in the development of such a model system was
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the preparation of antiserum dilution curves and unfortunately the
results obtained in these studies were not encouraging. When the 
#
fractions containing the first peak eluted from the mixed anhydride 
conjugation were pooled and added to the enzyme G6PDH a significant 
degree of inhibition resulted.
This inhibition could be almost totally abolished by the 
addition of sufficient quantities of anti-methotrexate antiserum. These 
two results would be required in the proposed model system. However, it 
was also discovered that when normal sheep serum was used in place of 
the specific antiserum, the same abolition of inhibition occurred. 
Further studies showed that the inhibition resulting from unreacted 
Cibacron Blue itself was also abolished in the presence of both 
antiserum and normal sheep serum. This was not investigated in more 
detail but it was assumed that the regeneration of the enzyme activity 
was due to non-specific binding of the Cibacron Blue to proteins 
(particularly albumin) present in the serum. This non-specific effect 
appeared to mask any specific interaction which may or may not have 
occurred between the conjugate and the antibodies in the 
anti-methotrexate serum.
This problem of non-specific binding of the dye could be 
overcome by cleaning up the antiserum in some way. This could be carried 
out simply by selective protein precipitation using ammonium sulphate, 
or more efficiently using affinity chromatography.
Although such solutions to the problem are possible, it was 
decided that this extra complication, coupled with the lower than hoped 
for potency of inhibition of Cibacron Blue 3GA, would diminish the 
usefulness of the dye in a model system and so another enzyme/inhibitor 
combination was investigated.
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4.3 DIHYDROFOLATE REDUCTASE
4.3.1 ENZYME STUDIES
4.3.1.1 INTRODUCTION
Due to the non-specific effects seen with Cibacron Blue and to 
the fact that the alternative G6FDH inhibitor, aurine tricarboxylic 
acid, was significantly less potent, it was decided that a change to a 
system involving a much stronger enzyme inhibitor might be beneficial. 
This change would hopefully mean that less antiserum would be required 
per tube and hence mean that any non-specific effects would be reduced 
to negligible proportions.
The new system chosen for study was that in which methotrexate
was used, not as the measured hapten, but as an inhibitor of the enzyme
dihydrofolate reductase (EC 1.5.1.3).
Published literature indicated that values for the
interaction of methotrexate and dihydrofolate reductase were in the 
range 2.3iklO'"%I to 5.0xl0~^^M depending on the source and preparation of 
enzyme used (Williams e^ al., 1980; White, 1979). The structure of 
methotrexate has already been given in Figure 4.6. It inhibits the 
enzyme in a competitive manner, acting as an analogue of folic acid. In 
a system involving the use of dihydrofolate reductase, interference from 
enzyme present in the serum sample would not be expected as, although 
the enzyme occurs in human cells, it is not normally found in the 
extracellular space (Bergmeyer, 1974).
The enzyme activity detection method used was a modification of
a published system (Bergmeyer 1974) in which the substrates were NADPH
and dihydrofolate. (Folate can also be used as a substrate, but the rate 
of reaction is much slower.) The NADPH was obtained commercially while 
the unstable dihydrofolate was synthesised weekly from folate by 
chemical reduction.
Initial studies aimed to determine the kinetic properties of 
the enzyme preparation used under the experimental conditions employed.
4.3.1.2 MATERIALS
Folic acid and bovine liver dihydrofolate reductase were 
purchased from Sigma Chemical Company Limited, Fancy Road, Poole, 
Dorset, BH17 7NH. Concentrated hydrochloric acid was from Fisons 
Scientific Apparatus, Loughborough, Leicestershire. Reduced nicotinamide 
adenine dinucleotide phosphate was obtained from Cambrian Chemicals, 
Beddington Farm Road, Croydon CRO 4XB. All other chemicals were obtained 
from British Drug Houses Chemicals Limited, Poole, Dorset, BH12 4NN.
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All reagents were of the highest grade or purity available.
4.3.1.3 METHODS
(a) Synthesis of Dihydrofolate (as reported by Bergmeyer (1974))
Ascorbic acid (Ig) was dissolved in 4ml of distilled water in a 
25ml conical flask with stirring achieved using a magnetic stirrer. The 
pH was adjusted to 6.0 by the careful addition of IM sodium hydroxide 
and then a further 10ml of distilled water was added. Folic acid 
(38,2mg) was dissolved in 1.6ml of IM sodium hydroxide and added to the 
ascorbate solution. Sodium dithionite (400mg) was added with stirring. 
When the dithionite was completely dissolved the stirring was continued 
for a further 5 minutes. The mixture was then cooled in an ice bath to 
below 5°C while continuing to be stirred. All following steps were 
carried out with the temperature of the reaction mixture maintained at 
less than 5°C. The pH was reduced to 2.8 by the dropwise addition of IM 
hydrochloric acid. After stirring for 5 minutes at this pH, the 
precipitate was concentrated using a refrigerated centrifuge (5 minutes 
lOOOg). The supernatant was removed and the precipitate resuspended in 
10ml of 10% sodium ascorbate solution. While the liquid was stirred the 
pH was brought to 6.0 by the addition of IM sodium hydroxide. The slow 
dropwise addition of IM hydrochloric acid was then used to produce the 
crystallisation of dihydrofolate. The crystallisation was complete 5 
minutes after the attainment of pH 2.8. The precipitate was concentrated 
by centrifugation as before and washed three times with approximately 
10ml of cold 5mM hydrochloric acid.
The crystals were resuspended in 4ml of 5mM hydrochloric acid 
and stored in the dark 0 °C. Concentrations of dihydrofolate were 
determined using the published extinction coefficient of a solution of 
dihydrofolate in lOmM potassium hydroxide. (£=22cm^/pmol at 283nm)
(b) Enzyme assays
The method used was that of Bergmeyer (1974). All absorbance 
measurements were carried out using a Cecil CE 292 Digital 
Spectrophotometer fitted with micro-Sipette and digital printer. The use 
of this spectrophotometer enabled absorbance measurements to be both 
frequent and precise. The reaction was monitored by following the 
decrease in absorbance at 340nm due to the oxidation of NADPH. In a 
final reaction volume of 0 .6ml the following components were present : 
Citrate buffer (O.IM pH 5.4), 2-mercaptoethanol (12.5mM), NADPH (varied 
in five stages from 0.04mM to ImM), dihydrofolate (varied in five stages 
from 1.4pM to 34.7pM), and dihydrofolate reductase (13mU/ml). The
reaction at 30oç ^ 3 5 followed for 1 .5 minutes with readings being taken
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every 10 seconds. In the inhibition studies methotrexate was present at 
the final concentrations of 0.2 to 20nM. The procedure adopted for the 
determination and calculation of the kinetic constants was as described 
for glucose-6-phosphate dehydrogenase.
4.3.1.4 RESULTS
As previously, duplicate or triplicate measurements were taken 
and the mean values used in the calculations. These calculations were 
carried out both manually and by computer analysis for the reasons 
already discussed.
The computer calculated values are shown tabulated below.
NADP Dihydrofolate
Km 2.34 X 10"3m 4.46 X l Q - %
NADP Dihydrofolate
varied varied
methotrexate 2.19 X 10-% 1.03 X 10-%
4.3.1.5 DISCUSSION
These results are more encouraging than those obtained with the 
G6PDH system described previously. The high potency of the inhibition 
seen with methotrexate would mean that should a suitable conjugate be 
produced much less antiserum would theoretically be needed to block the 
inhibitory action than would theoretically be required with the use of a 
less potent inhibitor such a Cibacron Blue. This may well prevent 
problems due to non-specific interactions. It should, in principle, also 
result in a more sensitive assay. The next stage of the investigation 
was to attempt to produce suitable conjugates with the inhibitor 
methotrexate.
4.3.2 CONJUGATION STUDIES USING METHOTREXATE
4.3.2.1 INTRODUCTION
Obviously the use of methotrexate as an inhibitor meant that it 
could no longer be used as a model hapten and therefore it was necessary 
to select new model haptens. As has already been stated, haptens were 
chosen on the basis of (i) availability of antiserum, (ii) presence of 
suitable functional groups on the hapten and (iii) clinical usefulness 
of the measurement of the hapten.
Factor (ii) is important in a consideration of methotrexate as
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its high potency of inhibition is dependent on the specific structure of 
the pteroyl rings. Therefore the conjugation would need to take place at 
the ’other end’ of the methotrexate molecule i.e. via the carboxyl 
groups of the glutamic acid residue. On the basis of this, and with the 
other two factors borne in mind, the tricyclic antidepressant 
nortriptyline and the thyroid hormone thyroxine were selected for 
further study. Figure 4.14 shows the structure of these two compounds.
4.3.2.2 MATERIALS
L-Thyroxine was purchased from the Sigma Chemical Company 
Limited, Fancy Road, Poole, Dorset, BH17 7NH. L-(3’,5’-^^^I) thyroxine 
was obtained from The Radiochemical Centre, Amersham, Buckinghamshire, 
HP7 9LL. Sephadex G 15 was obtained from Pharmacia Fine Chemicals, 
Uppsala, Sweden. Nortriptyline hydrochloride was a gift from Mrs. E. 
Piall of the Department of Biochemistry, University of Surrey Guildford, 
Surrey. The anti-thyroxine serum (HP/R/142-I), anti-nortriptyline serum 
(259 29/6/76), donkey anti-rabbit serum (D66 19/9/79) and normal sheep 
serum were all obtained from Guildhay antisera. Division of Clinical 
Biochemistry, Department of Biochemistry, University of Surrey, 
Guildford, Surrey, GU2 5XH. The sources of all other chemicals used have 
already been detailed earlier in this chapter.
All reagents were of the highest grade or purity available.
4.3.2.3 METHODS
(a) Nortriptyline Conjugation Methods
The methods used for the conjugations were the mixed anhydride 
method (Marks al., 1978) and the carbodiimide method (Dray ^  al.,
1975) as previously.
(i) Mixed Anhydride Method
Methotrexate (6 .8mg) was dissolved in dimethylformamide (0.1ml) 
before the addition of lOpl of tri-n-butylamine. After cooling to 10°C, 
lOpl of isobutylchloroformate was added and the mixture left, with 
occasional mixing, at this temperature for 30 minutes. After the 
addition of 3.3mg of nortriptyline previously dissolved in 2.0ml of 
distilled water, the pH was adjusted to 7.0 and the reaction mixture 
allowed to stand overnight at 4°C. The reaction products were separated 
using a Sephadex G 15 (fine grade) column of dimensions 15cm x Icm^. The 
eluant was Tris buffer pH 7.5 O.IM. The fractions produced were examined 
spectrophotometrically for methotrexate (360nm) and nortriptyline 
(240nm).
(ii) Carbodiimide Method
Methotrexate (5mg) was dissolved in 1ml of Tris-HCl buffer
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FIGURE 4.14
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(O.IM pH 7.5) at room temperature, followed by the addition of 1.4ml of 
IM l-ethyl-3(3-dimethylaminopropyl hydrochloride) carbodiimide. After 
mixing for 30 minutes at room temperature, 3.3mg of nortriptyline was 
added as a solution in 1ml of distilled water. The solution was left at 
room temperature for a further two hours with occasional mixing and
stood overnight at 4°C before being fractionated as above. The fractions 
were examined in the way described above.
(b) Enzyme inhibition and activity regeneration experiments
In all of the experiments the same conditions were used as for 
the determination of the kinetic constants, the only extra components 
being a dilution of the fraction under test and a dilution of 
nortriptyline antiseum (Guildhay 259 29/6/76). The specific antiserum 
was replaced in control experiments by normal sheep serum to monitor the 
effect of any non-specific actions. The study was carried out on a pool 
of fractions 7-10 from the separation of the carbodiimide reaction
products. The antiserum and normal sheep serum was added to a final
dilution of 1/24.
(c) Thyroxine conjugation method
The other hapten investigated for possible conjugation to 
methotrexate was thyroxine. The conjugation method employed was that 
involving the use of a mixed anhydride. The method was as follows. 
Methotrexate (6 .8mg) was dissolved in dimethylfor^mide (0.1ml) before 
the addition of l.Ojil of tri-n-butylamine. After cooling to 10°C
isobutylchloroformate (lOpl) was added and the solution left with 
occasional mixing for 30 minutes. A solution containing 13.3mg of 
thyroxine in 2ml of distilled water adjusted to pH 9.5 with sodium 
hydroxide was added. The solution was left at 10°C for a further 4 hours 
with occasional mixing and the maintenance of the pH in the range 9.0 to 
9.5.
Separation of the reaction products was achieved using a 
Bio-gel P2 column of dimensions 52cm by 0.5cm^. The eluant was Tris-HCl 
buffer O.IM pH 7.6. The fractions were examined for methotrexate (by 
absorption at 360nm) and for thyroxine (by radioimmunoassay).
(d) Thyroxine radioimmunoassay
This assay used a first antiserum raised in rabbits, and 
anti-rabbit globulin from donkeys as a separation method. After 
centrifugation and aspiration of the supernatant, the radioactivity 
present in the pellet was counted. The reagents used were as follows : 
Barbitone buffer 0.05M pH 8 . 6 was mixed with 0.1% bovine serum albumin 
to produce the assay diluent, the 1^25 labelled thyroxine was obtained
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commercially and mixed with assay diluent so that lOOyl contained 
approximately 400pg of thyroxine, rabbit anti-thyroxine was
obtained from Guildhay (HP/R/142-I) and used at a final dilution of 
1/1500, donkey anti-rabbit IgC was obtained from Guildhay (D6 6 19/9/79) 
and used at a final dilution of 1/80, and thyroxine standards in assay 
diluent in the range 15 to 240 nmol/1 were prepared on the day of use 
from frozen aliquots of a stock solution of 3.729pg/ml (dilution of the 
stock solution 1 in 10 gives a 480nmol/l solution). As equilibrium 
between a low molecular weight antigen and its antibody is rapidly 
reached it was thus possible to add first and second antisera at the 
beginning of a single overnight 4°C incubation. Centrifugation, 
aspiration and radioactivity counting took place the next day. The assay 
protocol is shown in Figure 4.15.
4.3.2.4 RESULTS
Both of the conjugation methods employed in the linking of 
nortriptyline to methotrexate gave similar elution patterns. The 
fractionation of the carbodiimide reaction products is shown in Figure 
4.16. It can be seen that although the results are not as clear as might 
have been hoped there is some indication of conjugation formation.
This indication was confirmed by the studies involving the 
addition of antiserum. An aliquot of a pool of fractions 7 to 10 was 
shown to inhibit the enzyme dihydrofolate reductase. The addition of 
normal sheep serum had very little effect on the system while the 
addition of the same dilution of specific antiserum to nortriptyline 
resulted in the regeneration of more than a third of the enzyme activity 
lost due to the presence of the conjugate. These results are shown 
below.
Enzyme Activity Enzyme Activity 
Regenerated
Unhibited reaction rate 1 0 0% —
Rate in presence of fraction 
pool diluted 1/600 (final)
52.4% —
Rate in presence of fraction 
pool and normal sheep serum (1/24)
53.3% 1.7%
Rate in presence of fraction 
pool and antiserum (1/24)
1
69.0%
. .......  1
34.8%
1
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As a result of these encouraging findings (which would be 
observed in the proposed system), a standard curve was produced. The 
enzyme system described previously was used. The only extra components 
being nortriptyline antiserum (1/24), fraction pool (1/600), and 
nortriptyline solution. The results for the addition of 1.5 and 3.0yg of 
nortriptyline were encouraging as the addition of the drug seemed to 
regenerate the conjugate’s inhibitory activity. However, when the 
standard curve was extended up to 62.5pg of drug added it was found that 
more inhibition was regenerated than had initially been lost. This 
implies that the nortriptyline itself was inhibiting the enzyme. The 
standard curve obtained is shown in Figure 4.17 and the result is 
further discussed below.
The fractionation of the products of the thyroxine conjugation 
also produced two peaks, both at 360nm (methotrexate) and in the 
thyroxine radioimmunoassay. The fractionation patterns obtained are 
shown in Figure 4.18. These results seem to indicate the production of 
the required conjugate but a consideration of the molar amounts of the 
two compounds present in the first peak indicates a considerable excess 
of methotrexate. It was thought that this was possibly the result of the 
first peak containing not only the required methotrexate-thyroxine 
conjugate, but also cross-linked methotrexate dimers. To check this the 
conjugation was repeated in the absence of thyroxine. The elution 
profile of the reaction products at 360nm was very similar to that shown 
in Figure 4.18, so indicating that the reaction conditions are 
responsible for the formation of larger molecules, composed only of 
methotrexate, which elute from the column at the same time as the 
thyroxine containing conjugate. This result is discussed further below.
4.3.2.5 DISCUSSION
The two conjugations involving nortriptyline seemed to produce 
suitable products, a finding that was confirmed by the antiserum 
studies. The attempt to produce a standard curve, however, gave the 
unexpected finding of inhibition of dihydrofolate reductase by 
nortriptyline itself. The use of a different batch of the drug showed in 
a repeat experiment that this result was not an artefact due to 
contamination of the drug material used. It was decided to carry out a 
very brief investigation of this, apparently novel, observation of 
inhibitory action. Many inhibitors of dihydrofolate reductase have been 
discovered and synthesised, but all contain in their structure a 
particular arrangement of functional groups which is not found in 
nortriptyline. Although the inhibition seen with nortriptyline is
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FIGURE 4.18
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several orders of magnitude weaker than that seen for methotrexate, it 
was still far from negligible. To further investigate this finding, the 
values for nortriptyline and five other tricyclic drugs were 
determined. The results are shown in Table 4,2. While the significance 
of these results is uncertain, it is clear that the presence of 
nortriptyline reduces the measured activity of dihydrofolate reductase, 
and for this reason it is unsuitable for use as a hapten in the proposed 
methotrexate-based assay system.
The experiments involving the use of thyroxine as the hapten in 
conjugations with methotrexate also encountered unforseen difficulties. 
The results shown in Figure 4,18 indicate the presence of a thyroxine 
containing conjugate which eluted earlier from the column than the 
unreacted hormone. However, further investigations and control 
experiments revealed that methotrexate-methotrexate conjugates produced 
by the reaction conditions were eluting in the same fraction as the 
thyroxine containing conjugate. The column used in these studies was 
52cm long and it would therefore seem that the use of the simple gel 
filtration column of reasonable proportions would not be sufficient to 
separate the cross-linked methotrexate from the required 
thyroxine-methotrexate conjugate. Two solutions to this problem are 
possible, firstly to improve the separation method so that the required 
conjugate can be purified from the reaction products, or secondly, to 
improve the conjugation procedure so as to prevent the formation of the 
cross-linked methotrexate. It was decided that this second approach was 
to be preferred as if successful, it would result in a better overall 
yield of conjugate than would be achieved by an improvement in 
separation conditions only. To this end various attempts were made to 
prevent methotrexate cross linking by the use of methods routinely used 
in peptide synthesis,
4,3,3 CONJUGATION EXPERIMENTS USING METHODS EMPLOYED IN PEPTIDE
SYNTHESIS
4,3,3,1 INTRODUCTION
One of the basic criteria of peptide synthesis is that all
reactions should lead to a single product (Bodanszky and Ondetti,
1976), This has led to the development of many different reagents
suitable for the blocking of functional groups capable of participating
in unwanted side reacions. In the synthesis of large peptides even minor
impurities can cause a severe reduction in the overall yield of the
required product. The blocking reagents developed have the dual property 
of remaining attached to the groups to be blocked throughout the peptide
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TABLE 4.2
THE INHIBITION OF DIHYDROFOLATE REDUCTASE 
BY TRICYCLIC DRUGS
DRUG STRUCTURE
■k
OF SIDE CHAIN
K. VALUES**t}lM)
V  NADPH V  DHF
NORTRIPTYLINE
" c "
II
CH-CH^-CH^-NH-CH^ 45(±15) 70 (±17)
* *
PROTRIPTYLINE
V'
1
CH^-CH^-CH^-NH-CH^ 61(±11) 86(±23)
AMITRIPTYLINE
II
CH-CH^-CH^-N(CH^)^ 146 (±28) 177(±252)
DESMETHYL-
NORTRIPTYLINE
" c "
II
CH-CH^-CH^-NH^ 249 (±109) 240 (±101)
IMIPRAMINE
'‘N' CH- 
1 3 
CH^-CH^-CH^-N
“ 3
647 (±314) 330 (±133)
BUTRIPTYLINE
'C'
1
CH^-CH-CH^-N(CH^)^
CH3
No
inhibition
No
inhibition
METHOTREXATE 4-amino-N^^-methyl 
pteroylglutamicac id
(see figure 
4.6)
21.9nM 10.3nM
* For Tricyclic Ring Structure See Figure 4.14
** Protriptyline has a double bond in the ring 
. between carbon atoms 5 and 6 . (See Figure 4.14)
*** Standard deviations shown in parentheses
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bond forming reaction, but being easily removable once that process has 
been completed.
In the proposed reaction scheme involving the conjugation of 
methotrexate and thyroxine, it should be possible to block the two free 
amino groups present in the methotrexate molecule (see Figure 4,6). This 
blocking of amino groups would eliminate the possibility of 
cross-linking occurring between methotrexate molecules, and enable the 
carboxylic acid groups present on the molecule to be activated in 
preparation for reaction with thyroxine amino groups.
Two different N-protecting reagents were employed in the 
studies; carbobenzoxy chloride and di-tert-butyl dicarbonate,
4.3.3.2 MATERIALS
Carbobenzoxy chloride was purchased from Aldrich Chemical 
Company, The Old Brickyard, New Road, Gillingham, Dorset, SP8 4JL, 
Di-tert-butyl dicarbonate and ninhydrin were from Sigma Chemical Company 
Limited, Fancy Road, Poole, Dorset, BH17 7NH, The silica gel thin layer 
chromatography sheets (product number 17181) were from Eastman Kodak 
Company, Rochester, NY 14650, USA, Methanol and absolute ethanol were 
obtained from James Burrough Limited, Fine Alcohols Division, 60 
Montford Place, London, SEll, Sodium bicarbonate and butan-l-ol were 
from British Drug Houses Chemical Company, Poole, Dorset, BH12 4NN, 
Diethyl ether, ammonia solution (33% w/w), chloroform and glacial acetic 
acid were purchased from May and Baker Limited, Dagenham.
The sources of the other chemicals used have been detailed 
earlier in the chapter.
Unless specified, all reagents were of the highest grade , or 
purity available,
4.3.3.3 METHODS
(a) Amino group blocking studies
The first method employed involved the use of carbobenzoxy 
chloride (often referred to as benzoyloxycarbonyl chloride or CBZ), The 
structure of this compound is shown in Figure 4,19, CBZ is one of the 
older N-protective groups, having been described fifty years ago by 
Bergmann and Zervas (1932), It was selected for use because it has been 
shown to be more generally applicable than some of the more recently 
developed blocking agents (Bodanszky and Ondetti, (1976),
An outline of the proposed reaction scheme is shown in Figure
4,20,
It was adapted from that used by Bergmann and Zervas (1932) in 
their studies on a wide range of amino acids. The reaction between
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FIGURE 4.19
THE STRUCTURE OF CARBOBENZOXY CHLORIDE
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FIGURE 4.20
AN OUTLINE OF THE PROPOSED SYNTHESIS EMPLOYING 
CARBOBENZOXY CHLORIDE AS A BLOCKING AGENT
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methotrexate and CBZ was carried out using a modified procedure 
described by Greenstein and Winitz (1961), This procedure consisted of 
treating a sodium bicarbonate solution of methotrexate with the acid 
chloride at room temperature. Maintenance of the pH of the solution in 
the slightly alkaline range by the sodium bicarbonate eliminates the 
need for repeated alternation between the addition of acid chloride and 
alkali which is required in the unmodified method. The details of the 
method used for blocking the amino groups as follows; Methotrexate
(73mg) was added to 2,5ml of IM sodium bicarbonate and stirred
vigorously at room temperature on a magnetic stirrer. Five lOpl portions 
of CBZ were added at approximately equal time intervals during the
following 30 minutes. The stirring was then continued for a further 60 
minutes. The products of the reaction were separated using a Bio-gel P2 
column (200-400 mesh, 43cm x Icm^) with 0,2M Tris buffer pH 7,6 as the 
eluant. Fractions of volume 1ml were collected and examined for
absorbance at 360nm as a measure of the presence of methotrexate.
The second method employed in an attempt to block the 
methotrexate amino groups was kindly suggested by Dr, D, Brundish of 
Ciba Geigy and involved the use of di-tert-butyl dicarbonate as the 
blocking agent. The structure of this compound is shown in Figure 4,21, 
and an outline of the proposed reaction scheme is given in Figure 4.22, 
The details of the blocking reaction method were as follows;
Methotrexate (25mg) was dissolved in SOOpl of a mixture of dioxan and 
water (1;1 v/v) which had been adjusted to pH9 by the addition of sodium 
hydroxide, Di-tert-butyl dicarbonate (50pl) was added and the solution 
was stirred for one hour at room temperature. The reaction products were 
washed twice with diethyl ether, the ether washings being discarded. The 
aqueous layer contained a precipitate which was collected and dried 
under a stream of air,
(b) Thin-layer Chromatography
This was carried out using plastic-backed 20cm x 20cm Silica 
gel plates which had been commercially prepared. Many different solvent 
systems were studied, and two were selected for use which gave good 
separation of methotrexate and thyroxine. There were (i) ethanol/2M 
aqueous ammonia 6;1 v/v (Mucha ^  al,, 1979) and (ii) chloroform/ 
methanol 1 ;2 v/v (Pataki, 1966), After allowing the solvents to run 
approximately 15cm the plates were removed from the solvents and dried 
in air. Methotrexate is strongly yellow in colour and was detected 
visually while free thyroxine was located using the ninhydrin reaction. 
This method involved the use of a spray of 0,2% ninhydrin in butanol
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FIGURE 4.21
THE STRUCTURE OF DI-TERT-BUTYL DICARBONATE
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FIGURE 4.22
AN OUTLINE OF THE PROPOSED SYNTHESIS EMPLOYING 
DI-TERT-BUTYL DICARBONATE AS A BLOCKING AGENT
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saturated with water and containing 5% acetic acid. After being sprayed 
with this reagent, the plates were heated in an oven at 70°C for 10 
minutes. Conjugated thyroxine would not be expected to give a positive 
reaction to the ninhydrin spray, and to detect the presence of the 
conjugated hormone the thyroxine used in the conjugation experiments was 
'spiked* with il25 labelled thyroxine. After detection of free thyroxine 
using ninhydrin, the thin-layer plates were cut into 0.5cm strips 
parallel to the solvent front. The radioactivity contained in each of 
these strips was determined using a LKB 'Multigamma' counter,
4.3.3.4 RESULTS
Both of the methods detailed above failed to provide the 
required products.
The first method, which involved the use of CBZ, produced only 
one methotrexate containing peak when the gel filtration fractions were 
examined spectrophotometrically. This peak eluted in the same fraction 
as unreacted methotrexate when applied to the same column. This was 
taken to indicate that the blocking reaction had not occurred.
The second method, that suggested by Dr, Brundish, resulted in 
the formation of the blocked methotrexate but it was found that this 
product was insoluble in both of the solvents suggested by Dr, Brundish 
for the peptide bond forming reaction (see Figure 4,22), The outline of 
the reaction scheme shows that the peptide bond is formed via the 
formation of an anhydride, and this limits the choice of solvent 
available as any solvent which reacts with anhydrides would obviously be 
unsuitable.
Various attempts were made to overcome this problem by using 
other solvents such as dioxan and dimethylsulphoxide. The conjugation 
reaction was also attempted using a suspension of the blocked 
methotrexate in dimethylformamide, The progress of the reactions was 
monitored using the thin-layer chromatography systems described above. 
However none of the conditions employed produced detectable quantities 
of methotrexate-thyroxine conjugate,
4.3.3.5 DISCUSSION
The experimental work involving the use of methods commonly 
employed in peptide synthesis took several months to carry out and yet 
very little positive information seems to have been produced. However 
the practical studies have led to several conclusions which would be 
useful in any further development of this work.
The first major conclusion, was the realisation that although a 
plethora of reagents and methods for protein synthesis have become
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available, and despite the fact that many synthetic peptides are now 
produced in a 'routine* manner, the science of peptide synthesis is 
still a very specialised one. It became obvious after conversations with 
Dr. Brundish that experienced peptide chemists and groups very familiar 
with the use of the various methodologies still encounter difficulties 
with particular reactions which may take years to solve. In some cases 
these problems are insurmountable, and a full chemical synthesis from 
basic components is the only way a particular compound can be produced. 
Such a chemical synthesis would not, of course, be a viable solution in 
the production of a conjugate for the inhibitor based enzyme 
immunoassay, as one of the main advantages proposed for the new 
methodology was that the labelling procedure should be simpler than that 
involved in current techniques.
This leads on to the second major conclusion, which concerns 
the use of methotrexate as the inhibitor. One of the criteria considered 
to be important in the initial selection of the inhibitor for study was 
that the inhibitor should contain functional groups suitable for 
conjugations to be carried out. In retrospect it has become obvious that 
it would have been better to extend this criterion to require that the 
inhibitor selected should not contain functional groups capable of 
forming cross-linked inhibitor polymers under simple conjugation 
conditions. This would however restrict even further the choice of 
enzyme inhibitors available.
The final chapter of the thesis considers in more detail the 
potential for the future development of an inhibitor based enzyme 
immunoassay system in the light of the experimental findings reported 
here, and discusses the significance of inhibitor based methods 
published since this project was commenced.
148
CHAPTER FIVE 
GENERAL CONCLUSIONS
5.1 INTRODUCTION ; A 'PERFECT' IMI-flJNOASSAY?
This present study investigated the practical possibilities of 
two new theoretical enzyme immunoassay protocols and aimed to produce 
working model systems. One protocol was used to develop a model assay 
which compared well with techniques in current routine use, but the 
production of a model method based on the other protocol encountered a 
series of unexpected problems which prevented the development of a 
working system within the time available.
In this final chapter, the important principles and future 
potential of each of the two assay protocols will be considered. 
However, before such a discussion can take place, it is necessary to 
define the reasons for the development of new immunoassay methods so 
that a balanced assessment of the protocols studied can be made.
Advantages of new immunoassay systems which have been proposed 
as reasons why the particular methods should be widely introduced have 
included savings in the time required and financial cost, increases in 
sensitivity, safety and reagent shelf life and decreases in both assay 
complexity and non-specific interference. From a consideration of these 
factors it might be proposed that a perfect immunoassay could be 
theoretically described. Such a definition, however, is meaningless in 
practical terms if it does not also relate to the clinical requirements 
of the investigation for which the immunoassay is being used, or to the »
analytical situation in which the assay is being carried out.
Taking the factors listed above in turn, and relating them to 
the practical situation produces useful guidelines for the evaluation of 
immunoassay protocols. (The factor of specificity has not been 
considered in this context as it is more related to the properties of 
the antibody preparation employed than to the particular protocol of the 
immunoassay method.)
(a) Time. The time taken for an assay to be completed is an 
important factor in the consideration of any new method. A technique 
which takes two or three days to complete but can be used with batches 
of samples several hundred in number would be well suited for use in 
large scale screening programmes but not useful in situations where 
rapid * emergency’ measurements are required. Another technique may not 
be suitable for large numbers of samples but may be capable of producing 
a result within a few hours or even minutes of the sample being received
in the laboratory. It is clear, therefore, that the value of the
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rapidity of an immunoassay is determined largely by the clinical purpose 
to which it is put and is not a simple question of 'which method is 
quickest'.
(b) Cost. Again a simple evaluation of the importance of this 
factor is not possible. The cost of an immunoassay method is composed of 
two different components; capital cost and running cost, it is the 
capital costs involved in many of the immunoassay methods developed 
recently that havt prevented their more widespread introduction. At the 
present time, few laboratories have the finance available for capital 
investment in order to introduce techniques with which they are not 
familiar. Conversely, this factor has increased the introduction of 
immunoassay methods which utilise existing laboratory equipment such as 
colorimeters and fluorimeters.
The running cost of any assay will be affected both by the cost 
of reagents and by the number and experience of staff required. The 
staff costs will be largely unrelated to the number of samples assayed 
and techniques requiring skilled personnel may be uneconomical if only a 
limited number of investigations are to be carried out. In times of 
limited finance, this factor again favours the introduction of 
immunoassay techniques which employ detection methods which do not 
require the training or employment of specialist staff.
(c) Sensitivity. The sensitivity of an immunoassay is one of 
the parameters most frequently quoted in assay assessment, but, as with 
the factors previously discussed, the clinical situation in which the 
assay will be used should also be considered. The introduction of 
radioimmunoassay techniques enabled highly sensitive assays to be 
developed and the method has played a significant role in the 
elucidation of many physiological and pharmacological processes. The 
sensitivities claimed for some immunoassay methods, particularly the 
combination of enzyme immunoassay and radioimmunoassay referred to as 
Ultra-sensitive enzymatic radioimmunoassay (Harris ^  al., 1979) has
brought immunoassay to the point where the limit of sensitivity is 
measured in terms of the number of molecules or antigenic sites that can 
be detected. Interesting, and exciting, as this may be, in many 
situations such sensitivity is far in excess of what is clinically 
required. Homogeneous techniques such as the EMIT homogeneous enzyme 
immunoassay method are often criticised as being insensitive, but it 
should be remembered that this does not limit the value of an assay 
method as such, but acts only in limiting the applicability of the 
method to the measurement of compounds present in relatively high
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concentrations in the test fluid. Provided that the sensitivity achieved 
is sufficient to be of value in the clinical situation, then an 
'insensitive* method may be perfectly adequate for routine use.
(d) Safety, More than any other factor, safety has been the 
feature of non-radioactive labels which has provided the impetus for 
their introduction. As was mentioned in the opening chapter of this 
thesis, the assessment of risk is not an easy task, particularly in 
relatively low-risk situations. The debate between those who claim that 
there is a 'cut-off point' below which radioactive emissions are totally 
safe, and those who claim that even low levels of radioactivity produce 
a significant health risk is not easy to resolve. As with other factors, 
therefore, the situation is not as simple as at first appears and care 
is needed in order to distinguish between the risks that are involved in 
the process of reagent synthesis and those encountered during the 
routine use of the method.
With regard to reagent synthesis, there is little doubt as to 
the serious risks encountered in the preparation of bulk quantities of 
radioactive compounds and if 'in-house' preparation of radiolabelled 
compounds is to take place then expensive containment facilities are 
required. This financial commitment can be avoided by the use of 
alternative labels which can safely be prepared on the laboratory bench.
The situation regarding the routine use of dilute solutions of 
radioactive compounds is less clear, and there is no definitive evidence 
that laboratory workers who use only 'kit' methods or separately 
purchased pre-prepared reagents are exposed to health risks higher than 
those commonly encountered in a clinical laboratory. It should be noted 
in this context that the absence of evidence of toxic effects does not 
prove that a compound is safe, and in the use of non-radioisotopic
labels, as in all laboratory procedures, 'good laboratory practice' is 
essential if health risks are to be minimised.
(e) Shelf-life. This is another factor which can only be 
interpreted in the light of the relevant clinical situation. If the 
assay is carried out very frequently then the shelf life of the labelled
reagent may not be a limiting factor in its usefulness. However,
reagents with short shelf-lives are not suited to investigations which 
are only carried out at irregular intervals. The synthesis of a new 
batch of label in order to study one or two samples is extremely
wasteful in both time and finance. Stable labels, such as enzymes, which 
can be stored for many months, if not years, with little alteration in 
their performance, are particularly well suited to such investigations
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and their use will enable small laboratories to carry out a far wider 
range of investigations than is now economically possible. At present in 
the National Health Service of this Country, assays which are required 
only infrequently are normally carried out in Supra-Regional Centres, 
with the cost and delay of transfer of the samples and results between 
the small laboratory and the Supra-Regional Centre being more than 
compensated for by the greatly increased range of investigations that 
the small laboratory can offer to the clinician. The use of more stable 
reagents would enable many of these less common analyses to be carried 
out locally. This would reduce the delay between request and result and 
consequently lead to an improvement in patient care.
(f) Assay Complexity. This feature of an immunoassay can, like
s
some of the other feature^ already discussed, be considered to be 
composed of two components; label production and routine assay use. If a 
new immunoassay method is to be advantageous in practical terms then it 
must be relatively simple in both of these areas. The process of label 
production should be simple, quick and reproducible and involve the use 
only of equipment and reagents which are commonly available. It should 
be possible for workers without previous experience to prepare labels 
which meet the required performance standards. The routine use of the 
method should also be possible for a worker without specific previous 
experience if it is to be easily introduced. These factors are 
particularly important in developing countries where the depth and range 
of experience of the laboratory workers may at present be limited. In 
such circumstances the simplicity of a technique may be one of the most 
important factors in determining the usefulness of a new assay system. 
Enzyme immunoassays in which the end point detection method involves 
either simple visual inspection or the use of a crude portable 
photometer are particularly suited to such situations and may enable 
diagnoses to be made in small clinics possessing extremely limited 
laboratory facilities. In more advanced laboratories, the factor of 
assay complexity may be more related to the degree to which the method 
can be automated. In such laboratories the desire for automation may 
favour the introduction of homogeneous techniques.
(g) Non-specific Interference. This is the last of the 
features discussed here, and once again its importance is largely 
determined by the use to which the assay is put. Homogeneous 
immunoassays are obviously more prone to such interference as signal 
measurement takes place in an environment containing the test fluid. An 
assay which suffers from severe interference problems when used to
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determine serum levels may prove perfectly adequate for analysis of 
urine samples.
From this brief consideration of some of the factors important 
in assessing a new immunoassay procedure, it is clear that in practical 
terms there is no such thing as the ideal or perfect immunoassay 
procedure. The usefulness of any system is largely related to the 
particular measurement that is to be carried out and to the laboratory 
environment in which the assay is to be performed.
With this consideration in mind, the two new protocols 
developed in this thesis will now be evaluated.
5.2 SIMULTANEOUS MULTI-HAPTEN IMMUNOASSAY
5.2.1 IMPORTANT PRINCIPLES
It has been noted for some time (Wisdom, 1976; O'Sullivan et 
al., 1979) that enzyme labels were of potential use in the development 
of simultaneous multiple-component immunoassays. This present study 
carefully defined the theoretical principles important in the 
development of such a system and produced the first experimental 
evidence as to the feasibility of the proposed system.
Many of the important principles have already been listed and 
discussed (see Section 2.1 and Table 2.1 in particular). The factors 
important in the development of multiple simultaneous methods can be 
divided into two major areas of concern. Firstly, the assay systems must 
be separate and not interfere with each other. To this end the enzyme 
specificity and product absorption spectra must be such that no cross 
detection occurs between the various enzyme labels. This was appreciated 
prior to the experimental work being carried out and these thoughts find 
expression in several of the points listed in Table 2.1. Secondly, 
however, the assay systems must be compatible with each other. This 
concerns both the immunological reaction and the detection of enzyme 
activity. For example, each of the immunological reactions should occur 
at a common pH and require the same length of time for incubation, the 
separation of the bound and free fractions in each of the assays should 
be achieved by the same method and under the same conditions and in the 
ideal system only one pH and incubation time would be required for the 
colour forming reactions.
The importance of this second aspect, that of assay 
compatibility was not fully appreciated prior to the development of the 
model dual system and this led to the selection of two enzymes (alkaline 
phosphatase and p-galactosidase) which were not ideal for the purpose. A
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study of the pH ranges over which these two enzymes were active had
CK
indicted a region of overlap, but further investigation revealed that if 
the required sensitivity was to be achieved then a colour forming 
reaction incubation of unacceptable duration would be required.
In the initial studies concerning the development of a 
three-hapten method it was decided to select three enzymes with very 
similar pH optima for use in the model system in order to eliminate the 
need to alter the pH of the final reaction buffer during the incubation. 
Three enzymes were selected for use for which colorogenic substrates 
were available. In the course of the brief investigation, however, it 
was realised that if three products were to be detected in the visible 
wavelength range, then a compromise in the detection wavelengths 
employed would be involved if cross detection was to be avoided. 
Sufficient time was not available for this work to be completed and for 
the extent of the effect of this compromise to be assessed.
5.2.2 FUTURE POTENTIAL
The dual-hapten simultaneous enzyme immunoassay would seem to 
have significant potential for future use. The model system had several 
limitations, but as has already been explained, these were connected 
with characteristics of the model system rather than with the assay 
principle itself. Even with these limitations, the model system 
represents a notable advance in the exploitation of the concept of 
immunoassay. In recent years several groups of workers have attempted to 
develop simultaneous methods using radioisotopes but at present none of 
the fully investigated techniques is without considerable problems in 
terms of either reagent stability (where ll31 used) or assay
complexity (where multicomponent tubes and two 1^25 labels are 
involved). The use of enzymes in this present study produced a system 
which was as simple to perform as single hapten methods and involved the 
use of reagents possessing a long shelf life. For these two reasons the 
use of enzymes is to be preferred over the use of radioisotopes.
Compared to single-hapten enzyme immunoassays, the dual method 
has several advantages. Its use would, for example, produce savings in 
the time taken for results to be obtained in that the assay takes no 
longer to complete than the single hapten double antibody techniques and 
yet provides double the amount of information. The dual system would 
also produce savings in running costs, both in terms of reagents used 
and in staff required. The dual system is no more complex in either 
reagent synthesis or routine use than the single-hapten methods and the 
model system did not involve any particularly hazardous procedures.
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The factors of sensitivity and non-specific interference would 
be influenced by the use for which the system was employed. In the model 
method for the two thyroid hormones, the sensitivity was more than 
adequate to cover the range of hormone levels found in human serum, and 
no non-specific interference was noted.
The dual method would therefore seem to be technically 
competent to play a role in the future use of immunoassay. What that 
role is will be largely influenced by the needs of the clinician. Since 
the introduction of multi-channel analysers into routine laboratory use, 
it has become apparent that many diagnoses are aided by the broad 
spectrum of information that such analysers provide. Multi-component 
profiles can of course be abused and it must always be remembered that 
by definition of the 'normal range', one in every twenty results will be 
'abnormal' in healthy subjects. However, providing that this is 
remembered, and providing that interpretation of results is carried out 
in a careful way, it is clear that more information aids rather than 
hinders diagnosis. If a laboratory is able to provide two results in the 
same time as one, and for a relatively small increase in cost then this 
is an obvious advantage.
Although in theory any two haptens could be determined 
simultaneously, the cost, in time and finance, of the development of a 
particular method would only be justified if it lead to an increase in
useful information in a significant number of investigations.
Pairs of haptens suitable for use together could be determined 
by a study of the requests for investigations sent to a clinical
chemistry laboratory. Such a study would need to examine two types of 
'request pairs'. Firstly, pairs of investigations that were requested
simultaneously, and secondly pairs that were requested consecutively in 
which the second measurement was requested as a further step in
differential diagnosis once the result of the first test had been
obtained. In both of these circumstances, dual hapten methods would 
hopefully lead to a more rapid and more efficient diagnosis.
Even without the benefit of such a survey, there are various 
combinations of measurements which if carried out simultaneously would 
appear to offer a potential improvement in diagnosis and patient care.
The two chosen for the model system form probably the most
obvious pair. The simultaneous measurement of thyroxine and
triiodothyronine provides an aid to diagnosis because although the serum 
levels of thyroxine are very much higher than those of triiodothyronine, 
the triiodothyronine is metabolically more active and as a result both
1 qq
hormones are equally important in physiological and pathological 
processes.
In the early stages of hyperthyroidism, for example, it is
often the triiodothyronine concentration which is initially elevated. At 
this stage the thyroxine levels remain within the 'normal range' and 
only become raised as the disease condition progresses. In a particular 
form of hyperthyroidism, referred to as triiodothyronine thyrotoxicosis, 
the thyroxine levels remain within the reference range and the clinical 
signs observed in this condition result from the elevated levels of 
circulating triiodothyronine. In circumstances of iodine deficiency, or 
after treatment for hyperthyroidism, a clinically euthyroid state may be 
seen even though the thyroxine levels are low. This is because the ratio 
of triiodothyronine to thyroxine which is secreted is increased. Again
the analysis of both hormones would aid the interpretation of the 
clinical observations.
The monitoring of the process of pregnancy is another area 
where the dual system would be of use. Two hormones are frequently 
measured in maternal serum during pregnancy; oestriol and human 
placental lactogen. From about the thirteenth week of pregnancy the 
foetus and the placenta form an integrated endocrine unit and both are 
required for oestriol production. The levels of this hormone, therefore, 
provide an indication of both placental and foetal function. Human
placental lactogen, on the other hand, is synthesised entirely in the
placenta as its name implies. It can be detected in maternal serum after 
the eig^h week of gestation. It has been used as a monitor of placental 
function, particularly in the assessment of threatened abortion.
The 'normal range' for both oestriol and human placental 
lactogen is wide, and for this reason a series of readings is of 
considerably more value than a single estimation. A sudden drop in 
levels of either hormone is more likely to indicate dysfunction than a 
single low value. The measurement of both hormones simultaneously would 
aid diagnosis in that a concurrent fall in the circulating levels of 
both hormones would be a very strong indication of placental 
malfunction.
Drugs, as well as hormones, could be measured by the dual 
simultaneous system provided that the frequency of dual administration 
of the drugs was sufficient to warrant the development of the method. 
One area of treatment where combinations of two or more drugs are often 
given together in a singe therapy schedule is the use of chemotherapy in 
the treatment of cancer. Anti-cancer drugs are, by their very mode of 
action, toxic, and the blood levels that result from the administration
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hormones are equally important in physiological and pathological 
processes.
In the early stages of hyperthyroidism, for example, it is 
often the triiodothyronine concentration which is initially elevated. At 
this stage the thyroxine levels remain within the 'normal range' and 
only become raised as the disease condition progresses. In a particular 
form of hyperthyroidism, referred to as triiodothyronine thyrotoxicosis, 
the thyroxine levels remain within the reference range and the clinical 
signs observed in this condition result from the elevated levels of 
circulating triiodothyronine. In circumstances of iodine deficiency, or 
after treatment for hyperthyroidism, a clinically euthyroid state may be 
seen even though the thyroxine levels are low. This is because the ratio 
of triiodothyronine to thyroxine which is secreted is increased. Again
the analysis of both hormones would aid the interpretation of the 
clinical observations.
The monitoring of the process of pregnancy is another area 
where the dual system would be of use. Two hormones are frequently 
measured in maternal serum during pregnancy; oestriol and human
placental lactogen. From about the thirteenth week of pregnancy the 
foetus and the placenta form an integrated endocrine unit and both are 
required for oestriol production. The levels of this hormone, therefore, 
provide an indication of both placental and foetal function. Human
placental lactogen, on the other hand, is synthesised entirely in the
placenta as its name implies. It can be detected in maternal serum after 
the eigth week of gestation. It has been used as a monitor of placental 
function, particularly in the assessment of threatened abortion.
The 'normal range' for both oestriol and human placental 
lactogen is wide, and for this reason a series of readings is of 
considerably more value than a single estimation. A sudden drop in 
levels of either hormone is more likely to indicate dysfunction than a 
single low value. The measurement of both hormones simultaneously would 
aid diagnosis in that a concurrent fall in the circulating levels of 
both hormones would be a very strong indication of placental 
malfunction.
Drugs, as well as hormones, could be measured by the dual 
simultaneous system provided that the frequency of dual administration 
of the drugs was sufficient to warrant the development of the method. 
One area of treatment where combinations of two or more drugs are often 
given together in a singe therapy schedule is the use of chemotherapy in 
the treatment of cancer. Anti-cancer drugs are, by their very mode of 
action, toxic, and the blood levels that result from the administration
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of a drug need to be carefully controlled. A single immunoassay which 
could monitor the levels of two drugs simultaneously would be a useful 
aid for both research and routine use of such combination therapy.
Time was not available for the three-hapten system to be fully
studied experimentally but the brief investigation carried out did not
reveal any reason why further development might not yield a working 
model. The number of occasions when three determinations would be 
required simultaneously would obviously be less than for two 
investigations and once again a full study of the requests made to a 
routine clinical chemistry laboratory would be required in order to 
identify suitable combinations of assay methods. The measurement of 
three anti-cancer drugs or of thyroid stimulating hormone in addition to 
thyroxine and triidothyronine are two obvious possibilities. (Thyroid 
stimulating hormone was not selected as the third component of the model 
system proposed in chapter three as a suitable antiserum was not 
available within the Department for the quantitation of this hormone.)
In conclusion then, there would appear to be significant future 
potential for the use of multi-component enzyme immunoassay systems. The 
model dual-hapten method has shown that the theoretical advantages of 
the system can be achieved in practice. There would seem to be several 
areas of clinical study where such simultaneous two and three component 
estimations would provide significant advantages both in aiding 
diagnosis and in improving patient care.
5.3 INHIBITOR-BASED HOMOGENEOUS ENZYME IMMUNOASSAY
5.3.1 IMPORTANT PRINCIPLES
The advantages of homogeneous immunoassays in terms of speed 
and ease of automation are well established. The presence in the final 
reaction mixture of the biological fluid being examined can produce 
non-specific interference which may limit the sensitivity that can be 
obtained, but, providing the compound to be determined is present in the 
test fluid in sufficiently high concentrations then this factor need not 
limit the usefulness of the homogeneity principle.
The patented EMIT system involves the direct conjugation of the 
enzyme to the hapten to be measured. The production of such a conjugate 
in which the enzyme retains its activity when the hapten is free, but is 
inhibited by binding of the hapten to its specific antibody, is 
theoretically a difficult task and may have limited the number of 
homogeneous systems developed.
An alternative approach is the use of 'enzyme active 
substances' as the covalently bound labels with the enzyme in such
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systems being present free in solution. The published methods in which 
cofactors, prosthetic groups or substrates have been used in this way 
are reviewed in Section 1.3.4. When this present research was commenced, 
no systems had been described in which an enzyme inhibitor was used 
covalently linked to a hapten as an immunoassay label.
A consideration of the reactions involved in the proposed 
inhibitor-based system indicated that an important aspect would be the 
strength of the interaction between the inhibitor and the enzyme. In 
order to be suitably sensitive, an inhibitor with an inhibition constant 
of at least lO”^  would in theory be required. One other important
principle is that, as with all homogeneous enzyme immunoassay systems, 
the enzyme involved should be absent from the biological fluid to be 
tested if interference is to be avoided.
The need for a high affinity inhibitor was highlighted by Ngo
and Lenhoff (1980) who produced the first publication outlining the
principle of the inhibitor based enzyme immunoassay. These workers
considered not only the conventional enzyme inhibitors studied in this 
thesis but also included in their discussions the use of anti-enzyme 
antibodies and enzyme receptors as inhibitory agents. Ngo and Lenhoff 
pointed out how each of these three types of molecule could be used in 
an inhibitor-based system but the experimental findings they reported 
were limited to the use of anti-enzyme antibodies. The publication
detailed the development of an assay for dinitrophenyllysine in which
the activity of a peroxidase enzyme could be inhibited by 
anti-peroxidase antibodies linked to dinitrophenol residues provided 
that the dinitrophenol portion of the conjugate was not bound to its
specific antibodies. The authors point out the advantage of the use of
inhibitors over the use of substrates as labels (e.g. Wong , 1979)
in that the inhibitor approach provides an intrinisic amplifying power 
because the unhibited enzyme can continuously generate products. In 
their closing comments, Ngo and Lenhoff note that there are numerous 
theoretical ways in which potent modulators of enzyme activity could be 
employed in immunoassay systems. They list as examples the use of the 
avidin biotin interaction, the use of transition state analogues such as 
coformycin (which inhibits adenosine deaminase with an inhibition 
constant of 1 0“^^) and the use of enzyme activators which can produce a 
dramatic increase in the activity of some mutant enzymes.
Later in 1980 the first, and at present only, practical use of 
a conventional enzyme inhibitor in a homogeneous enzyme immunoassay was 
published by Finley, Williams and Lichti. These workers evaluated an
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enzyme inhibition immunoassay for serum thyroxine which had been 
developed by Abbott Diagnostics, Dallas, Texas, USA.
The method is based on the inhibition of hydrolysis of the 
substrate acetylp-(methylthio)choline iodide by acetylcholine esterase 
(acetylcholine hydrolase EC 3.1.1,7). Thyroxine covalently linked to a 
cholinesterase inhibitor (a phosphonate) irreversibly inhibits the 
enzyme when free but is not inhibitory when bound to thyroxine 
antibodies. N-methylorphenandrine sulphate is added to the reaction 
mixture to block any interfering pseudocholinesterase present in the 
serum.
In the method protocol, the sample containing thyroxine is 
mixed with thyroxine antibodies, the acetycholine esterase enzyme and 
agents that inhibit the binding of thyroxine to serum proteins. Then a 
second reagent containing the thyroxine conjugate, the enzyme substrate 
and the chromogenic thiol, 5,5’-dithiobis(2-nitrobenzoic acid) (DTNB) is 
added.
The colour reaction that occurs is indicated below. 
Acetylp-Cmethylthio)choline iodide ■ ' "> methylthiocholine
DTNB
thionitrobenzoate (absorbance maximum at 415nm)
Finley et al., examined sera from 231 subjects, both by the new 
method and by radioimmunoassay. Of the samples studied, nine showed 
unusually large discrepancies between the two methods. The authors state 
in the abstract that none of these discrepancies would result in a 
confused clinical interpretation but in the text of the paper their 
claims are less bold. One of the nine pairs of discrepant results would 
only lead to the same clinical interpretation after calculation of the 
free thyroxine index, and for one other pair the calculation of this 
index could still lead to different interpretations depending on which 
immunoassay results were used. No adequate explanation of these 
differences is given and for the second example quoted above, the only 
reason given by the authors for the observed discrepancy was that 'the 
sample tested by radioimmunoassay may have been technically in error'. 
These unexplained discrepancies indicate that a fuller investigation of 
the potential problems of the new method may be required. One problem 
which will certainly need consideration is pointed out by the authors.
160
This is the possibility of interference by erythrocyte membrane bound 
acetylcholinesterase. Due to the fact that, depending on genotype, the 
enzyme may be tightly or loosely bound to the cell membrance, the
results of tests on haemolysed samples vary unpredictably, and hence the 
authors sensibly suggest that samples which are even slightly haemolysed 
should not be assayed. The developers of the Abbot system have
recognised the need for a high affinity inhibitor, but have placed less 
importance on the second guiding principle i.e. that endogenous enzyme 
should not be present in the test fluid. This has led to the problem of 
interference with haemolysed samples. It is clear, therefore, that
although an inhibitor based method has been produced there is still
considerable room for improvement on the published method, and that both 
of the principles originally outlined need to be given due consideration 
in the development of model systems.
The inhibitor-based method proposed in this thesis differs in 
theoretical approach to that evaluated by Finley et al. (1980 b) only in 
the use of a high affinity reversible inhibitor rather than the 
irreversible phosphonate used in the published method. In theory the use 
of methotrexate as employed in the later stages of the developmental 
work would have led to a method less susceptible to interference as 
although the enzyme dihydrofolate reductase occurs in human cells it is 
not normally found in the extracellular space (Bergmeyer 1974).
5.3.2 FUTURE POTENTIAL
The development of an inhibitor-based method that was carried 
out as part of this present research encountered a series of setbacks. 
Some of the problems (such as the non-specific binding observed with the 
use of Cibacron Blue) should possibly have been identified as potential 
difficulties, others, (such as the inhibition of dihydrofolate reductase 
by nortriptyline and similar compounds) could not have been expected.
During the development of the simultaneous multiple hapten 
enzyme immunoassay it became obvious that theoretical ideals had, in one 
way or another, to be replaced by experimental compromise if a working 
model system was to be produced. The same may be true for the inhibitor- 
based system, and it is possible that the failure to produce a working 
model system based on this protocol resulted from the wrong theoretical 
principle being compromised. Throughout the experimental work the 
principles consistently given priority in the selection of inhibitors 
for study concerned the potency of inhibition, the lack of endogenous 
enzyme activity and the ease of the end point detection method. The 
suitability for easy and unambiguous synthesis of inhibitor-hapten
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conjugates was not given an equally high ranking in the selection 
process and this may have contributed to the difficulties experienced. 
The problems encountered with haemolysed samples in the method evaluated 
by Finley et al. (1980 b) indicate that absence of endogenous enzyme 
should remain of the highest priority. This leaves the potency of 
inhibition and ease of end point detection as possible areas of 
compromise. That some such compromise is necessary is apparent from the 
failure in both literature studies and experimental investigations to 
find inhibitors which fully possess all of the ideal requirements.
From theoretical considerations inhibitors of lower potency 
would lead to less sensitive assays and this should obviously be avoided 
if possible. It may be therefore, that the re-examination of enzymes 
with slightly more complex end point detection methods may provide a 
more suitable inhibitor/enzyme system for developing a model inhibitor- 
based method.
Returning the the methotrexate system under development in the 
later stages of the practical work, it should be noted that this system 
may yet prove suitable for use. The discussions with Dr. D. Brundish of 
Ciba Geigy revealed some of the complexities of the specialised skills 
of protein synthesis. The practical assistance or collaboration of a 
group of workers familiar with the use of the range of reagents 
available for synthetic methods may in a relatively short time yield a 
solution to the problem of methotrexate cross-linking.
Considering finally the concept of inhibitor based enzyme 
immunoassay in general terms, it should be said that despite the 
problems encountered in this present study, it is a method which may 
still hold significant potential for the future. The difficulties which 
prevented a model system being developed in this work, and which 
resulted in the only published method being susceptible to interference, 
are not insurmountable should more time and practical expertise in 
synthetic methods be made available. If a suitable inhibitor/enzyme 
system was developed then the resulting assay, possessing the benefits 
of stability and safety of non-radioactive labels, and with the added 
advantages of time saving, simplicity and ease of automation due to its 
homogenous nature, would provide a useful addition to the range of 
immunoassays available to the biochemist.
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